Compositions Comprising Pneumococcal Polysaccharide-Protein Conjugates and Methods of Use Thereof - Patent application
Multivalent immunogenic compositions with polysaccharide-protein conjugates in aprotic solvents address the limitations of current vaccines by offering broad pneumococcal protection and improving immune response efficacy.
Patent Information
- Application Number
- JP2023200623
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-12-06
- Filing Date
- 2023-11-28
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2039-08-30
AI Technical Summary
Current multivalent pneumococcal vaccines do not provide comprehensive protection against a diverse range of Streptococcus pneumoniae serotypes, as certain serotypes emerge and evade the immune response, necessitating the development of additional vaccine compositions that can offer complementary protection.
The development of multivalent immunogenic compositions comprising polysaccharide-protein conjugates covalently linked to a carrier protein, specifically using a conjugation reaction in an aprotic solvent like DMSO, which enhances stability and immunogenicity, covering a broader spectrum of S. pneumoniae serotypes including 15A, 16F, 23A, 23B, 24F, 31, and 35B, among others.
These compositions induce a robust protective immune response, providing enhanced coverage against a variety of pneumococcal serotypes, including those not covered by existing vaccines, and can be administered alongside or after conventional vaccines to boost immunity.
Smart Images

Figure 0007587666000037 
Figure 0007587666000038 
Figure 0007587666000039
Abstract
Description
[Technical field]
[0001] The present invention provides multivalent immunogenic compositions having distinct polysaccharide-protein conjugates. Each conjugate is conjugated to a carrier protein, preferably CRM197. Different serotypes of Streptococcus pneumoniae were examined. The immunogenic composition comprises a capsular polysaccharide prepared from the Streptococcus pneumoniae strain of Streptococcus pneumoniae. Provide coverage. [Background technology]
[0002] Streptococcus pneumoniae is a gram-positive bacterium. It is the most common cause of invasive bacterial diseases in infants and young children (such as pneumonia, bacteremia, meningitis, and otitis media). Pneumococci are encapsulated with chemically bound polysaccharides that confer serotype specificity. There are more than 90 known serotypes of pneumococcus, and the capsule is a protective layer on the inner surface of the bacterium. The main virulence determinant of pneumococci, not only because it protects against the body but also because it is poorly immunogenic in itself Polysaccharides are T-cell independent antigens and interact mostly with T cells. However, they cannot be processed or presented by MHC molecules. The immune system can be stimulated through alternative mechanisms, including cross-linking of surface receptors on the immune system.
[0003] The multivalent pneumococcal polysaccharide vaccine, which has been licensed for many years, is used in adults, especially the elderly and have been shown to be beneficial in preventing pneumococcal disease in people at high risk for pneumonia. However, infants do not respond adequately to unconjugated pneumococcal polysaccharides. The seven most frequently isolated serotypes causing invasive pneumococcal disease (4, 6B, 9V, 1 4, 18C, 19F and 23F) Revnar® was first approved in the United States in February 2000. Serum present in Prevnar® after universal use of Evnar® The study was published in the journal ClinicalTrials.gov / pubmed / 1122444. sease Control and Prevention,MMWR Morb M See Oral Wkly Rep 2005,54(36):893-7. However, serotype coverage by Prevnar® in certain parts of the world is limited. There is some evidence that certain serotypes are emerging in the United States. (e.g., 19A, etc.). O'Brien et al., 2004, Am J Epi demiol 159:634-44;Whitney et al.,2003,N Engl J Med 348:1737-46;Kyaw et al.,2006, N Engl J Med 354:1455-63;Hicks et al.,20 07,J Infect Dis 196:1346-54;Traore et al .,2009,Clin Infect Dis 48:S181-S189 sea bream.
[0004] US Patent Application Publication No. 2006 / 0228380 discloses serotypes 1, 3, 4, 5, 6 13-valent pneumocytes containing A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F This paper describes a bacterial polysaccharide-protein conjugate vaccine. No. 1590224 covers serotypes 1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 1 14-valent pneumococcal polysaccharide-protein complex containing 4, 18C, 19A, 19F and 23F The present invention describes a jugate vaccine.
[0005] Other PCVs cover serotypes 7, 10, 11 or 13, which are included in PCV-15. (US Patent Application Publication No. 2011 / 0195086), but immunity to some serotypes Interference (e.g., low protection against serotype 3 of PCV-11 from GSK) and Pfiz The response rate of PCV-13 (PREVNAR® 13) to serotype 6B in patients with erythropoietin-related pulmonary disease was Prymula et al., 2006, Lancet 367:740-48 and Kieninger et al., Safety and Immunologic Non-inferiority of 13-valen t Pneumococcal Conjugate Vaccine Compare d to 7-valent Pneumococcal Conjugate Vac cine Given as a 4-Dose Series in Healthy Infants and Toddlers,presented at the 4 8 th Annual ICAAC / ISDA 46 th Annual Meeting g, Washington DC, October 25-28, 2008 stomach.
[0006] Current multivalent pneumococcal vaccines limit the risk of pneumococcal disease associated with the serotypes present in the vaccine. However, there are currently no vaccines available that are There has been an increasing prevalence of pneumococci expressing serotypes not associated with pneumococcal infection. It provides protection against a different set of pneumonia strains that are not present in currently available vaccines. There is a need for additional pneumococcal vaccine compositions that can provide complementary protection against pneumococcal serotypes. It is considered essential. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] US Patent Application Publication No. 2006 / 0228380 [Patent Document 2] China Patent Application Publication No. 101590224 [Patent Document 3] US Patent Application Publication No. 2011 / 0195086 [Non-patent literature]
[0008] [Non-Patent Document 1] Centers for Disease Control and Prevention, MMWR Morb Mortal Wkly Rep 2005,54(36):893-7 [Non-Patent Document 2] O'Brien et al., 2004, Am J Epidemiol 159:634-44 [Non-Patent Document 3] Whitney et al.,2003,N Engl J Med 348:1737-46 [Non-Patent Document 4] Kyaw et al.,2006,N Engl J Med 354:1455-63 [Non-Patent Document 5] Hicks et al.,2007,J Infect Dis 196:1346-54 [Non-Patent Document 6] Traore et al., 2009, Clin Infect Dis 48:S181-S189 [Non-Patent Document 7] Prymula et al.,2006,Lancet 367:740-48 [Non-Patent Document 8] Kieninger et al.,Safety and Immunologic Non-inferiority of 13-valent Pneumococcal Conjugate Vaccine Compared to 7-valent Pneumococcal Conjugate Vaccine Given as a 4-Dose Series in Healthy Infants and Toddlers,presented at the 48th Annual ICAAC / ISDA 46th Annual Meeting,Washington DC,October 25-28,2008 Summary of the Invention [Means for solving the problem]
[0009] The present invention provides a pneumococcal (S. pneumoniae) polysaccharide-protein conjugate. A multivalent immunogenic composition comprising: The polysaccharides of the serotype S. pneumoniae conjugated thereto, and the serotype of S. pneumoniae is as defined herein. A composition is provided.
[0010] In a particular embodiment of the invention, the serotype of S. pneumoniae is a) 15A, 16F, 23A, 23B, 24F, 31 and 35B; b)15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 1 1A, 12F, 15C, 17F and 20; and c)3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20 The set of serotypes selected from the group consisting of:
[0011] In a further particular embodiment of the present invention, the serum of S. pneumoniae The type is a) 15A, 16F, 23A, 23B, 24F, 31 and 35B; b)15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 1 1A, 12F, 15C, 17F and 20A; and c)3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20A The set of serotypes selected from the group consisting of:
[0012] In a further particular embodiment of the present invention, the serum of S. pneumoniae The type is a) 15A, 16F, 23A, 23B, 24F, 31 and 35B; b)15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 1 1A, 12F, 15C, 17F and 20B; and c)3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20B The set of serotypes selected from the group consisting of:
[0013] In some embodiments, the pneumococcus (S. pneumoniae) strain listed in a), b), or c) is moniae serotype set includes serotype 6C, serotype 6A, or serotype 6A and Further contains 6B.
[0014] In some embodiments, at least one of the polysaccharide protein conjugates is a non- Conjugation reactions involving protic solvents, such as dimethylsulfoxide (DMSO), In a specific embodiment, each of the polysaccharide-protein conjugates is is formed by a conjugation reaction involving an aprotic solvent. As described above, DM was used as a solvent during the reductive amination of polysaccharide-protein conjugates. The use of SO reduced the expression of these blood samples compared to the same conjugates prepared under aqueous conditions. The unexpectedly superior stability and enhanced immunogenicity of the purified form are obtained.
[0015] A method for inducing a protective immune response in a human patient comprising administering to the patient a multivalent immunogenic composition of the invention. In some embodiments of the methods of the invention, the method comprises administering to The patient had previously been treated with a multivalent pneumococcal vaccine.
[0016] The multivalent immunogenic compositions of the invention are useful in treating regimens with different complementary pneumococcal vaccines. Thus, the present invention can be used as part of a method for inducing a protective immune response in a human patient. A method comprising the steps of administering, in any order, a multivalent immunogenic composition of the invention to a patient. and further comprising the step of administering a multivalent pneumococcal vaccine to the patient. In certain embodiments, the multivalent pneumococcal vaccine comprises multiple S. pneumoniae strains. e) polysaccharide-protein conjugates, each of which comprises a carrier Polysaccharides of S. pneumoniae serotypes conjugated to proteins In another embodiment, the multivalent pneumococcal vaccine comprises a non-conjugated capsular polysaccharide. Rinaru.
[0017] Conjugation reaction in aprotic solvents for the detection of serotype 8 pneumococcus (Streptococcus pneumoniae) To prepare polysaccharide-protein conjugates of Enterococcus pneumoniae wherein the conjugation reaction does not involve the use of cyanoborohydride. A method for doing so is also provided.
[0018] The present invention also relates to S. pneumoniae polysaccharide protein conjugates. and a multivalent immunogenic composition comprising a conjugate, each of the conjugates being linked to a carrier protein. comprising a polysaccharide of a serotype S. pneumoniae conjugated to Here, the selected serotype of S. pneumoniae is cross-reactive with other selected serotypes. Provides responsiveness. [Brief description of the drawings]
[0019] [Figure 1] Figure 1 shows a 600 MHz one-dimensional 1H NMR spectrum of the capsular polysaccharide of S. pneumoniae serotype 6C in deuterium oxide (DO) at 50°C. Signals arising from internal standards (DMSO and DSS-d6) and residual water (HOD) are shown. Minor signals indicated with * are due to S. pneumoniae cell wall residues such as C-polysaccharide and / or peptidoglycan. [Diagram 2]Figure 1 shows a 600 MHz one-dimensional 1H NMR spectrum of the capsular polysaccharide of S. pneumoniae serotype 15A in deuterium oxide (DO) at 50°C. Signals arising from internal standards (DMSO and DSS-d6) and residual water (HOD) are shown. Minor signals indicated with * are due to S. pneumoniae cell wall residues such as C-polysaccharide and / or peptidoglycan. [Diagram 3] Figure 1 shows a 600 MHz one-dimensional H NMR spectrum of the capsular polysaccharide of S. pneumoniae serovar de-O-acetylated 15B in deuterium oxide (DO) at 50°C. Signals arising from internal standards (DMSO and DSS-d6) and residual water (HOD) are shown. Minor signals indicated with * are due to S. pneumoniae cell wall residues such as C-polysaccharide and / or peptidoglycan. [Figure 4] Figure 1 shows a 600 MHz one-dimensional 1H NMR spectrum of the capsular polysaccharide of S. pneumonia serotype 35B in DO at 50°C. Signals arising from internal standards (DMSO and DSS-d6) and residual water (HOD) are shown. Minor signals indicated with * are due to S. pneumonia cell wall residues such as C-polysaccharide and / or peptidoglycan. [Diagram 5] FIG. 1 shows 1H NMR identification regions useful for serotype identification of S. pneumoniae serotype 6C. The signal positions of each anomeric proton of the repeating unit from each monosaccharide residue are indicated. [Figure 6] FIG. 1 shows 1H NMR identification regions useful for serotype identification of S. pneumoniae serotype 15A. The signal positions of each anomeric proton of the repeating unit from each monosaccharide residue are indicated. [Figure 7] FIG. 1 shows 1H NMR identification regions useful for serotype identification of S. pneumoniae serotype de-O-acetylated 15B. The signal positions of each anomeric proton from each monosaccharide residue are indicated. [Figure 8]FIG. 1 shows 1H NMR identification regions useful for serotype identification of S. pneumoniae serotype 35B. The signal positions of each anomeric proton of the repeating unit from each monosaccharide residue are indicated. [Figure 9A] FIG. 1 shows a 600 MHz one-dimensional 1H NMR spectrum of native capsular polysaccharide of S. pneumoniae serotype 15B. [Figure 9B] FIG. 1 shows a 600 MHz one-dimensional 1H NMR spectrum of de-O-acetylated capsular polysaccharide of S. pneumoniae serotype 15B. [Figure 9C] Figure 1 shows a 600 MHz one-dimensional 1H NMR spectrum of the capsular polysaccharide of S. pneumonia serotype 15C. The spectrum was acquired at 50°C in deuterium oxide (DO). Signals arising from internal standards (DMSO and DSS-d6) and residual water (HOD) are shown. Signals indicated with * are due to S. pneumonia cell wall residues such as C-polysaccharide and / or peptidoglycan. [Figure 10A] FIG. 1 shows the anomeric region of the 600 MHz one-dimensional 1H NMR spectrum of native capsular polysaccharide of S. pneumoniae serotype 15B. [Figure 10B] FIG. 1 shows the anomeric region of the 600 MHz one-dimensional 1H NMR spectrum of de-O-acetylated capsular polysaccharide of S. pneumoniae serotype 15B. [Figure 10C] FIG. 1 shows the anomeric region of the 600 MHz one-dimensional 1H NMR spectrum of the capsular polysaccharide of S. pneumoniae serotype 15C. [Figure 10D] FIG. 1 shows the spectral region of O-acetyl and N-acetylmethyl signals of native capsular polysaccharide of S. pneumoniae serotype 15B. [Figure 10E] FIG. 1 shows the spectral region of O-acetyl and N-acetyl methyl signals of de-O-acetylated capsular polysaccharide of S. pneumoniae serotype 15B. [Figure 10F]FIG. 1 shows the spectral region of O-acetyl and N-acetyl methyl signals of S. pneumonia serotype 15C capsular polysaccharide. [Figure 11] FIG. 1 shows the effect of time and temperature (4° C. up to 12 weeks—diamonds, 25° C. up to 4 weeks—squares, 37° C. up to 4 weeks—triangles) on the polysaccharide concentration of PCV16 (0.128 mg / mL) or PCV21 (0.084 mg / mL or 0.169 mg / mL) formulations using HPSEC-UV / MALS / RI (see Example 39). [Figure 12] FIG. 1 shows the effect of horizontal rotary agitation and temperature (1 week at either 4° C., 25° C. or 37° C.) on the polysaccharide concentration of PCV16 (0.128 mg / mL) or PCV21 (0.084 mg / mL or 0.169 mg / mL) formulations dispensed into prefilled syringes (see Example 39). [Figure 13] FIG. 1 shows the effect of PS concentration over time and temperature (up to 4 weeks at either 4° C., 25° C. or 37° C.) on the average molecular weight (Mw and Mn) of PCV16 (0.128 mg / mL) or PCV21 (0.084 mg / mL or 0.169 mg / mL) formulations using HPSEC-UV / MALS / RI. [Figure 14A] FIG. 1 shows the effect of time and temperature (up to 1 week at 4° C. or 37° C.) on the stability of pneumococcal conjugate vaccines (PCV15 formulated using all-aqueous conjugation) prepared with drug substances conjugated in protic solvents using intrinsic protein fluorescence spectroscopy at an excitation wavelength of 280 nm (see Example 40). [Figure 14B] FIG. 1 shows the effect of time and temperature (up to 1 week at 4° C. or 37° C.) on the stability of a pneumococcal conjugate vaccine (PCV16 formulated using all-DMSO conjugation at 0.064 mg / mL PnPs) prepared with a drug substance conjugated in an aprotic solvent using intrinsic protein fluorescence spectroscopy at an excitation wavelength of 280 nm (see Example 40). [Figure 15]Figure 1 shows ELISA IgG antibody dilution titers (post dose 2) of rabbits immunized with S. pneumoniae monovalent serotypes conjugated to CRM197 and formulated in aluminum phosphate adjuvant (APA). Symbols indicate individual antibody titers and error bars represent 95% confidence intervals (CI) of the geometric mean titers (GMT). [Figure 16] FIG. 1 shows serotype-specific OPA dilution antibody titers (post-dose 2) of rabbits immunized with S. pneumoniae monovalent serotypes conjugated to CRM197 and formulated in aluminum phosphate adjuvant (APA). Symbols indicate individual antibody titers and error bars represent 95% confidence intervals (CI) of the geometric mean titers (GMT). [Figure 17] Figure 1 shows ELISA IgG antibody dilution titers (after dose 2) of rabbits immunized with S. pneumoniae serotype 15 monovalent conjugate. The x-axis indicates the vaccine used to immunize the rabbits. The dashed lines separate three separate ELISA assays that used different pneumococcal polysaccharides as coating antigens. Symbols indicate individual antibody titers and error bars represent 95% confidence intervals (CI) of the geometric mean titers (GMT). [Figure 18] Serotype-specific OPA dilution antibody titers (pre-immunization, post-dose 1 (PD1, pooled) and post-dose 2 (PD2)) of rabbits immunized with S. pneumoniae serotype 15 monovalent conjugate. The X-axis indicates the vaccine used to immunize the rabbits. The dashed lines separate the three OPA assays using distinct S. pneumoniae strains. Symbols indicate individual antibody titers and error bars represent the 95% confidence interval (CI) of the geometric mean antibody titers (GMT). [Figure 19A] Figure 1 shows a comparison of PD1 antibody responses in NZWR (5 mice per group) following vaccination with 4, 2, 1, 0.4, 0.08 or 0.016 μg / dose of PCV21. Symbols indicate PD1 geometric mean titer (GMT) ratios (2 μg / dose group vs. other dose groups) and error bars represent 95% confidence intervals (CI). [Figure 19B]FIG. 19B shows PCV21 dose comparison PD1 GMT ratios (95% CI) corresponding to the GMT ratios in FIG. 19A, where GMT ratios whose lower 95% confidence limit is greater than 1.0 are in light grey and GMT ratios whose upper 95% confidence limit is less than 1.0 are in dark grey. Serotype 15B data are included to assess cross-protection. [Figure 20A] Figure 1 shows a comparison of PD2 antibody responses in NZWR (5 mice per group) after vaccination with 4, 2, 1, 0.4, 0.08 or 0.016 μg / dose of PCV21. Symbols indicate PD2 GMT ratios (2 μg / dose group vs. other dose groups) and error bars represent 95% CI. [Figure 20B] FIG. 20 shows PCV21 dose comparison PD2 GMT ratios (95% confidence intervals) corresponding to the GMT ratios in FIG. 20A where GMT ratios with their lower 95% confidence limit >1.0 are in light grey. Serotype 15B data are included to assess cross-protection. [Figure 21A] Figure 1 shows serotype-specific PD1 OPA dilution antibody titers in rabbits immunized with PCV21 (2 μg / PnPs). Symbols indicate individual antibody titers and error bars represent 95% confidence intervals (CI) of geometric mean titers (GMT). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 21B] Figure 1 shows serotype-specific PD2 OPA dilution antibody titers for rabbits immunized with PCV21 (2μg / PnPs). Symbols indicate individual antibody titers and error bars represent 95% confidence intervals (CI) of the geometric mean titers (GMT). ****p<0.0001. Serotype 15B data are included to assess cross-protection. [Figure 22A] FIG. 1 shows the effect of time and temperature (i.e., 4° C. for 7 days, 37° C. for 1 day, or 37° C. for 7 days) on the stability of pneumococcal conjugate vaccine (PCV1) prepared with all drug substances conjugated in aqueous or DMSO solvents using intrinsic protein fluorescence spectroscopy at an excitation wavelength of 280 nm. [Figure 22B]FIG. 1 shows the effect of time and temperature (i.e., 4° C. for 7 days, 37° C. for 1 day, or 37° C. for 7 days) on the stability of pneumococcal conjugate vaccine (PCV7) prepared with all drug substances conjugated in aqueous or DMSO solvents using intrinsic protein fluorescence spectroscopy at an excitation wavelength of 280 nm. [Figure 22C] FIG. 1 shows the effect of time and temperature (i.e., 4° C. for 7 days, 37° C. for 1 day, or 37° C. for 7 days) on the stability of pneumococcal conjugate vaccine (PCV14) prepared with all drug substances conjugated in aqueous or DMSO solvents using intrinsic protein fluorescence spectroscopy at an excitation wavelength of 280 nm. [Figure 22D] FIG. 1 shows the effect of time and temperature (i.e., 7 days at 4° C. or 37° C.) on the stability of 21-valent pneumococcal conjugate vaccine (PCV21 at 0.084 mg / mL PnPs) prepared with all drug substances conjugated in DMSO solvent using intrinsic protein fluorescence spectroscopy at an excitation wavelength of 280 nm. [Figure 23] FIG. 1 shows the effect of temperature (4° C. or 37° C. for 7 days) and agitation at 4° C. on particle size distribution as analyzed by nanoparticle tracking analysis (NTA) of six PCV21 pneumococcal conjugate vaccine formulations formulated with PS-20 (0%, 0.025%, 0.05%, 0.1%, 0.15% or 0.2%; all w / v PS-20) at 0.084 mg / mL PnPs. [Figure 24] Figure 1 shows the effect of temperature (4°C and 37°C) and agitation on the average molecular weight of three PCV21 formulations analyzed by HPSEC / UV / MALS / RI assay. The three PCV21 pneumococcal conjugate vaccine formulations were formulated with different concentrations of PS-20 (0.05%, 0.1% and 0.15% w / v) at 0.084 mg / mL PnPs. [Diagram 25] FIG. 1 shows that PCV21-immunized mice are protected from intratracheal challenge with S. pneumoniae 24F. [Figure 26A]FIG. 1 shows pre(pool), PD1(pool) and PD2 IgG antibody dilution titers determined by ECL for rabbits immunized with non-adjuvanted PCV21. [Figure 26B] Figure 1 shows Pre(pool), PD1(pool) and PD2 IgG antibody dilution titers as determined by ECL for rabbits immunized with PCV21 formulated with APA. Error bars represent 95% confidence intervals (CI) of the geometric mean titers (GMT). Serotype 15B data are included to assess cross-protection. [Figure 27A] FIG. 1 shows pre(pool), PD1(pool) and PD2 IgG antibody dilution titers determined by ECL for rabbits immunized with non-adjuvanted PCV8. [Figure 27B] FIG. 1 shows pre(pool), PD1(pool) and PD2 IgG antibody dilution titers determined by ECL for rabbits immunized with non-adjuvanted PCV16. [Figure 27C] Figure 1 shows Pre(pool), PD1(pool) and PD2 IgG antibody dilution titers as determined by ECL for rabbits immunized with PCV31 using APA. Error bars represent 95% confidence intervals (CI) of geometric mean titers (GMT). Serotype 15B data are included to assess cross-protection. [Figure 28] Figure 1 shows a comparison of PD2 ECL antibody responses in NZWR (5 mice per group) after vaccination with PCV21 with or without APA. Symbols indicate PD2 GMT ratios and error bars represent 95% CI. Serotype 15B data is included to assess cross-protection. [Figure 29] Figure 1 shows a comparison of PD2 ECL antibody responses in NZWR (5 per group) for common and cross-protective serotype 15B after vaccination with PCV21, PCV8 or PCV16. Symbols indicate PD2 ECL GMT ratios and error bars represent 95% CI. [Diagram 30]Figure 1 shows a comparison of PD2 ECL antibody responses in NZWR (5 mice per group) for common and cross-protective serotype 15B following vaccination with PCV21 / APA or PCV31 / APA. Symbols indicate PD2 ECL GMT ratios and error bars represent 95% CI. [Figure 31A] FIG. 1 shows serotype-specific pre-(pooled) OPA dilution antibody titers for rabbits immunized with PCV. [Figure 31B] FIG. 1 shows serotype-specific pre-(pooled) OPA dilution antibody titers for rabbits immunized with PCV. [Figure 31C] FIG. 1 shows serotype-specific PD2 OPA dilution antibody titers for rabbits immunized with PCV. [Figure 31D] Figure 1 shows serotype-specific PD2 OPA dilution antibody titers for rabbits immunized with PCV. Error bars represent 95% CI of GMT. PCV21 was used as the benchmark for statistical comparison. *p<0.05. Figures A and C show data for the eight common serotypes of all PCVs evaluated (6C, 15A, 16F, 23A, 23B, 24F, 31, 35B) and an additional eight common serotypes of PCV16, PCV21 and PCV31 (8, 9N, 10A, 11A, 12F, 15C, 17F, 20B). Figures B and D show data for an additional 16 serotypes not included in Figures A and C. Five of these serotypes are also common serotypes in PCV21 and PCV31 (3, 7F, 19A, 22F, 33F), and 10 serotypes are only found in PCV31 (1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F, 23F). Serotype 15B data are included to assess cross-protection. [Diagram 32] Figure 1 shows pre-, PD1, PD2 and PD3 IgG antibody dilution titers as determined by ECL for adult rhesus macaques (n=8) immunized with PCV21. Error bars represent 95% CI of GMT. Serotype 15B data are included to assess cross-protection. [Diagram 33]Figure 1 shows pre, PD1 (pooled) and PD3 OPA dilution antibody titers in adult rhesus macaques (n=8) immunized with PCV21. Error bars represent 95% CI of GMT. Serotype 15B data are included to assess cross-protection. [Diagram 34] FIG. 1 shows pre- and PD3 (day 70) OPA antibody titers against four serotypes not included in the PCV21 vaccine for adult rhesus macaques immunized with PCV21. [Diagram 35] Figure 1 shows a comparison of PD1 ECL antibody responses in adult rhesus macaques (5 per group) after vaccination with PCV21 with or without APA. Symbols indicate PD1 ECL GMT ratios (PCV21 vs. PCV21 / APA) and error bars represent 95% CI. Serotype 15B data are included to assess cross-protection. [Diagram 36] Figure 1 shows PD1 IgG antibody responses to serotypes 3, 7F, 19A, 22F and 33F in adult rhesus macaques (2-5 per group) following vaccination with PCV21 compared to PCV15 or Prevnar 13. Symbols indicate PD1 ECL GMT ratios and error bars represent 95% CI. [Figure 37A] FIG. 13 shows ELISA IgG antibody dilution titers against 6A, 6B and 6C ((pre-immune and PD1, pooled) and PD2) for rabbits immunized with 6A-CRM197 monovalent formulation. [Figure 37B] ELISA IgG antibody dilution titers for 6A, 6B and 6C (pre-immune and PD1, pooled) and PD2 for rabbits immunized with 6B-CRM197 monovalent formulation. Bars indicate geometric mean titers (GMT) and error bars indicate 95% confidence intervals (CI) of GMT. [Figure 38A] FIG. 13 shows serotype-specific OPA dilution antibody titers against 6A, 6B and 6C ((pre-immune and PD1, pooled) and PD2) for rabbits immunized with the 6A-CRM197 monovalent formulation. [Figure 38B]Serotype-specific OPA dilution antibody titers against 6A, 6B and 6C (pre-immune and PD1, pooled) and PD2) for rabbits immunized with the 6B-CRM197 monovalent formulation. Bars indicate geometric mean antibody titers (GMTs) and error bars indicate 95% confidence intervals (CIs) of the GMTs. [Figure 39A] FIG. 13 shows serotype-specific OPA dilution antibody titers against 20A and 20B (pre-immune (pooled), PD1 and PD2) for rabbits immunized with 20A-CRM197 / APA. [Figure 39B] FIG. 1 shows serotype-specific OPA dilution antibody titers for rabbits immunized with PCV21 against 20A and 20B (pre-immune (pooled), PD1 and PD2). Bars indicate geometric mean antibody titers (GMTs) and error bars indicate 95% confidence intervals (CIs) of the GMTs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The present invention is a multivalent immunogenic composition comprising a pneumococcal polysaccharide-protein conjugate. wherein each of the conjugates is a pneumococcal antibody conjugated to a carrier protein. (S. pneumoniae) serotype polysaccharides, where S. pneumoniae moniae) serotypes as defined herein. In an embodiment of the present invention, the immunogenic composition comprises: (a) 15A, 16F, 23A, 23B, 24F, 31 and 35B; (b) 15A, 16F, 23A, 23B, 24F, 31, 35B, 8 , 9N, 10A, 11A, 12F, 15C, 17F and 20; and (c) 3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8 , 9N, 10A, 11A, 12F, 15C, 17F and 20 In some embodiments, the immunogenic composition comprises a set of pneumococcal serotypes. 5A, 16F, 23A, 23B, 24F, 31 and 35B; (b) 15A, 16F, 2 3A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 1 7F and 20B; and (c) 3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, The set of pneumococcal serotypes selected from the group consisting of 17F and 20B. In the form, the immunogenic composition includes (a) 15A, 16F, 23A, 23B, 24F, 31, and and 35B;(b) 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N , 10A, 11A, 12F, 15C, 17F and 20A; and (c) 3, 7F, 19 A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9 Lungs selected from the group consisting of N, 10A, 11A, 12F, 15C, 17F and 20A In a further embodiment, the immunogenic composition comprises a set of Streptococcus pneumoniae serotypes. (ii) serotypes 6A and 6B; or (iii) serotype 6C. In one embodiment, the present invention provides a pneumococcal S. pneumoniae polysaccharide template. and protein conjugates, each of which is conjugated to a carrier protein. 10. The method of claim 1, further comprising administering to said patient a polysaccharide of a serovar S. pneumoniae which is juxtaposed to said polysaccharide of said serovar S. pneumoniae, The serotypes of Streptococcus pneumoniae are serotypes 3, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, The compositions include 23A, 23B, 24F, 31, 33F and 35B. It was immunogenic in mice and produced functional antibodies that killed vaccine-type bacterial strains at all doses tested. In another specific embodiment, the present invention provides a method for treating multiple pneumonia. comprising a polysaccharide-protein conjugate of the cocci Streptococcus pneumoniae (S. pneumoniae), Here, each of the conjugates is a pneumococcus (S. pneumoniae serotype polysaccharides, where S. pneumoniae iae) serotypes are serotypes 3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 1 1A, 12F, 15C, 17F, 20, 6A, 15A, 15C, 16F, 23A, 23B In another specific embodiment, the present invention provides a method for the preparation of a pneumocyte-specific antibody comprising administering to said patient a therapeutically effective amount of said antibody, ... The compound contains a polysaccharide-protein conjugate of the bacterium Streptococcus pneumoniae (S. pneumoniae), Here, each of the conjugates is a pneumococcus (S. pneumoniae) conjugated to a carrier protein. pneumoniae serotype polysaccharides, where S. pneumoniae iae) serotypes are serotypes 3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 1 1A, 12F, 15C, 17F, 20B, 6A, 15A, 15C, 16F, 23A, 23 In another specific embodiment, the present invention includes multiple pneumonia. comprising a polysaccharide-protein conjugate of the cocci Streptococcus pneumoniae (S. pneumoniae), wherein each of the conjugates comprises Streptococcus pneumoniae (S pneumoniae serotype polysaccharides, where S. pneumoniae niae) serotypes are serotypes 3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6A, 15A, 15C, 16F, 23A, 2 Includes 3B, 24F, 31 and 35B.
[0021] The multivalent immunogenic composition of the present invention is a vaccine-type S. pneumoniae serovar. and used different complementary pneumococcal vaccine(s) to immunize patients against serotypes. The present invention is therefore useful as part of a treatment regimen to induce a protective immune response in a human patient. A method for inducing a pulmonary edema comprising administering to a patient, in any order, a multivalent immunogenic composition of the invention. and further comprising the step of administering a multivalent pneumococcal vaccine to the patient. In another embodiment, the multivalent immunogenic composition of the invention is a method for the preparation of a multivalent pulmonary It is administered to patients who have been immunized with the pneumococcal vaccine.
[0022] In an embodiment of the invention, the conjugate from at least one pneumococcal serotype is D It is prepared using reductive amination in an aprotic solvent such as MSO. In embodiments, the multivalent immunogenic compositions each comprise a multivalent immunogen that is capable of undergoing reductive amination in an aprotic solvent. The pneumococcal conjugates were prepared using the method described above, each of which was reduced in an aprotic solvent. PCV1, PCV7, PCV14, PCV ... V16 and PCV21 (defined below) preparations are derived from carbohydrate depolymerization or chemical degradation. and is shown herein to be stable to protein aggregation in formulations. (See Example 40 and Example 45.) When DMSO solvent is used, the carrier tank Covalent association of polysaccharides with proteins through the direct consumption of lysine residues on the protein surface The increased covalent association was observed in polysaccharide antigens conjugated in DMSO. Increasing the stability of a polysaccharide-protein conjugate of a multivalent immunogenic composition comprising directly benefit.
[0023] I. Definitions and Abbreviations As used throughout this specification and the appended claims, the following abbreviations apply: R: APA Aluminum phosphate adjuvant APC antigen presenting cells CI Confidence Interval DMSO Dimethyl sulfoxide DS Polysaccharide-Protein Drug Substance GMC geometric mean concentration GMT Geometric mean titer HPSEC High Performance Size Exclusion Chromatography IM Intramuscular or intramuscularly LOS Lipooligosaccharide LPS lipopolysaccharide MALS multi-angle light scattering MBC Monovalent Bulk Conjugate MOPA multiplex opsonophagocytic assay MW molecular weight NMWCO Nominal Molecular Weight Cutoff NZWR New Zealand White Rabbit OPA opsonophagocytosis assay PCV Pneumococcal Conjugate Vaccine PD1 administration 1 day later PD2 after 2nd dose PnPs Pneumococcus polysaccharide Ps polysaccharide PS-20 Polysorbate-20 RI Refractive Index UV ultraviolet light w / v Weight per volume.
[0024] In order that the present invention may be more readily understood, certain technical and scientific terms are specifically defined below. Unless specifically defined elsewhere in this document, all techniques used herein are Technical and scientific terms have the meanings commonly understood by those of ordinary skill in the art to which this invention belongs. has.
[0025] As used throughout this specification and the appended claims, the singular forms "a," "a "n" and "the" are used to refer to plurals unless the context clearly indicates otherwise. Includes the target.
[0026] A reference to "or" means either, unless the context clearly indicates one of the possibilities indicated. Indicate either or both possibilities. In some cases, emphasize either or both possibilities. "And / or" is used here to illustrate the point.
[0027] The term "aqueous solvent" or "aqueous conditions" refers to a conjugation reaction such as reductive amination. When used in this context, it refers to the use of water as a solvent for the conjugation reaction. may contain buffers and other ingredients except that organic solvents are absent.
[0028] The terms "aprotic solvent", "DMSO solvent" or "DMSO conditions" refer to When used in conjugation such as selective amination, aprotic solvents, or combinations of aprotic solvents (or Aprotic solvents are used at concentrations up to, for example, 1%, 2%, 5% It may contain some water present, eg 10% or 20%.
[0029] The term "comprises" when used in reference to the immunogenic compositions of the present invention includes adjuvants and and the inclusion of other optional ingredients such as excipients, or one or more polysaccharides not specifically listed. The term "consists of" refers to the addition of polysaccharide-protein conjugates. - When used in protein conjugate mixtures, certain S. pneumoniae oniae polysaccharide-protein conjugates and other pneumococci of different serotypes (S pneumoniae) refers to a mixture that does not have polysaccharide-protein conjugates. "consists essentially of" and " "consist essentially of" or "consist essentially of "consisting essentially of" Such variations include the inclusion of a recited element or elements and the administration regimen, method or method specified. or composition of matter similar to the recited elements that do not materially change the basic or novel characteristics of the composition. The term indicates the optional inclusion of other elements of the same or different nature.
[0030] An "effective amount" of the composition of the present invention is an amount that is effective to inhibit or inhibit the proliferation of microorganisms, such as Streptococcus pneumoniae (S. pneumoniae) during a subsequent exposure. significantly increased the likelihood or severity of infection with It refers to the dose required to induce antibodies that reduce
[0031] As used herein, the term "required to prevent pneumococcal disease" means The phrase refers to a vaccine or immunogenic composition that has been approved for use by one or more regulatory agencies, such as the U.S. Food and Drug Administration. These include, but are not limited to, pneumococcal disease in general, pneumococcal pneumonia, pneumococcal meningitis pneumococcal bacteremia, caused by Streptococcus pneumoniae (S. pneumoniae) Invasive disease and middle ear infection caused by S. pneumoniae pneumonia caused by any serotype of Streptococcus pneumoniae, including pneumonia "Any medical device approved for use in treating a medical condition or for preventing one or more of the conditions listed in this section is considered to be a medical condition or for preventing ...."
[0032] A "multivalent pneumococcal vaccine" is a vaccine that contains two or more strains of pneumococcus (S. pneumoniae). Provides active immunity against a disease or pathological condition caused by a serotype, two or more The active agent (e.g., pneumococcal capsular polysaccharide or pneumococcal polysaccharide protein conjugate) It is a medicine that contains
[0033] The term "polysaccharide" refers to any of the antibodies commonly used in immunology and bacterial vaccine technology. "Sugar" is meant to include, but is not limited to, raw sugar elements (or antigenic units); "Oligosaccharides", "polysaccharides" or "lipopolysaccharides", "lipooligosaccharides (LOS)", "lipopolysaccharides" (LPS), glycosylate, and glycoconjugate This includes "ate" etc.
[0034] "PCV1" as used herein refers to a PCV1 conjugated to a carrier protein. One pneumococcus (S. pneumoniae) containing capsular polysaccharide of the serotype Monovalent pneumococcal conjugates containing Streptococcus pneumoniae polysaccharide-protein conjugates A gate vaccine, in which the serotype of pneumococcus (S. pneumoniae) is 3 In certain embodiments, the vaccine is The body protein is CRM197.
[0035] "PCV7" as used herein refers to a PCV7 vector conjugated to a carrier protein. Seven pneumococci containing capsular polysaccharides of the identified S. pneumoniae serotypes Heptavalent pneumococcal vaccine containing S. pneumoniae polysaccharide-protein conjugate A conjugate vaccine comprising a serogroup containing S. pneumoniae The types are 3, 8, 9N, 11A, 19A, 15A and 10A. , carrying one or more of the S. pneumoniae polysaccharide-protein conjugates In a further embodiment, the body protein is CRM197. oniae) polysaccharide-protein conjugates, each of which has a carrier protein of CRM197. be.
[0036] "PCV8" as used herein refers to a PCV vaccine that is conjugated to a carrier protein. Eight pneumococci containing capsular polysaccharides of the identified S. pneumoniae serotypes Octavalent pneumococcal vaccine containing S. pneumoniae polysaccharide protein conjugate A conjugate vaccine comprising a serogroup containing S. pneumoniae The types are 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B. In one embodiment, a S. pneumoniae polysaccharide protein conjugate is In a further embodiment, the one or more carrier proteins of the pneumococcus ( Each carrier protein of the S. pneumoniae polysaccharide-protein conjugate It's CRM197.
[0037] "PCV14," as used herein, refers to a PCV14 vector, each of which is conjugated to a carrier protein. Fourteen pneumoniae strains containing capsular polysaccharides of the identified S. pneumoniae serotypes were 14-valent pneumococcus containing S. pneumoniae polysaccharide-protein conjugate A bacterial conjugate vaccine, comprising: Serotypes are 3, 7F, 8, 9N, 10A, 11A, 12F, 15A, 16F, 17F, and 19 A, 20, 22F and 33F. In a specific embodiment, the pneumococcus moniae) polysaccharide-protein conjugates, one or more of which is a carrier protein, CRM19 7. In a further embodiment, the S. pneumoniae polysaccharide protein The carrier protein for each of the protein conjugates is CRM197.
[0038] "PCV15," as used herein, refers to a PCV15 vector, each of which is conjugated to a carrier protein. 15 pneumoniae strains containing capsular polysaccharides of the identified S. pneumoniae serotypes 15-valent pneumococcus containing S. pneumoniae polysaccharide-protein conjugate A bacterial conjugate vaccine, comprising: Serotypes are 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 2 2F, 23F and 33F. In a specific embodiment, the niae) One or more carrier proteins of the polysaccharide-protein conjugate are CRM197 In a further embodiment, the S. pneumoniae polysaccharide protein The carrier protein in each of the conjugates is CRM197.
[0039] "PCV16," as used herein, refers to a PCV vaccine that is conjugated to a carrier protein. Sixteen pneumonia samples containing capsular polysaccharides of the identified S. pneumoniae serotypes were 16-valent pneumococcus containing S. pneumoniae polysaccharide-protein conjugate A bacterial conjugate vaccine, comprising: Serotypes are 6C, 8, 9N, 10A, 11A, 12F, 15A, 16F, 17F, 20A, 23A, 23B, 24F, 31 and 35B and the following serogroup 15 serotypes: 15B , 15C or de-O-acetylated 15B. In certain embodiments, The serotype of serogroup 15 is serotype 15C or de-O-acetylated 15B. As shown (see Example 3 below), de-O-acetylated serotype 15B pneumococcal polysaccharide is equivalent to the serotype 15C pneumococcal polysaccharide and has an identical NMR spectrum. In a preferred embodiment, a S. pneumoniae polysaccharide protein conjugate is In a further embodiment, the one or more carrier proteins of the pneumococcus Each carrier protein of the S. pneumoniae polysaccharide-protein conjugate is CRM197.
[0040] "PCV21," as used herein, refers to a PCV21 vector, each of which is conjugated to a carrier protein. Twenty-one pneumoniae strains containing capsular polysaccharides of the identified S. pneumoniae serotypes were 21-valent pneumococcus containing S. pneumoniae polysaccharide-protein conjugate A bacterial conjugate vaccine, comprising: Serotypes are 3, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 16F, and 17F. , 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B and and at least one of the following serogroup 15 serotypes: 15B, 15C, or de-O-acetylated 15B. In a specific embodiment, the serotype of serogroup 15 is serotype 15C or de-O- In a specific embodiment, the 15B is acetylated 15B. ) One or more carrier proteins of the polysaccharide-protein conjugate is CRM197. In a further embodiment, the S. pneumoniae polysaccharide protein conjugate The carrier protein for each of the gates is CRM197.
[0041] S. pneumoniae serotypes 20A and 20B have been identified by genetic analysis. It was identified in serogroup 20 in 2012 (Calix, JJ et al., JB iol.Chem.(2012)287(33):27885-27894). Cali As discussed by JJ et al., traditional serotyping methods and commercially available antibodies These two serotypes could not be distinguished previously, and serotyping of serotypes 20A and 20B was There is currently limited information on the prevention and control of serogroup 20. The prevalence of 20A or 20B disorders within the identified disorders is not fully understood. Thus, one of skill in the art would be able to incorporate this into a S. pneumoniae vaccine composition. The inclusion of either or both of these two serotypes (20A and / or 20B) On the other hand, serotype 20 polysaccharide antigen-containing S. pneumoniae It is also possible that the niae vaccine may be cross-protective against other serotypes ( For example, the polysaccharide protein conjugate of S. pneumoniae serotype 20A A vaccine containing serotype 20B polysaccharide-protein conjugate and not serotype 20B polysaccharide-protein conjugate was , cross-protection against infection with S. pneumoniae serotype 20B Thus, as used herein, "serotype 20" includes serotypes 20A and 20B. and / or a composition comprising a polysaccharide-protein conjugate of serotype 20B.
[0042] "CpG-containing nucleotide", "CpG-containing oligonucleotide", "CpG oligonucleotide" "Nucleotide" and similar terms refer to a sequence of 6 to 50 nucleotides that contains an unmethylated CpG moiety. For example, Wang et al., 2003, Vaccine See, for example, U.S. Pat. No. 21:4297. CpG-containing oligonucleotides may be synthetic nucleosides. These include modified oligonucleotides using inter-chain linkages, modified bases and / or modified sugars.
[0043] As defined herein, an "adjuvant" is an agent that enhances the immunogenicity of the immunogenic composition of the invention. Immune adjuvants are substances that help to improve immunity by inhibiting immune responses to certain antigens. For example, immunity to an antigen that induces no or weak antibody titers or cell-mediated immune responses enhance the response, increase the antibody titer to an antigen, and / or achieve an immune response in an individual Thus, adjuvants can reduce the effective dose of antigen required to produce a It is typically given to enhance the immune response and is well known to those skilled in the art.
[0044] A "patient" (or "subject" as used herein) is a person infected with Streptococcus pneumoniae (S. pneumoniae). In a preferred embodiment, the patient is a human. Patients can be treated prophylactically or therapeutically. Prophylactic treatment is with pneumococcal Sufficient to reduce the likelihood or severity of an infection or its effects, e.g., pneumococcal pneumonia Therapeutic treatment provides sufficient protective immunity against S. pneumoniae infections. Or it may be performed to reduce the severity of its clinical effects or prevent recurrence. As described herein, the multivalent immunogenic compositions of the invention can be used to perform prophylactic treatments. The compositions of the invention can be administered to the general population or to individuals at high risk for pneumococcal infection. people, such as older people or those who live with or care for older people The drug can be administered individually.
[0045] Those who "need treatment" include those who have had previous exposure to S. pneumoniae or or infected with pneumococcus, or those who have previously been vaccinated against S. pneumoniae People who have been infected, as well as people who are prone to infection or for whom it is desirable to reduce the chance of infection, such as Examples include immunocompromised, elderly, children, adults or healthy individuals.
[0046] A "stable" multivalent immunogenic composition is one that is stable at least at refrigerated temperatures (e.g., 2-8°C or 4°C). Significant changes at 1 month, 2 months, 3 months, 6 months, 12 months, and / or 24 months Further, a "stable" composition is one in which no observed Temperature over periods including 1 month, 3 months, 6 months, 12 months and / or 24 months. Typical acceptance criteria for stability are as follows: The variation of the above is about 5%, about 10%, about 15%, or about 20% or less: (a) in the composition Number-average molecular weight of S. pneumoniae polysaccharide-protein conjugates (Mn), (b) the amount of pneumococcal (S. pneumoniae) polysaccharide protein cofactor in the composition (c) the weight average molecular weight (Mw) of the conjugate; (d) the total polysaccharide concentration in the composition; Compositions measured using intrinsic protein fluorescence spectroscopy at an excitation wavelength, e.g., 280 nm. and (e) measured using intrinsic protein fluorescence spectroscopy at specific excitation wavelengths. The term "stable" also refers to the degree of specificity of a multivalent immunogenic composition. It may also be used to refer to pneumococcal conjugates. The term refers to a conjugate that exhibits a desired property over time at a particular temperature, such property being , about 5%, about 10%, about 15%, or about 20% or less over the times and temperatures recited Only it changes.
[0047] II. Multivalent Immunogenic Compositions The present invention relates to a multi-polysaccharide protein conjugate of S. pneumoniae. A multivalent immunogenic composition comprising a conjugate, wherein each of the conjugates is linked to a carrier protein. Contains polysaccharides of S. pneumoniae serotypes conjugated to a substrate Different aspects and embodiments of the multivalent immunogenic compositions of the invention are described below. Posted.
[0048] In one embodiment (embodiment E1), the invention provides a method for the preparation of medicaments comprising administering to said patient a therapeutically effective amount of a medicament, each of which is conjugated to a carrier protein. Multiple pneumococci, including capsular polysaccharides of selected S. pneumoniae serotypes, Polyvalent immunogenic compositions containing S. pneumoniae polysaccharide-protein conjugates wherein the serotype of pneumococcus (S. pneumoniae) is (1) 15A, (2) 16F, (3) (a) 23A and 23B, (b) 23A and 23F, (c) 23B and 2 One or more serogroups selected from 3F, (d) 23A, (e) 23B, and (f) 23F 23 serotypes, (4) 24F, (5)31, and (6)35B The present invention provides a composition comprising, consisting of, or consisting essentially of:
[0049] In a subembodiment of embodiment E1, the one or more serotypes of serogroup 23 are 23A and 23B and 23B (i.e., no other serogroup 23 serotypes are present). In one subembodiment, the one or more serogroup 23 serotypes are 23A and 23F. In another subembodiment of form E1, one or more of the serogroup 23 serotypes are 23B and 23F. In yet another subembodiment of embodiment E1, 23A is the only serotype of serogroup 23. In a further subembodiment of embodiment E1, 23B is the only serotype of serogroup 23. In yet a further subembodiment of embodiment E1, 23F is the only serogroup 23 serogroup It is a Kiyoshi type.
[0050] In a second embodiment (embodiment E2), the present invention provides a method for the preparation of a medicament for the treatment of cancer, comprising the steps of: Multiple pneumococci, including capsular polysaccharides of selected S. pneumoniae serotypes Multivalent immunogenic compositions comprising S. pneumoniae polysaccharide-protein conjugates The method of claim 1, wherein the serotype of S. pneumoniae is or any subembodiment of embodiment E1, comprising a serotype: (1) (1) 6C; (2) 6A; or (3) 6A and 6B.
[0051] In a subembodiment of embodiment E2, the composition comprises serotype 6C. In a further subembodiment, the composition comprises serotypes 6A and 6B, and does not comprise serotype 6C. In another subembodiment of embodiment E2, the composition comprises serotype 6A.
[0052] In a third embodiment (embodiment E3), the present invention provides a method for the preparation of a medicament for the treatment of cancer, comprising the steps of: Multiple pneumococci, including capsular polysaccharides of selected S. pneumoniae serotypes Multivalent immunogenic compositions comprising S. pneumoniae polysaccharide-protein conjugates The method of claim 1, wherein the serotype of S. pneumoniae is or any subembodiment of embodiment E1, or embodiment E2, or embodiment E2, including any of the serotypes set forth in any of the subembodiments thereof, and including the serotype: (1)8, (2) 9N, (3) 11A (4) 12F, (5) 15B or 15C, (6) 17F, and (7) 20A and / or 20B The composition further comprises:
[0053] In a fourth embodiment (embodiment E4), the present invention provides a method for the preparation of a medicament for the treatment of cancer, comprising administering to said patient a therapeutically effective amount of said medicament ... Multiple pneumococci, including capsular polysaccharides of selected S. pneumoniae serotypes Multivalent immunogenic compositions comprising S. pneumoniae polysaccharide-protein conjugates The method of claim 1, wherein the serotype of S. pneumoniae is -E3 or any subembodiment thereof, and , serotype: 10A or 39.
[0054] In a fifth embodiment (embodiment E5), the present invention provides a method for the preparation of a pneumococcus strain as described above. 1. A multivalent immunogenic composition comprising a M. umoniae polysaccharide-protein conjugate, Here, the serotypes of pneumococcus (S. pneumoniae) are 8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 3 The present invention provides a composition comprising, consisting of, or consisting essentially of 1 and 35B.
[0055] In a sixth embodiment (embodiment E6), the present invention provides a method for the preparation of a pneumococcus strain comprising the steps of: 1. A multivalent immunogenic composition comprising a M. umoniae polysaccharide-protein conjugate, Here, the serotypes of pneumococcus (S. pneumoniae) are 8, 9N, 39, 11A, 1 2F, 15C, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B.
[0056] In a seventh embodiment (embodiment E7), the present invention provides a method for the preparation of a pneumococcus strain as described above. 1. A multivalent immunogenic composition comprising a M. umoniae polysaccharide-protein conjugate, Here, the serotypes of pneumococcus (S. pneumoniae) are 8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 3 The present invention provides a composition comprising, consisting of, or consisting essentially of 1 and 35B.
[0057] In an eighth embodiment (embodiment E8), the present invention provides a method for the preparation of a pneumococcus strain comprising the steps of: 1. A multivalent immunogenic composition comprising a M. umoniae polysaccharide-protein conjugate, Here, the serotypes of pneumococcus (S. pneumoniae) are 8, 9N, 39, 11A, 1 2F, 15B, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B.
[0058] In a ninth embodiment (embodiment E9), the present invention provides a method for the preparation of a pneumococcus strain as described above. 1. A multivalent immunogenic composition comprising a M. umoniae polysaccharide-protein conjugate, Wherein the S. pneumoniae serotype is any of the embodiments E1 to E8 (or and any subembodiment thereof), and serotype: 3 The composition further comprises:
[0059] In a tenth embodiment (embodiment E10), the present invention provides a method for the preparation of a plurality of pneumococci (Sp The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. Wherein the S. pneumoniae serotype is any of the embodiments E1 to E9 (or or any subembodiment thereof), and The composition further comprises 22F.
[0060] In an eleventh embodiment (embodiment E11), the present invention relates to a method for the preparation of a plurality of pneumococci (Sp The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. Wherein, the pneumococcus (S. pneumoniae) serotype is any of the embodiments E1 to E10 ( or any subembodiment thereof), and A composition is provided which further comprises Form 33F.
[0061] In a twelfth embodiment (embodiment E12), the present invention relates to a method for the preparation of a plurality of pneumococci (Sp The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. Here, the serotype of pneumococcus (S. pneumoniae) is (1) 15A, 16F, 23A, 23B, 24F, 31 and 35B, (2) 15A, 16F, 23F, 23B, 24F, 31 and 35B, (3) 15A, 16F, 23A, 23F, 24F, 31 and 35B, (4) 15A, 16F, 23A, 24F, 31 and 35B, (5) 15A, 16F, 23B, 24F, 31 and 35B, (6) 15A, 16F, 23F, 24F, 31 and 35B, (7) 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (8) 6C, 15A, 16F, 23F, 23B, 24F, 31 and 35B, (9) 6C, 15A, 16F, 23A, 23F, 24F, 31 and 35B, (10) 6C, 15A, 16F, 23A, 24F, 31 and 35B, (11) 6C, 15A, 16F, 23B, 24F, 31 and 35B, (12) 6C, 15A, 16F, 23F, 24F, 31 and 35B, (13) 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (14) 6A, 15A, 16F, 23F, 23B, 24F, 31 and 35B, (15) 6A, 15A, 16F, 23A, 23F, 24F, 31 and 35B, (16) 6A, 15A, 16F, 23A, 24F, 31 and 35B, (17) 6A, 15A, 16F, 23B, 24F, 31 and 35B, (18) 6A, 15A, 16F, 23F, 24F, 31 and 35B, (19) 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (20) 6A, 6B, 15A, 16F, 23F, 23B, 24F, 31 and 35B, (21) 6A, 6B, 15A, 16F, 23A, 23F, 24F, 31 and 35B, (22) 6A, 6B, 15A, 16F, 23A, 24F, 31, and 35B, (23) 6A, 6B, 15A, 16F, 23B, 24F, 31, and 35B, and (24) 6A, 6B, 15A, 16F, 23F, 24F, 31, and 35B The set of S. pneumoniae serotypes selected from the group consisting of The present invention provides a composition comprising, consisting of, or consisting essentially of.
[0062] In a thirteenth embodiment (embodiment E13), the present invention relates to a method for the preparation of a plurality of pneumococci (Sp The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. Here, the serotype of pneumococcus (S. pneumoniae) is (1)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (2)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 6C, 15A, 1 6F, 23A, 23B, 24F, 31 and 35B, (3)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (4)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 6C, 15A, 1 6F, 23A, 23B, 24F, 31 and 35B, (5)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 15A, 16F , 23A, 23B, 24F, 31 and 35B, (6)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6A, 6B, 1 5A, 16F, 23A, 23B, 24F, 31 and 35B, (7)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (8)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (9)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 6A, 6B, 15 A, 16F, 23A, 23B, 24F, 31 and 35B, (10)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (11)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 15A, 16 F, 23A, 23B, 24F, 31 and 35B, (12)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (13)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6A, 15A , 16F, 23A, 23B, 24F, 31 and 35B, (14)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 15A, 16F , 23A, 23B, 24F, 31 and 35B, (15)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 6A, 6B, 1 5A, 16F, 23A, 23B, 24F, 31 and 35B, (16)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (17)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6C, 15A , 16F, 23F, 24F, 31 and 35B, (18)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 6C, 15A, 16F, 23F, 24F, 31 and 35B, (19)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6C, 15A , 16F, 23F, 24F, 31 and 35B, (20)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 6C, 15A, 16F, 23F, 24F, 31 and 35B, (21)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 15A, 16 F, 23F, 24F, 31 and 35B, (22)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6A, 6B, 15A, 16F, 23F, 24F, 31 and 35B, (23)8, 9N, 10A, 11A, 12F, 15C, 17F, 20A, 6A, 15A , 16F, 23F, 24F, 31 and 35B, (24)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 15A, 16F , 23F, 24F, 31 and 35B, (25)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 6A, 6B, 1 5A, 16F, 23F, 24F, 31 and 35B, (26)8, 9N, 39, 11A, 12F, 15C, 17F, 20A, 6A, 15A, 16F, 23F, 24F, 31 and 35B, (27)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 15A, 16 F, 23F, 24F, 31 and 35B, (28)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6A, 6B, 15A, 16F, 23F, 24F, 31 and 35B, (29)8, 9N, 10A, 11A, 12F, 15B, 17F, 20A, 6A, 15A , 16F, 23F, 24F, 31 and 35B, (30)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 15A, 16F , 23F, 24F, 31 and 35B, (31)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 6A, 6B, 1 5A, 16F, 23F, 24F, 31 and 35B, and (32)8, 9N, 39, 11A, 12F, 15B, 17F, 20A, 6A, 15A, 16F, 23F, 24F, 31 and 35B The set of S. pneumoniae serotypes selected from the group consisting of The present invention provides a composition comprising, consisting of, or consisting essentially of.
[0063] A thirteenth embodiment (embodiment E13) provides a method for the preparation of a S. pneumoniae serum The present invention further includes a set of serotype rows (1) to (32), wherein serotype 20A in each set is It is replaced by either serotype 20 or serotype 20B.
[0064] In a fourteenth embodiment (embodiment E14) of the invention, the present invention relates to a method for the preparation of a pneumococcal Multivalent immunogenic compositions comprising S. pneumoniae polysaccharide-protein conjugates The product, wherein the S. pneumoniae serotype is as described in embodiment E13. Streptococcus pneumoniae ( A set of S. pneumoniae serovars, consisting of, or consisting essentially of The present invention provides a composition further comprising serotypes 23A and / or 23B.
[0065] In a fifteenth embodiment (embodiment E15), the present invention provides a method for the preparation of a plurality of pneumococci (Sp The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. Here, the serotype of pneumococcus (S. pneumoniae) is (1)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 15 C, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35 B. (2)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15C , 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B , (3)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 15 B, 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35 B. (4)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15B , 17F, 20A, 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B , (5)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 15 C, 17F, 20A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (6)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 15 C, 17F, 20A, 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and and 35B, (7)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 15 C, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35 B. (8)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15C , 17F, 20A15A, 16F, 23A, 23B, 24F, 31 and 35B, (9)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15C , 17F, 20A, 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (10)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 C, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35 B. (11)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (12)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (13)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 3 5B, (14)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 15A, 16F, 23A, 23B, 24F, 31 and 35B, (15)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and and 35B, (16)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35 B. (17)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5C, 17F, 20A, 6C, 15A, 16F, 23F, 24F, 31 and 35B, (18)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 C, 17F, 20A, 6C, 15A, 16F, 23F, 24F, 31 and 35B, (19)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 6C, 15A, 16F, 23F, 24F, 31 and 35B, (20)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 6C, 15A, 16F, 23F, 24F, 31 and 35B, (21)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5C, 17F, 20A, 15A, 16F, 23F, 24F, 31 and 35B, (22)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5C, 17F, 20A, 6A, 6B, 15A, 16F, 23F, 24F, 31 and 35 B. (23)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5C, 17F, 20A, 6A, 15A, 16F, 23F, 24F, 31 and 35B, (24)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 C, 17F, 20A, 15A, 16F, 23F, 24F, 31 and 35B, (25)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 C, 17F, 20A, 6A, 6B, 15A, 16F, 23F, 24F, 31 and 35B , (26)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 C, 17F, 20A, 6A, 15A, 16F, 23F, 24F, 31 and 35B, (27)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 15A, 16F, 23F, 24F, 31 and 35B, (28)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 6A, 6B, 15A, 16F, 23F, 24F, 31 and 35 B. (29)3, 7F, 19A, 22F, 33F, 8, 9N, 10A, 11A, 12F, 1 5B, 17F, 20A, 6A, 15A, 16F, 23F, 24F, 31 and 35B, (30)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 15A, 16F, 23F, 24F, 31 and 35B, (31)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 6A, 6B, 15A, 16F, 23F, 24F, 31 and 35B , (32)3, 7F, 19A, 22F, 33F, 8, 9N, 39, 11A, 12F, 15 B, 17F, 20A, 6A, 15A, 16F, 23F, 24F, 31 and 35B, (33)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0B, (34)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0A, (35)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0B, (36)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0B, (37)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0A, (38)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0B, (39)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0 (40)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0 (41)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0 (42)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0 (43)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0, and (44)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24B, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0 The set of S. pneumoniae serotypes selected from the group consisting of The present invention provides a composition comprising, consisting of, or consisting essentially of.
[0066] In a sixteenth embodiment (embodiment E16) of the invention, the present invention relates to a method for the preparation of a pneumococcal Multivalent immunogenic compositions comprising S. pneumoniae polysaccharide-protein conjugates The product, wherein the S. pneumoniae serotype is as described in embodiment E15. Streptococcus pneumoniae ( A set of S. pneumoniae serovars, consisting of, or consisting essentially of The present invention provides a composition further comprising serotypes 23A and / or 23B.
[0067] In a seventeenth embodiment (embodiment E17), the present invention relates to a method for the preparation of a medicament for the treatment of cancer, comprising the steps of: Multiple pneumoniae strains containing capsular polysaccharides of the identified S. pneumoniae serotypes Multivalent immunogenicity containing S. pneumoniae polysaccharide-protein conjugates A composition, wherein the serotype of S. pneumoniae is i.6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B, ii.6C, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 1 0A, 11A, 12F, 15C, 17F and 20A, and iii.3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0A The present invention provides a composition comprising a set of serotypes selected from the group consisting of:
[0068] In a subembodiment of embodiment E17, the immunogenic composition comprises a further pneumococcus (S. pneumoniae eumoniae) polysaccharide-protein conjugates.
[0069] In an eighteenth embodiment (embodiment E18), the present invention relates to a method for the treatment of Streptococcus pneumoniae (S. pneumoniae iae) pods of serotypes 6C, 15A, 16F, 23A, 23B, 24F, 31, and 35B Multiple S. pneumoniae polysaccharide-protein conjugates, including membrane polysaccharides In a subembodiment of embodiment E18, a multivalent immunogenic composition is provided comprising a gate. The probiotic composition contains additional S. pneumoniae polysaccharide protein conjugates. Does not include ugate.
[0070] In a nineteenth embodiment (embodiment E19), the present invention relates to a method for the treatment of Streptococcus pneumoniae (S. pneumoniae iae) serotypes 6C, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9 Multiple pulmonary granulocytes containing capsular polysaccharides N, 10A, 11A, 12F, 15C, 17F, and 20A Polyvalent immunogens containing S. pneumoniae polysaccharide-protein conjugates In a subembodiment of embodiment E19, the immunogenic composition further comprises Does not contain S. pneumoniae polysaccharide-protein conjugates.
[0071] In a twentieth embodiment (embodiment E20), the present invention relates to a method for the treatment of Streptococcus pneumoniae (S. pneumoniae). iae) serotypes 3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 2 3B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and Multiple pneumococcal (S. pneumoniae) polysaccharide proteins, including capsular polysaccharides of 20A and 20B, are identified. A multivalent immunogenic composition comprising the protein conjugate is provided. In some embodiments, the immunogenic composition further comprises a S. pneumoniae polysaccharide protein. Contains no protein conjugates.
[0072] In another embodiment, the present invention relates to S. pneumoniae serotype 3, 7F , 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 3 Capsular polysaccharides of 5B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20A Contains multiple S. pneumoniae polysaccharide-protein conjugates Subembodiments of this embodiment (i.e., 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35 B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20A) were immunogenic. The composition may further comprise a S. pneumoniae polysaccharide-protein conjugate. Does not include the
[0073] In another embodiment, the present invention relates to S. pneumoniae serotype 3, 7F , 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 3 Contains capsular polysaccharides 5B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20. Contains multiple pneumococcal (S. pneumoniae) polysaccharide-protein conjugates Multivalent immunogenic compositions are provided. Subembodiments of this embodiment (i.e., 3, 7F, 1 9A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B , 8, 9N, 10A, 11A, 12F, 15C, 17F and 20) immunogenic composition The subject invention relates to a further S. pneumoniae polysaccharide-protein conjugate. Does not include.
[0074] In another embodiment, the present invention relates to S. pneumoniae serotype 3, 7F , 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 3 Capsular polysaccharides of 5B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20B Contains multiple S. pneumoniae polysaccharide-protein conjugates Subembodiments of this embodiment (i.e., 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35 B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20B) The composition may further comprise a S. pneumoniae polysaccharide-protein conjugate. Does not include the
[0075] As shown herein (see Example 3 below), de-O-acetylated serotype 15B lung The pneumococcal polysaccharide is equivalent to the serotype 15C pneumococcal polysaccharide and has an identical NMR spectrum. The de-O-acetylated serotype 15B pneumococcal polysaccharides described and disclosed herein is equivalent to serotype 15C pneumococcal polysaccharide, both in the range of 0-5% or 0-4%. % range, or 0-3% range, or 0-2% range, or 0-1% range, or O-acetyl content per repeat unit in the range of 0-0.5%, or 0-0.1% In a report by Spencer BL et al. may be slightly O-acetylated at 15C (Spencer, Blett, al., Clin.Vac.Immuno.(2017)24(8):1-13). death Thus, in any of the embodiments of the multivalent immunogenic compositions herein, instead of serotype 15C, Alternatively, de-O-acetylated serotype 15B can be used. The method for de-O-acetylation is For example, Rajam et al., Clinical and Vaccine I As described in immunology, 2007, 14(9):1223-1227 are known in the art.
[0076] Multivalent immunogens of the invention, including embodiments E1 to E20 and any subembodiments thereof In certain embodiments of any of the compositions, the composition further comprises a pharma- ceutically acceptable carrier. include.
[0077] Cross-reactivity In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is S. pneumoniae, including serotype 6C conjugated to a carrier protein iae) serotype polysaccharides, where the serotype of S. pneumoniae Type 6C is cross-reactive with serotypes 6A and 6B of S. pneumoniae. Compositions are provided that provide protection.
[0078] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 6C conjugated to a carrier protein. The polysaccharides of the S. pneumoniae serotype include Serotype 6C of S.pneumoniae is a type of The present invention provides a composition that provides cross-protection against serotypes 6A and 6B of H. pylori.
[0079] In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is a carrier. S. pneumoniae, including serotype 19A conjugated to body proteins iae) serotype polysaccharides, where the serotype of S. pneumoniae Serotype 19A provides cross-protection against serotype 19F of S. pneumoniae. A composition is provided.
[0080] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 19 antibody conjugated to a carrier protein. A polysaccharide of S. pneumoniae serotype A, Serotype 19A of S. pneumoniae is a type of e) provides a composition that provides cross-protection against serotype 19F.
[0081] In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is a carrier. Streptococcus pneumoniae containing serotypes 23A and / or 23B conjugated to body proteins (S. pneumoniae) serotype polysaccharides, where S. pneumoniae moniae serotypes 23A and / or 23B are The present invention provides a composition that provides cross-protection against serotype 23F of S. iae.
[0082] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 23 antibody conjugated to a carrier protein. Polysaccharides of S. pneumoniae serotypes including A and / or 23B wherein the serotypes 23A and / or 23B of S. pneumoniae are 3B provides cross-protection against serotype 23F of S. pneumoniae The present invention provides a composition for
[0083] In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is a carrier. S. pneumoniae containing serotype 6A conjugated to body proteins ae) serotype polysaccharides, where serotypes of S. pneumoniae 6A is for serotypes 6B and / or 6C of S. pneumoniae. The present invention provides compositions that provide cross-protection against
[0084] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 6A conjugated to a carrier protein. The polysaccharides of the S. pneumoniae serotype include Serotype 6A of S.pneumoniae is a type of The present invention provides compositions that provide cross-protection against serotypes 6B and / or 6C of H. pylori.
[0085] In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is a carrier. S. pneumoniae, including serotype 20A conjugated to body proteins iae) serotype polysaccharides, where the serotype of S. pneumoniae Serotype 20A provides cross-protection against serotype 20B of S. pneumoniae. A composition is provided.
[0086] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 20 conjugated to a carrier protein. A polysaccharide of S. pneumoniae serotype A, Serotype 20A of S. pneumoniae is a type of e) a composition that provides cross-protection against serotype 20B.
[0087] In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is a carrier. S. pneumoniae, including serotype 20B conjugated to body proteins iae) serotype polysaccharides, where the serotype of S. pneumoniae Serotype 20B provides cross-protection against serotype 20A of S. pneumoniae. A composition is provided.
[0088] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 20 conjugated to a carrier protein. pneumoniae serotype B, Serotype 20B of S. pneumoniae is a type of e) a composition that provides cross-protection against serotype 20A.
[0089] In one embodiment, the present invention provides a S. pneumoniae polysaccharide protein. A multivalent immunogenic composition comprising conjugates, wherein each of the conjugates is a carrier. S. pneumoniae containing serotype 15C conjugated to body proteins iae) serotype polysaccharides, where the serotype of S. pneumoniae Serotype 15C provides cross-protection against serotype 15B of S. pneumoniae. A composition is provided.
[0090] In another embodiment, the present invention relates to a method for treating Streptococcus pneumoniae (Sp) selected from embodiments E1 to E20. The present invention relates to a multivalent immunogenic composition comprising a polysaccharide-protein conjugate of B. neumoniae. wherein each of the conjugates is a serotype 15 antibody conjugated to a carrier protein. C, wherein the polysaccharides of S. pneumoniae serotypes include Serotype 15C of S. pneumoniae is a type of e) a composition that provides cross-protection against serotype 15B.
[0091] Carrier Proteins In a particular embodiment of the invention, CRM197 is used as the carrier protein. M197 has the following amino acid sequence: GADDVVDSSK SFVMENFSSY HGTKPGYVDS IQKGIQ KPKS GTQGNYDDDW KEFYSTDNKY DAAGYSVDNE NP LSGKAGGV VKVTYPGLTK VLALKVDNAE TIKKELGLS L TEPLMEQVGT EEFIKRFGDG ASRVVLSLPF AEGSS SVEYI NNWEQAKALS VELEINFETR GKRGQDAMYE Y MAQACAGNR VRRSVGSSLS CINLDWDVIR DKTKTKIE SL KEHGPIKNKM SESPNKTVSE EKAKQYLEEF HQTA LEHPEL SELKTVTGTN PVFAGANYAA WAVNVAQVID SETADNLEKT TAALSILPGI GSVMGIADGA VHHNTEE IVA QSIALSSLMV AQAIPLVGEL VDIGFAAYNF VES IINLFQV VHNSYNRPAY SPGHKTQPFL HDGYAVSWNT VEDSIIRTGF QGESGHDIKI TAENTPLPIA GVLLPT IPGK LDVNKSKTHI SVNGRKIRMR CRAIDGDVTF CR PKSPVYVG NGVHANLHVA FHRSSSEKIH SNEISSDSI G VLGYQKTVDH TKVNSKLSLF FEIKS (SEQ ID NO: 1) It is a non-toxic mutant (i.e., toxoid) of diphtheria toxin having the following structure:
[0092] In one embodiment, CRM197 is a recombinant gene grown in a casamino acid and yeast extract-based medium. Corynebacterium diphtheria strain C7(β19 7). In another embodiment, CRM197 is isolated from the culture of U.S. Pat. Typically, the recombinant vector is prepared recombinantly according to the methods described in CR 4,382. M197 is a combination of ultrafiltration, ammonium sulfate precipitation and ion exchange chromatography. In some embodiments, CRM197 is purified through combination with Pfenex. Expression Technology(TM) (Pfenex Inc., We used Pseudomonas fluorescens (Pseudomonas fluorescens) (San Diego, Calif.) rescens).
[0093] Other suitable carrier proteins include DT (diphtheria toxoid) or fragments of DT. Tetanus toxoid B (DTFB), TT (tetanus toxoid) or TT fragment C, pertussis toxoid toxoid, cholera toxoid (e.g., as described in WO 2004 / 083251); ), E. coli LT, E. coli ST, and Pseudomonas aeruginosa (Ps Additional inactivating bacterial toxins, such as exotoxin A of Eudomonas aeruginosa, Bacterial outer membrane proteins, such as outer membrane complex c (OMPC), porins, trans A ferrin-binding protein, pneumococcal surface protein A (PspA; WO 02 / 09 1998), pneumococcal adhesin protein (PsaA), group A or group B linkage C5a peptidase from cocci, or Haemophilus influenzae luenzae protein D, pneumococcal pneumolysin (Kuo et al., 1999) 95, Infect Immun 63;2706-13) (Detoxified in some way pl y, e.g., dPLY-GMBS (see WO 04 / 081515) or dPLY -Formol), PhtX (PhtA, PhtB, PhtD, PhtE and Ph t protein fusions, such as PhtDE fusions, PhtBE fusions (WO 01 / 98334 and WO 03 / 54007) may also be used. Ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin BSA or purified protein derivative of tuberculin (PPD), PorB (meningitis meningitidis), PD (Haemoph illus influenzae protein D; e.g., European Patent No. 0594 610 see specification) or their immunologically functional equivalents, synthetic peptides (European Patent No. 0378 881 and EP 0 427 347), heat shock proteins (See WO 93 / 17712 and WO 94 / 03208), Proteins (see WO 98 / 58668 and EP 0471177) ), cytokines, lymphokines, growth factors or hormones (WO 91 / 0114 6), an artificial tag containing multiple human CD4+ T cell epitopes of various pathogen-derived antigens. Protein (Falugi et al., 2001, Eur J Immunol 31 :3816-3824), e.g., the N19 protein (see Baraldoi et al. ., 2004, Infect Immun 72:4884-7), iron uptake protein proteins (see WO 01 / 72337), Clostridium difficile (C. difficile toxins A or B (see WO 00 / 61761), and Flagellin (Ben-Yedidia et al., 1998, Immunol L Other proteins such as ribosomal proteins (see Ett 64:9) can also be used as carrier proteins. Cut.
[0094] CRM 176 , CRM 228 , CRM 45 (Uchida et al., 1973, J Biol Chem 218:3838-3844);CRM 9 , CRM 45 , C.R. M 102 , CRM 103 and CRM 107 and Nicholls and You le in Genetically Engineered Toxins ,Ed:F Others described by Rankel, Maecel Dekker Inc, 1992 Mutation; Glu-148 to Asp, Gln or Ser and / or Ala 15 8 to Gly deletion or mutation and the disclosure of U.S. Pat. No. 4,709,017 or other mutations disclosed in U.S. Pat. No. 4,950,740; Residues Lys 516, Lys 526, Phe 530 and / or Lys 53 on 4 and the mutations described in U.S. Pat. No. 5,917,017 or U.S. Pat. No. 6,455, No. 5,673; or other mutations disclosed in U.S. Pat. No. 5,843,711. Other DT mutants, such as the fragments disclosed herein, can be used as carrier proteins. Such DT mutants can be used to clone B fragments containing the epitope region. It is also possible to generate DTFB mutants that contain
[0095] In certain embodiments, the carrier protein is an outer membrane protein complex (OMPC), tetanus toxoid, diphtheria toxoid, protein D and CRM197. It is selected.
[0096] In some embodiments of the invention, the second carrier is a polysaccharide protein in a multivalent immunogenic composition. The second carrier protein may be used in one or more of the protein conjugates. or non-toxic, non-reactogenic, in sufficient quantities and The second carrier protein also enhances the immunogenicity of the antigen. Conjugated or linked to S. pneumoniae polysaccharides to The carrier protein should be amenable to standard conjugation procedures. In an embodiment, each capsular polysaccharide that is not conjugated to a first carrier protein is the same conjugated to a second carrier protein (e.g., each capsular polysaccharide molecule is a single In another embodiment, the first carrier protein is conjugated to a carrier protein. Capsular polysaccharides that are not conjugated to a protein are conjugated to two or more carrier proteins. (each capsular polysaccharide molecule is conjugated to a single carrier protein) In such embodiments, each capsular polysaccharide of the same serotype is typically associated with the same carrier protein. It is conjugated to protein.
[0097] The embodiments of the present invention include any of the embodiments E1 to E20 and any subembodiments thereof. In embodiments, one or more of the polysaccharide serotypes (where applicable, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21) Conjugated to CRM197. In further embodiments of the invention, including any of the subembodiments, each of the polysaccharide serotypes is C Conjugated to RM197.
[0098] Formulation of the polysaccharide-protein conjugates of the present invention is art-recognized. For example, the individual pneumococcal conjugates can be prepared using methods such as The composition can be formulated using a physiologically acceptable vehicle to prepare the product. Examples of such vehicles include, but are not limited to, water, buffered saline, polio (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and and dextrose solutions.
[0099] In a preferred embodiment, the vaccine composition is an L-histidine buffer containing sodium chloride. It is formulated in a pharmaceutical preparation.
[0100] In some embodiments of the invention, the multivalent immunogenic composition is conjugated to a carrier protein. Multiple pulmonary specimens containing capsular polysaccharides of gated S. pneumoniae serotypes S. pneumoniae polysaccharide protein conjugates and adjuvants and wherein the S. pneumoniae serotype is as described herein. Suitable adjuvants for enhancing the effectiveness of the composition include, but are not limited to, These include, but are not limited to: (1) Aluminum salts (alum), such as aluminum hydroxide and aluminum phosphate aluminum sulfate, etc.; (2) Oil-in-water emulsion formulations (other specific immunostimulants, e.g. muramyl peptides) (as defined below) or bacterial cell wall components), such as (a) Mo del 110Y Microfluidizer (Microfluidics, Newton 5 is formulated into submicron particles using a microfluidizer such as % squalene, 0.5% Tween 80, and 0.5% Span 85 (various amounts MF59 (International Patent Application Publication No. WO 90 / 06336) containing MTP-PE / 14837), (b) microfluidized or vortexed into a submicron emulsion. Mixed to produce a larger particle size emulsion, 10% squalene, 0.4% Tw een 80, containing 5% Pluronic block polymer L121 and thr-MDP SAF, (c) 2% squalene, 0.2% Tween 80, and U.S. Pat. 3-O-deacylated monophospholipid A (MPL™) as described in US Pat. No. 5,209,444. ), trehalose dimycolate (TDM) and cell wall skeleton (CWS), preferably MP L+CWS (Ribi ( (Trademark) Adjuvant System (RAS) (Corixa, Hamilton, MT); and (d) Montanide ISA; (3) Saponin adjuvants, such as Quil A or STIMULON™ Q S-21 (Antigenics, Framingham, MA) (U.S. Pat. No. 5,055,333) No. 7,540) may be used, or particles made therefrom, such as I SCOM (Combination of cholesterol, saponin, phospholipids and amphiphilic proteins) (Immunostimulatory Complex Formed by Iscomatrix®) and Iscomatrix® (ISC has essentially the same structure as OM, but does not contain proteins); (4) bacterial lipopolysaccharide, a synthetic lipid A analogue, such as those available from Corixa; Aminoalkylglucosamine phosphatase as described in U.S. Pat. No. 6,113,918 phosphate compounds (AGPs) or derivatives or analogs thereof; one such AGP 529 (formerly known as RC529), formulated in aqueous form or as a stable emulsion. 2-[(R)-3-Tetradecanoyloxytetradecanoate], also known as 2-deoxy-4-O-phosphono-3-O-[(R)-3 -tetradecanoyloxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoyl] oxytetradecanoylamino]-bD-glucopyranoside, (5) Synthetic polynucleotides, e.g., oligonucleotides containing one or more CpG motifs. Otide (U.S. Pat. No. 6,207,646); and (6) Cytokines, such as interleukins (e.g., IL-1, IL-2, IL- 4, IL-5, IL-6, IL-7, IL-12, IL-15, IL-18, etc.), Inter -ferons (e.g., gamma interferon), granulocyte-macrophage colony-stimulating factor ( GM-CSF), macrophage colony-stimulating factor (M-CSF), tumor necrosis factor (TN F), costimulatory molecules such as B7-1 and B7-2; and (7) Complement, e.g., the trimer of complement component C3d.
[0101] In another embodiment, the adjuvant is a mixture of two, three or more of the above adjuvants. Compounds such as SBAS2 (also includes 3-deacylated monophosphoryl lipid A and QS21) oil-in-water emulsion).
[0102] Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-succinimide. Leonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L- Alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryl These include (methyl-1,2-dimethyl-2-propanediol), ...
[0103] In certain embodiments, the adjuvant is an aluminum salt. The vaccine may be an alum-precipitated or alum-adsorbed vaccine. Mu salt adjuvants are well known in the art and are described, for example, in Harlow, E. and D. Lane(1988;Antibodies:A Laboratory Manual Cold Spring Harbor Laboratory) and Nickla s,W.(1992;Aluminum salts.Research in Imm The aluminum salts are described in the Journal of Neurology 143:489-493. Examples include, but are not limited to, hydrated alumina, alumina hydrate, and alumina trihydrate (ATH). , Aluminum Hydrate, Aluminum Trihydrate, Alhydrogel, Superfo s, Amphogel, Aluminum(III) hydroxide, Aluminum hydroxyphosphate sulfate Aluminum hydroxyphosphate sulfate, phosphorus Aluminum acid adjuvant (APA), amorphous alumina, alumina trihydrate, or trihydrate Contains hydroxyaluminum.
[0104] APA is an aqueous suspension of aluminum hydroxyphosphate. APA is an aqueous suspension of aluminum chloride. Aluminum hydroxyphosphate is prepared by blending aluminum and sodium phosphate in a 1:1 volume ratio. After the mixing process, the material is sized in a high shear mixer. The product is then diafiltered against saline to achieve a monodisperse particle size distribution. , and steam sterilize.
[0105] In certain embodiments, commercially available Al(OH) 3 (For example, Denmark / Accura te Chemical and Scientific Co., Westbury; 50-200μg of TA using Alhydrogel or Superfos (NY) In another embodiment, the protein is adsorbed at a ratio of mg protein / mg aluminum hydroxide. Protein adsorption depends on the pI (isoelectric pH) of the protein and the pH of the medium. Proteins with low pI are more strongly attracted to positively charged aluminum ions than proteins with high pI. Aluminum salts act as depots of antigens that are slowly released over a period of 2-3 weeks. and / or can stimulate the innate immune system (probably through stimulation by uric acid). See t et al., 2009, Curr Opin Immunol 21:23 I want to be.
[0106] Monovalent bulk aqueous conjugates are typically blended together to a target concentration of 8 μg / mL. Dilute to a target of 4 μg / mL for all serotypes except for 6B, which is diluted. Once complete, the batch is filter sterilized and an equal volume of aluminum phosphate adjuvant is added, 250 μg Add aluminum aseptically to the adjuvant formulation batch to achieve a final aluminum concentration of 1 / mL. The drug will be filled into single-use 0.5 mL / dose vials.
[0107] In certain embodiments, the adjuvant comprises a CpG-containing nucleotide sequence, e.g., CpG Containing oligonucleotides, in particular CpG-containing oligodeoxynucleotides (CpG OD In another embodiment, the adjuvant is ODN 1826, which is Col It is available from ey Pharmaceutical Group.
[0108] Methods for using CpG oligonucleotides are well known in the art, e.g., Sur et al.,1999,J Immunol.162:6284-93;Verth elyi,2006,Methods Mol Med.127:139-58;and Yasuda et al.,2006,Crit Rev Ther Drug C Arrier Syst. 23:89-110.
[0109] In alternative embodiments, the immunogenic compositions are as described herein, e.g., in embodiments E1-E20 or E22. any of the subembodiments thereof. oniae) containing a polysaccharide-protein conjugate and no adjuvant .
[0110] formulation The compositions of the present invention may be provided in single dose vials, multi-dose vials, or pre-filled glasses. The formulation may be formulated as a capsule or plastic syringe.
[0111] In another embodiment, the compositions of the invention are administered orally and therefore may be in a form suitable for oral administration. Solid oral formulations include tablets, These include capsules, pills, granules, pellets, etc. Liquid oral preparations include liquids, suspensions, etc. , dispersions, emulsions, oils, etc.
[0112] Pharmaceutically acceptable carriers for liquid formulations include aqueous or non-aqueous solutions, suspensions, emulsions, and the like. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, chol and injectable organic esters, such as ethyl oleate. Aqueous carriers include: Includes water, alcohol / aqueous solutions, emulsions or suspensions, saline and buffered media Examples of oils include those of animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil. , olive oil, sunflower oil, fish liver oil, another marine oil, or milk or egg lipids.
[0113] Pharmaceutical compositions may be isotonic, hypotonic or hypertonic. It is generally preferred that a pharmaceutical composition be essentially isotonic when administered. For storage, the pharmaceutical composition may preferably be isotonic or hypertonic. If the solution is hypertonic for administration, it can be diluted to an isotonic solution prior to administration.
[0114] The isotonicity agent may be an ionic isotonicity agent, such as a salt, or a non-ionic isotonicity agent, such as a carbohydrate. Examples of ionic isotonicity agents include, but are not limited to, NaCl, 1L 2 , K Cl and MgCl 2 Examples of non-ionic isotonicity agents include, but are not limited to, includes mannitol, sorbitol and glycerol.
[0115] It is also preferred that the at least one pharma- ceutically acceptable excipient is a buffering agent. For example, if the pharmaceutical composition is intended for infusion or injection, the composition may be A buffer capable of buffering a liquid to a pH in the range of 4 to 10, for example 5 to 9, for example 6 to 8. It is usually desirable to include
[0116] Buffers include, for example, TRIS, acetate, glutamate, lactate, maleate, tartrate, etc. Salts, phosphates, citrates, carbonates, glycinates, histidine, glycine, succinate The buffer may be selected from the group consisting of salts and triethanolamine buffers.
[0117] The buffering agent is, particularly when the pharmaceutical preparation is for parenteral use, The buffer may be selected from SP compatible buffers. For example, the buffer may be acetic acid, benzoic acid, gluconic acid, Monobasic acids such as glyceric and lactic acid; aconitic acid, adipic acid, ascorbic acid , carbonic acid, dibasic acids such as glutamic acid, malic acid, succinic acid and tartaric acid, citric acid and and polybasic acids such as phosphoric acid; ammonia, diethanolamine, glycine, triethanolamine The base may be selected from the group consisting of bases such as diamine and TRIS.
[0118] Parenteral vehicles (for subcutaneous, intravenous, intraarterial, or intramuscular injection) include sodium chloride solution. Lactated Ringer's solution, Ringer's dextrose, Dextrose and sodium chloride, Lactated Ringer's solution and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, Examples include surfactants and and other pharma- ceutically acceptable adjuvants. There are several sterile liquids available. Commonly, these include water, saline, aqueous dextrose solutions, and related sugar solutions. Liquid, glycols such as propylene glycol or polyethylene glycol, polysols Polysorbate 80 (PS-80), Polysorbate 20 (PS-20), and Poloxamer 1 88 (P188) is a preferred liquid carrier, particularly for injectable solutions. Examples of oils are: Of animal, vegetable or synthetic origin, e.g. peanut oil, soybean oil, olive oil, sunflower oil , fish liver oil, another marine oil, or milk or egg lipids.
[0119] The formulations of the present invention may also include a surfactant. Preferred surfactants include, but are not limited to, Polyoxyethylene sorbitan ester surfactants (commonly Tween s), especially PS-20 and PS-80; sold under the trade name DOWFAX (trademark) Commercially available ethylene oxide (EO), propylene oxide (PO) and / or Copolymers of ethylene oxide (BO), such as linear EO / PO block copolymers; repeating Octoxynol (Octoxy) with variable number of ethoxy (oxy-1,2-ethanediyl) groups Toxinol-9 (Triton X-100, or t-octylphenoxypolyether (Octylphenoxy)polyethoxyethanol is particularly important; (Octylphenoxy)polyethoxyethanol (IGEPAL CA-630 / NP-40); phospholipids, e.g. phosphatidylcholine (lecithin); nonylphenol ethoxylates, such as Tergitol™ NP Series; Poly(lauryl, cetyl, stearyl and oleyl alcohols) Oxyethylene fatty ethers (known as Brij surfactants), e.g. triethylene Ethylene glycol monolauryl ether (Brij 30); and sorbitan ester Sorbitan trioleate (commonly known as SPAN), e.g. Preferred compounds for inclusion in emulsions include sorbitan monolaurate (n 85) and sorbitan monolaurate. A new surfactant is PS-80.
[0120] Mixtures of surfactants can be used, for example a PS-80 / Span 85 mixture. Polyoxyethylene such as polyoxyethylene sorbitan monooleate (PS-80) Triethylene sorbitan ester and t-octylphenoxypolyethoxyethanol (Trit Combinations of octoxynol such as octoxynol on X-100 are also suitable. The combination is Laureth 9 with polyoxyethylene sorbitan ester and / or octyldodecyl ester. Contains xynol.
[0121] The preferred amount (wt%) of surfactant is polyoxyethylene sorbitan ester (PS -80, etc.) 0.01 to 1%, especially about 0.1%; octyl- or nonylphenoxypoly Oxyethanol (Triton X-100, or other interfaces in the Triton series) Active agents, etc.) 0.001-0.1%, especially 0.005-0.02%; polyoxyethylene Ether (such as Laureth 9) 0.1 to 20%, preferably 0.1 to 10%, particularly 0.1 to 1% or about 0.5%.
[0122] In certain embodiments, the composition comprises 250 μg / mL APA (aluminum azide phosphate). 100 mM NaCl, pH 5.8, histidine (20 mM), saline (150 mM) and 0.2% PS-20 or 0.04% PS-80. can range from 0.005% to 0.3% (w / v) to prevent aggregation during simulated manufacturing. For controlled formulations and shipments using primary packaging, PS-20 or PS-80 is present. In another embodiment, PS-20 is in the range of 0.025% to 0.8% (w / v). In another embodiment, PS-20 may be in the range of 0.05% to 0.8% (w / v). In another embodiment, PS-20 may be in the range of 0.05% to 0.2% (w / v). The method involves the determination of up to 24 nucleotides in histidine, saline, and PS-20 or PS-80. A blend of serotypes is combined and the blended material is then incubated with a 50 mL aliquot of 100 mL of antimicrobial preservative. It consists of combining with or without APA and saline.
[0123] In certain embodiments, the multivalent immunogenic composition is an immunogenic composition for S. pneumoniae. polysaccharide-protein conjugates, each of which is linked to a carrier protein. It contains polysaccharides of S. pneumoniae serotypes conjugated to a saccharide. , where S. pneumoniae in a polysaccharide-protein conjugate The serotypes include any of the sets of serotypes set forth herein, and 20 to 80 Further comprising 100 mM histidine pH 5.8 and 150 mM NaCl. In one embodiment, the multivalent immunogenic composition further comprises 0.2% to 0.8% w / v polysorbate 20. Included.
[0124] The choice of surfactant may need to be optimized for different formulations and drug substances. For multivalent vaccines with the above serotypes, PS-20 and P188 are preferred. The choice of chemistry used to make the conjugate also plays an important role in the stabilization of the formulation. In particular, it can be used to prepare different polysaccharide-protein conjugates into multivalent compositions. When the conjugation reaction involves both aqueous and DMSO solvents, The surfactant system makes a significant difference in stability. Improving the stability of polysaccharide-protein conjugates The effect was seen with polysorbate 20 alone or with poloxamer 188 in combination with polyols. It was.
[0125] The exact mechanisms of how specific surfactants protect biopharmaceuticals are unclear. Possible stabilization mechanisms include priority hydration, preferential exclusion, air / liquid interface competition between biopharmaceuticals and surfaces, surface tension, and Surfactants and biopharmaceuticals that mask hydrophobic patches and / or act as aggregation seeds This includes face-to-face meetings.
[0126] Poloxamers may also be used in the compositions of the present invention. Poloxamers are polyoxyethylene Polyoxypropylene ( Nonionic triblock copolymers composed of a central hydrophobic chain of poly(propylene oxide) Poloxamers are also known by the trade name Pluronic®. The length of the polymer block can be customized, resulting in slightly different There are many different poloxamers with different properties. These copolymers are generally designated by the letter "P" (for poloxamer) followed by three digits. The first two digits x 100 represent the approximate molecular mass of the polyoxypropylene core. The last digit x 10 indicates the polyoxyethylene content (e.g., P407 = 4,000 With a polyoxypropylene molecular mass of 0 g / mol and a polyoxyethylene content of 70% Poloxamers). The Pluronic® trade name lists these copolymers as The coding is a letter that defines the physical form at room temperature (L=liquid, P=paste, F=flake). The first digit of the numeric display (for three-digit numbers) is followed by two or three digits. The molecular weight of the hydrophobic substance is calculated by multiplying the molecular weight by 300; the last digit is multiplied by 10 indicates the polyoxyethylene content (for example, L61 = 1,800 g / mol of polyoxyethylene) Pluronic (registered trademark) with 10% polyoxyethylene content and 10% propylene molecular mass. (Registered Trademark). See U.S. Patent No. 3,740,421.
[0127] Examples of poloxamers have the general formula: HO(C 2 H 4 O) a (C 3 H 6 O) b (C 2 H 4 O) a H (wherein a and b blocks The following values are available: Having: [Table 1]
[0128] Preferably, the poloxamer is generally between 1100 and 17,400 Da, between 7,500 and 1 5,000 Da, or in the range of 7,500 to 10,000 Da. The poloxamer may be selected from poloxamer 188 or poloxamer 407. The final concentration of poloxamer in the formulation is 0.001% to 5% weight / volume, or 0.025% 1% weight / volume. In certain embodiments, the polyol is propylene glycol; The final concentration is 1% to 20% weight / volume. In certain embodiments, the polyol is polyethylene. Glycol 400, with a final concentration of 1% to 20% weight / volume.
[0129] Polyols suitable for the formulation of the present invention include, but are not limited to, polymer polyols. No, but propylene glycol and polyethylene glycol, polyethylene glycol It is a polyether diol containing monomethyl ether. Propylene glycol is a mono Polyethylene glycols are available with molecular weights ranging from about 425 to about 2700. Polyethylene glycol monomethyl ether also has a molecular weight ranging from about 200 to about 35,000. Available in a range of molecular weights including but not limited to PEG200, PEG300, PEG400, PEG500, PEG600, PEG700, PEG800, PEG900, PEG1000, PEG1100, PEG1200, PEG1300, PEG1400, PEG1500, PEG1600, PEG1700, PEG1800, PEG1 00, PEG400, PEG1000, PEG MME 550, PEG MME 60 0, PEG MME 2000, PEG MME 3350 and PEG MME 40 00. A preferred polyethylene glycol is polyethylene glycol 400. The final concentration of polyol in the formulation of the present invention is 1% to 20% weight / volume or 6% to 20% weight / volume. It may be % weight / volume.
[0130] The formulation also includes a pH buffered saline solution. Buffers include, for example, TRIS, acetate, glutathione, and glycerol. Tamates, lactates, maleates, tartrates, phosphates, citrates, carbonates, glycines Phosphate, histidine, glycine, succinate, HEPES (4-(2-hydroxyethyl )-1-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid) sulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid) and triethanolamine The buffer may be selected from the group consisting of amine buffers. Alternatively, the pH may be buffered to a range of 5.8 to 7.0. Buffers include phosphate, succinate, histidine, MES, MOPS, HEPES, and acetate. or citrate. Buffering agents may also be used, for example, in particular pharmaceutical formulations. If is for parenteral use, select from USP compatible buffers for parenteral use The concentration of the buffering agent may be in the range of 1 mM to 100 mM. The concentration of the buffering agent may be in the range of 10 mM to The buffer concentration is in the range of 1mM to 50mM or 5mM to 50mM. In certain embodiments, the buffer is histidine at a final concentration of 5 mM to 50 mM, or In certain embodiments, the final concentration of histidine is 20 mM to 10 mM succinate. The final concentration is ±2 mM.
[0131] A saline solution (i.e., a solution containing NaCl) is preferred, but other salts suitable for the formulation may be used. Examples include, but are not limited to, CaCl 2 , KCl and MgCl 2 And these Combinations of sucrose, trehalose, mannose, etc. are included, but are not limited to. Non-ionic isotonicity agents, including nitrile, sorbitol, and glycerol, can be used in place of salt. Suitable salts may be used in the range of, but are not limited to, 25 mM to 500 mM. In one embodiment, the physiological saline is NaCl, and the physiological saline concentration is 20 mM to 40 mM. It may be present at a concentration of from 1 mM to 170 mM.
[0132] In a preferred embodiment, the formulation comprises an L-histidine buffer containing sodium chloride.
[0133] In another embodiment, the pharmaceutical composition is delivered in a controlled release system. It can be administered using intravenous infusion, a transdermal patch, liposomes, or other modes of administration. In another embodiment, the polymeric material is used, for example, in a microsphere or implant. It is used.
[0134] The amount of conjugate in each vaccine dose induced an immune protective response without significant adverse effects Such an amount may vary depending on the serotype of the pneumococcus. In particular, for polysaccharide-based conjugates, each dose contains 0.08-100 μg of each polysaccharide. In some embodiments of the invention, the dose of each polysaccharide conjugate is between 0.08 and 10 μg / mL. In further embodiments, the dose is 1-5 μg, 0.4-4 μg, 0.4-3 μg. g, 0.4 to 2 μg, or 0.4 to 1 μg. In some embodiments, one or more The doses of saccharide conjugates were 100, 150, 200, 250, 300, 400, 50 0 or 750ng or 0.4, 0.5, 0.6, 0.7, 0.75, 0.8, 0. 9, 1, 1.5, 2, 3, 4, 5, 6, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 25, 30, 40, 50, 60, 70, 80, 9 0 or 100 μg.
[0135] In some embodiments of the compositions of the present invention, all of the polysaccharide conjugate is present in the composition. In a further embodiment, the polysaccharide conjugates are present in different amounts in the composition. (i.e., at least one polysaccharide conjugate is present in a quantity not greater than the other polysaccharides of the composition) (the aryl group is present in an amount different from one or more of the aryl conjugates).
[0136] Optimal amounts of components of a particular vaccine can be determined through standard testing including observation of an appropriate immune response in a subject. For example, in another embodiment, the method may be used to administer the vaccine to humans. Dosages in this embodiment are determined by extrapolation from animal studies to human data. The dosage is empirically determined.
[0137] In one embodiment, the dose of aluminum salt is 10, 15, 20, 25, 30, 50, 7 0, 100, 125, 150, 200, 300, 500, or 700 μg, or 1, In yet another embodiment, the dose is 1.2, 1.5, 2, 3, 5 mg or more. of alum salt per μg of recombinant protein.
[0138] The compositions of the invention also contain one or more proteins of S. pneumoniae. Examples of S. pneumoniae proteins suitable for inclusion include: See, for example, International Patent Application Publication Nos. WO 02 / 083855 and WO 02 Examples include those identified in / 053761.
[0139] In certain embodiments, the compositions of the present invention are administered to a subject in one or more ways known to one of skill in the art. For example, parenteral, transmucosal, transdermal, intramuscular, intravenous, intradermal, intranasal, subcutaneous, intraperitoneal In one embodiment, the compositions of the present invention are administered intravenously and formulated accordingly. via epidermal, intramuscular, intravenous, intraarterial, subcutaneous, or intrarespiratory mucosal injection of the substance Liquid preparations for injection include solutions and the like.
[0140] III. Preparation method The capsular polysaccharides of Streptococcus pneumoniae are The polysaccharides can be prepared by standard techniques known to those skilled in the art. and can be isolated by known methods (e.g., the method described in EP 497524). and EP 497525), preferably using a homogenizer. This is achieved by microfluidisation or chemical hydrolysis. In one embodiment, each pneumococcal polysaccharide serotype The strains are grown in soy-based media and then subjected to standard filtration techniques including centrifugation, sedimentation and ultrafiltration. Through this step, individual polysaccharides can be purified. See U.S. Pat. No. 286,838 and U.S. Pat. No. 5,847,112. To reduce the viscosity of the sugar sample and / or to reduce the viscosity of the sugar sample by mechanical or chemical sizing To improve the filterability of conjugated products using such techniques, polysaccharides have been added as supports. Chemical hydrolysis can be carried out using acetic acid. Mechanical Ising may be carried out using high pressure homogenizing shear.
[0141] The purified polysaccharides are chemically activated to make the saccharides reactive with the carrier protein. The purified polysaccharide can be linked to a linker. Once attached to the linker or polymerase, each capsular polysaccharide can be individually conjugated to a carrier protein. The polysaccharide conjugates are formed by coupling with other glycoconjugates using known coupling agents. The compositions may be prepared by gelling techniques.
[0142] The polysaccharide is coupled to a linker, and the free end of the linker is an ester group. Thus, the linker can be formed by forming a linker-linker intermediate. The other end reacts with the polysaccharide to form a polysaccharide-linker. The copolymer is selected so as to be capable of forming an anchor intermediate.
[0143] The polysaccharide can be coupled to the linker using primary amine groups in the polysaccharide. In this case, the linker typically has an ester group at each end. by reacting one of the terephthalic acid groups with a primary amine group in the polysaccharide via nucleophilic acyl substitution. The reaction is carried out by coupling the polysaccharide to the linker via an amide bond. This results in a coupled polysaccharide-linker intermediate.
[0144] Thus, the linker contains a first ester group for reacting with the primary amine groups of the polysaccharide. A bifunctional linker that provides a second ester group for reaction with a primary amine group of the carrier molecule. A typical linker is adipic acid N-hydroxysuccinimide diester (S IDEA).
[0145] Coupling can also be done indirectly, i.e. by derivatizing the polysaccharide prior to coupling to the linker. This can also be done with an additional linker used for derivatization.
[0146] The polysaccharide is coupled to an additional linker using the carbonyl group at the reducing end of the polysaccharide. This coupling is carried out in two steps: (a1) reacting the carbonyl group with an additional linker; and (a2) reacting the free end of the additional linker with the linker. In these embodiments, the additional linker typically comprises a primary amine at each end. group, which allows one of the primary amine groups to be attached to the carbonyl of the polysaccharide by reductive amination. Step (a1) can be carried out by reacting the carbonyl group of the polysaccharide with the A primary amine group reactive with the amine group is used. A hydrazide or hydroxylamino group is suitable. Typically, the additional linker has the same primary amine group at both ends. Polysaccharide-additional linker, in which the saccharide is coupled to the additional linker via a C-N bond - yielding intermediates.
[0147] The polysaccharides can be coupled to additional linkers using different groups in the polysaccharide, particularly the carboxyl groups. This coupling can be carried out in two steps: (a1) by coupling the group to an additional linker; and (a2) reacting the free end of the additional linker with the linker. In this case, the additional linker is typically provided with primary amine groups at both termini. whereby EDAC activation attaches one of the primary amine groups to the carboxyl group of the polysaccharide. Step (a1) can be carried out by reacting the EDAC activity of the polysaccharide with the aryl group. A primary amine group reactive with the functionalized carboxyl group is used. A hydrazide group is suitable. Typically, the additional linker has the same primary amine group at both ends. A polysaccharide-additional linker intermediate coupled to an additional linker via an amido bond. results.
[0148] In one embodiment, the carrier tandem is prepared by chemical activation of the polysaccharide followed by reductive amination. Conjugation with proteins is described in U.S. Pat. Nos. 4,365,170 and 4,6 Nos. 73,574 and 4,902,506, U.S. Pat. Appln. Pub. No. 20 Specification No. 06 / 0228380, Specification No. 2007 / 184072, Specification No. 2007 / 0231340 and 2007 / 0184071, as well as International Publication No. WO 2006 / 110381, WO 2008 / 079653 and WO 2008 / 079653. This can be achieved by the means described in US Pat. No. 5,999,200. The chemistry is periodic acid. salts (containing sodium periodate, potassium periodate or periodic acid) of pneumococcal polysaccharides by reaction with any oxidizing agent that oxidizes the terminal hydroxyl groups to aldehydes. This reaction may involve the random oxidative activation of adjacent hydroxyl groups on carbohydrates. It is cleaved to form a reactive aldehyde group.
[0149] Coupling to carrier proteins is via direct amination of the lysyl groups of the protein. For example, conjugation can be achieved by the reaction of activated polysaccharides with carrier proteins. The mixture of compounds is reacted with a reducing agent such as sodium cyanoborohydride in the presence of nickel. The conjugation reaction can be carried out in aqueous or DMSO. It can be carried out in the presence of SO. See, for example, U.S. Patent Application Publication No. 2015 / 023127. 0, U.S. Patent Application Publication No. 2011 / 0195086 and European Patent No. See US Pat. No. 4,711,777. Then, a strong ion exchange agent such as sodium borohydride is added. A reducing agent is added to cap any unreacted aldehydes.
[0150] Reductive amination involves (1) the oxidation of polysaccharides to form reactive aldehydes, and (2) the activation Stable amides are obtained by reduction of imines (Schiff bases) formed between polysaccharides and carrier proteins. The oxidation process involves two steps: formation of amine conjugate bonds and the silencing of the polysaccharide. Mechanical methods (e.g., homogenization) or chemical hydrolysis may be used to reduce the The chemical hydrolysis can be carried out using acetic acid. The oxidation step can be carried out using periodic acid. For the purposes of the present invention, the term "periodate" refers to Includes both periodate and periodic acid; the term also includes metaperiodate (IO 4 ) and orthoperiodate (IO 6 ), as well as various periodates (e.g., periodic acid salts). In one embodiment, the capsular polysaccharide comprises metathesis. In the presence of periodate, preferably sodium periodate (NaIO 4 ) in the presence of acid In another embodiment, the capsular polysaccharide is preferably oxidized in the presence of orthoperiodate. is oxidized in the presence of periodate.
[0151] In one embodiment, the oxidizing agent is: Stable nitroxy compounds such as piperidine-N-oxy or pyrrolidine-N-oxy compounds or nitroxide radical compounds (as described in WO 2014 / 097099). In the reaction, the actual oxidant is N-oxoammonium in the catalytic cycle. In one embodiment, the stable nitroxyl or nitroxide radical compound is a nitroxyl salt. is a piperidine-N-oxy or pyrrolidine-N-oxy compound. The stable nitroxyl or nitroxide radical compound is TEMPO(2,2,6 ,6-tetramethyl-1-piperidinyloxy) or PROXYL(2,2,5,5- In one embodiment, the stable nitro The xyl radical compound is TEMPO or a derivative thereof. is a molecule having an N-halo moiety. In one embodiment, the oxidizing agent is N-chlorosuccinic acid. Imide, N-bromosuccinimide, N-iodosuccinimide, dichloroisocyanuric acid Acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, dib Bromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6 -trione, diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-tri Preferably, the oxidizing agent is selected from the group consisting of azinane-2,4,6-trione. N-chlorosuccinimide.
[0152] In certain embodiments, the oxidizing agent is 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) free radical and N-chlorosuccinimide (NC) as a co-oxidant S) (as described in WO 2014 / 097099). Thus, in one embodiment So, the glycoconjugates of S. pneumoniae are: a) in aqueous media; In this study, sugars were treated with 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and and N-chlorosuccinimide (NCS) to obtain an activated sugar; and b) reacting the activated sugar with a carrier protein that contains one or more amine groups. (the method was subsequently called "TEMPO / NCS reductive amination") (I).
[0153] A quenching agent may be added to quench the oxidation reaction. , 1-, 2-amino alcohols, amino acids, glutathione, sulfites, bisulfates, dithionite Sulfates, metabisulfites, thiosulfates, phosphites, hypophosphites or phosphorous acids (Gly Glycerol, ethylene glycol, propane-1,2-diol, butane-1,2-diol or butane-2,3-diol, ascorbic acid, etc.
[0154] In certain embodiments, the present invention utilizes conjugation reactions in aprotic solvents. Serotype 8 Streptococcus pneumoniae polysaccharides for use - a method for preparing a protein conjugate, comprising the steps of: In a further embodiment, the conjugate is free of cyanoborohydride. The oxidization reaction is a Schiff base reduction or a reductive amination. The protein is a tetanus toxoid, a diphtheria toxoid, or CRM197. In another embodiment, the protein is CRM197. The conjugation reaction is a reductive amination. In a further embodiment, the reductive amination is , performed in dimethyl sulfoxide (DMSO).
[0155] In some embodiments, the oxidized polysaccharide prior to conjugation is between 30 kDa and 1,0 The molecular weight was determined by size exclusion chromatography (SEC) and multiple Calculate by combining the multi-angle light scattering detector (MALS) and the refractive index detector (RI) In some embodiments, the polysaccharide has a molecular weight of between 50 kDa and 300 kDa. In some embodiments, the polysaccharide has a molecular weight of 50 kDa to 1,000 kDa. In additional embodiments, the polysaccharide has a molecular weight of between 70 kDa and 900 kDa. In one embodiment, the polysaccharide has a molecular weight of between 100 kDa and 800 kDa. In a further embodiment, the polysaccharide has a molecular weight of 200 kDa to 600 kDa. Polysaccharides are: 100kDa-1,000kDa; 100kDa-900kDa; 100kDa a~800kDa;100kDa~700kDa;100kDa~600kDa;100 kDa~500kDa;100kDa~400kDa;100kDa~300kDa;1 50kDa~1,000kDa;150kDa~900kDa;150kDa~800k Da;150kDa~700kDa;150kDa~600kDa;150kDa~50 0kDa;150kDa~400kDa;150kDa~300kDa;200kDa~ 1,000kDa;200kDa~900kDa;200kDa~800kDa;200 kDa~700kDa;200kDa~600kDa;200kDa~500kDa;2 00kDa~400kDa;200kDa~300;250kDa~1,000kDa; 250kDa~900kDa;250kDa~800kDa;250kDa~700kDa a;250kDa~600kDa;250kDa~500kDa;250kDa~400 kDa;250kDa~350kDa;300kDa~1,000kDa;300kDa ~900kDa;300kDa~800kDa;300kDa~700kDa;300k Da~600kDa;300kDa~500kDa;300kDa~400kDa;40 0kDa~1,000kDa;400kDa~900kDa;400kDa~800kDa a;400kDa~700kDa;400kDa~600kDa;500kDa~600 It has a molecular weight of 10 kDa.
[0156] The second step of the conjugation method involves the use of a reducing agent to activate the polysaccharide and the carrier. Reduces the imine (Schiff base) bond between the protein to form a stable conjugate bond The formation of a cyclic aryl group (known as reductive amination) is carried out by the formation of a cyclic aryl group. Suitable reducing agents include cyanoborohydride, (such as sodium cyanoborohydride or sodium borohydride). In embodiments, the reducing agent is sodium cyanoborohydride.
[0157] In certain embodiments, the reductive amination reaction is carried out in an aprotic solvent (or In one embodiment, the reduction reaction is carried out in DMSO or DMF (a mixture of solvents). Methylformamide) solvent. If lyophilized, DMSO or DMSO The F solvent may be used to reconstitute the activated polysaccharide and the carrier protein. In the example, the aprotic solvent is DMSO.
[0158] At the end of the reduction reaction, unreacted aldehyde groups may remain in the conjugate. , which can be capped using a suitable capping agent. The capping agent is sodium borohydride (NaBH 4 ) is a suitable alternative. The reaction products include the catalysis of sodium triacetoxyborohydride in the presence of Bronsted or Lewis acids. boranes, such as sodium or zinc borohydrides, amine boranes, such as pyridine boranes, borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t -BuMe'PrN-BH 3 , benzylamine-BH 3 or 5-ethyl-2-methylpyridine Poly(ethylene glycol) borane (PEMB) or borohydride exchange resin. After the reduction reaction and optional capping, the glycoconjugate can be synthesized by the method known to those skilled in the art. Purification (enrichment in terms of the amount of polysaccharide-protein conjugate) can be achieved by various techniques currently available. These techniques include dialysis, concentration / diafiltration, tandem Flow filtration, precipitation / elution, column chromatography (ion exchange chromatography) , multimodal ion exchange chromatography, DEAE or hydrophobic interaction chromatography In one embodiment, the glycoconjugates The resulting product is purified by diafiltration or ion exchange chromatography or size exclusion chromatography. Purify by chromatography.
[0159] Glycoconjugates prepared using reductive amination in aprotic solvents Commonly used in multivalent pneumococcal conjugate vaccines. Therefore, all serotypes are In certain embodiments of the multivalent composition that is not prepared in a protic solvent, the remaining blood The reduction reaction of the supernatant type was carried out in an aqueous medium (e.g., PBS (phosphate buffered saline), MES (2- (N-morpholino)ethanesulfonic acid), HEPES(4-(2-hydroxyethyl)- 1-Piperazineethanesulfonic acid), Bis-Tris, ADA (N-(2-acetamide) iminodiacetic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)) , MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), BES (N,N -bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), MOPS(3-(N -morpholino)propanesulfonic acid), DIPSO(3-bis(2-hydroxyethyl) Amino-2-hydroxypropane-1-sulfonic acid, MOBS (4-(N-morpholino ) butanesulfonic acid), HEPPSO (N-(2-hydroxyethyl)piperazine-N- (2-hydroxypropanesulfonic acid)), POPSO (piperazine-1,4-bis(2 -Hydroxy-3-propanesulfonic acid), TEA (triethanolamine), EPP S(4-(2-hydroxyethyl)piperazine-1-propanesulfonic acid), pH 6.0 ~8.5, 7.0~8.0 or 7.0~7.5 Bicine It can be done.
[0160] Streptococcus pneumoniae (S) can be prepared using reductive amination in aprotic solvents. pneumoniae capsular polysaccharide-protein conjugates include, but are not limited to, No, but serotypes: 3, 6A, 6B, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 23F, 24F, 31, 33F, 35B and 39. S. pneumoniae capsules can be prepared using reductive amination Membrane polysaccharide-protein conjugates include, but are not limited to, serotypes: 3, 6 A, 6B, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 23F, 24F, 31, 33 These include 35F, 35B and 39. These are prepared using reductive amination in aprotic solvents. Pneumococcus (S. pneumoniae) capsular polysaccharide-protein conjugates that can be produced The serotypes include, but are not limited to: serotypes 3, 6A, 6B, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 2 Includes 0B, 22F, 23A, 23B, 23F, 24F, 31, 33F, 35B and 39. Polysaccharides can be used in the form of oligosaccharides. These can be used in the form of oligosaccharides (e.g. hydrolyzed They are conveniently formed by fragmentation of purified polysaccharides (by digestion), usually followed by the production of the desired saccharides. Fragments of the size are purified.
[0161] In certain embodiments, serotypes 3, 6A, 6B, 6C, 7F, 8, 9N, 10A, 11A , 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A , 23B, 23F, 24F, 31, 33F, 35B, and 39 pneumococcal polysaccharides -Protein conjugates are prepared using reductive amination in aprotic solvents In certain embodiments, serotypes 3, 6A, 6B, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20, 22F, 2 Pneumococcal polymorphisms: 3A, 23B, 23F, 24F, 31, 33F, 35B, and 39 Sugar-protein conjugates can be synthesized using reductive amination in aprotic solvents. In certain embodiments, serotypes 3, 6A, 6B, 6C, 7F, 8, 9N, 10 A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20B, 22 Pneumonia classified as one or more of F, 23A, 23B, 23F, 24F, 31, 33F, 35B, and 39 Cocci polysaccharide-protein conjugates were synthesized using reductive amination in aprotic solvents. In certain embodiments, each of the serotypes in the multivalent immunogenic composition is prepared using a non-promoter serotype. In certain embodiments, the multivalent structure is prepared using reductive amination in a rotonic solvent. Polysaccharides of one or more serotypes in the composition can be purified using reductive amination in an aprotic solvent. The conjugated and one or more serotype polysaccharides are subjected to reductive amino acid synthesis in an aqueous medium. In certain embodiments, two or more antibodies in a multivalent composition are conjugated using a conjugation method. Polysaccharides of the tert-butyl type were conjugated using reductive amination in aprotic solvents. In other embodiments, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more in a multivalent composition. Top, 9 and above, 10 and above, 11 and above, 12 and above, 13 and above, 14 and above, 15 and above, 16 and above , ≥17, ≥18, ≥19, ≥20, or ≥21 serotype polysaccharides are non-protease The conjugation is carried out using reductive amination in a rotonic solvent. The polysaccharides of one or more serotypes in the multivalent composition are dissolved in an aprotic or aqueous solvent. Possibly other chemistries are used for conjugation.
[0162] Thus, the present invention provides a method for the preparation of a pneumococcus (S. pneumoniae) antibody conjugated to a carrier protein. pneumoniae serotypes, including capsular polysaccharides of S. pneumoniae serotypes ae) a multivalent immunogenic composition comprising a polysaccharide-protein conjugate, The serotypes of S. pneumoniae are described herein (i.e., in Section II, "Multivalent Immunogenic Compositions "" in which the polysaccharide-protein conjugate The one or more polysaccharides are thereby conjugated to a carrier protein. In certain embodiments, the reaction is in an aprotic solvent. At least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% are prepared in aprotic solvents. The remainder of the serotypes are prepared in alternative solvents. The compounds are prepared using chemicals and / or in aqueous solvents.
[0163] DMSO was used as a solvent in the reductive amination of polysaccharide-protein conjugates. When used in combination with ELISA, the predicted serotypes were significantly improved compared to the same conjugates prepared under aqueous conditions. It has been determined that this results in unexpectedly superior stability and enhanced immunogenicity (U.S. Patent Application Serial No. 6 (See US Pat. Nos. 2 / 463,216 and 62 / 555,444). As shown in Example 40, reduction in an aprotic solvent (e.g., DMSO) Formulations containing the pneumococcal conjugates of the invention prepared using reactive amination are Using a protic (i.e., aqueous) solvent during reductive amination in a jugation method Superior physical and chemical stability compared to vaccines using formulated drug substances Thus, in some embodiments, the pneumococcal polysaccharide conjugates in the multivalent composition All of the gates are prepared in aprotic solvents.
[0164] In certain embodiments of the present invention, the total polysaccharide concentration in the composition is from about 0.02 to about 0.175 In certain embodiments of the present invention, the total polysaccharide concentration in the composition is about 0.0 In certain embodiments of the present invention, the total polysaccharides in the composition are from about 0.3 to about 0.175 mg / mL. In another embodiment, the total concentration of the composition is about 0.04 to about 0.175 mg / mL. The polysaccharide concentration is about 0.065 to about 0.085 mg / mL, about 0.070 to about 0.080 mg / mL. g / mL, about 0.065 to about 0.080 mg / mL, about 0.070 to about 0.085 mg / mL, about 0.110 to about 0.128 mg / mL, about 0.110 to about 0.175 mg / mL , about 0.10 to about 0.175mg / mL, about 0.110 to about 0.170mg / mL, about 0 .115~approx. 0.15mg / mL, approx. 0.110~approx. 0.15mg / mL, approx. 0.110 ~0.125mg / mL, approx. 0.150~0.170mg / mL, approx. 0.150~approx. 0.165mg / mL, about 0.140 to about 0.170mg / mL, about 0.130 to about 0. 170mg / mL, about 0.150 to about 0.175mg / mL, about 0.070 to about 0.17 0 mg / mL, about 0.065 to about 0.175 mg / mL, or about 0.065 to about 0.18 0 mg / mL.
[0165] One or more or all of the polysaccharide-protein conjugates in the multivalent immunogenic composition may be non-proteolytic. In embodiments of the invention that are formulated in a rotonic solvent, the total polysaccharide concentration in the composition is at 37° C. It is stable for at least 4 weeks at room temperature, at least 4 weeks at 25°C, and at least 12 weeks at 4°C.
[0166] One or more or all of the polysaccharide-protein conjugates in the multivalent immunogenic composition may be non-proteolytic. In certain embodiments of the present invention prepared in a rotonic solvent, the pneumococcus (Sp Weight average molecular weight (Mw) of all polysaccharide-protein conjugates of P. neumoniae (average of all conjugates in the composition) is about 3,500 to about 4,700 kDa, 3,500~4,600kDa, 3,500~4,500kDa, 3,500~ Approximately 4,400 kDa, approximately 3,500 to approximately 4,300 kDa, approximately 3,500 to approximately 4,200 kDa, about 3,600 to about 4,700kDa, about 3,600 to about 4,600kDa, about 3 ,600~about 4,500 kDa, about 3,600~about 4,400 kDa, about 3,600~about 4,300kDa, approximately 3,600~4,200kDa, approximately 3,700~4,700k Da, about 3,700 to about 4,600kDa, about 3,700 to about 4,500kDa, about 3, 700 to 4,400 kDa, 3,700 to 4,300 kDa, 3,700 to 4 ,200kDa, about 3,800 to about 4,700kDa, about 3,800 to about 4,600kD a, about 3,800 to about 4,500kDa, about 3,800 to about 4,400kDa, about 3,8 00~about 4,300kDa, about 3,800~about 4,200kDa, about 3,900~about 4, 700kDa, approx. 3,900~approx. 4,600kDa, approx. 3,900~approx. 4,500kDa , about 3,900 to about 4,400 kDa, about 3,900 to about 4,300 kDa, or about 3, 900 to approximately 4,200 kDa.
[0167] The polysaccharide-protein conjugates in the multivalent immunogenic composition are prepared in aprotic solvents. In certain embodiments of the present invention, the S. pneumoniae ) The Mw of each of the polysaccharide-protein conjugates (for a single serotype) is approximately 1.00 0 to about 10,000 kDa, about 1,500 to about 5,500 kDa, about 1,500 to about 5, 600kDa, approx. 1,500~approx. 5,700kDa, approx. 1,500~approx. 5,800kDa , about 1,500 to about 5,900 kDa, about 1,500 to about 6,000 kDa, about 1,00 0 to about 5,500 kDa, about 1,000 to about 5,000 kDa, about 1,000 to about 4,0 00kDa, about 1,000 to about 4,500kDa, about 1,000 to about 4,000kDa or about 1,000 to about 3,500 kDa. The Mw of the purified conjugates is approximately 1,000 kDa, approximately 1,100 kDa, and approximately 1,200 kDa. 0kDa, approx. 1,300kDa, approx. 1,400kDa, approx. 1,500kDa, approx. 1,60 0kDa, approx. 1,700kDa, approx. 1,800kDa, approx. 1,900kDa, approx. 2,00 0kDa, approx. 2,100kDa, approx. 2,200kDa, approx. 2,300kDa, approx. 2,40 0kDa, approx. 2,500kDa, approx. 2,600kDa, approx. 2,700kDa, approx. 2,80 0kDa, approx. 2,900kDa, approx. 3,000kDa, approx. 3,100kDa, approx. 3,20 0kDa, approx. 3,300kDa, approx. 3,400kDa, approx. 3,500kDa, approx. 3,60 0kDa, approx. 3,700kDa, approx. 3,800kDa, approx. 3,900kDa, approx. 4,00 0kDa, approx. 4,100kDa, approx. 4,200kDa, approx. 4,300kDa, approx. 4,40 0kDa, approx. 4,500kDa, approx. 4,600kDa, approx. 4,700kDa, approx. 4,80 0kDa, approx. 4,900kDa, approx. 5,000kDa, approx. 5,100kDa, approx. 5,20 0 kDa, about 5,300 kDa, about 5,400 kDa or about 5,500 kDa.
[0168] In certain embodiments of the invention, the polysaccharide-protein conjugate in the multivalent immunogenic composition The acetate is prepared in an aprotic solvent (as opposed to being prepared in a protic solvent). ) Streptococcus pneumoniae (S. pneumoniae) conjugated to a carrier protein in an aprotic solvent Compositions with a high proportion of (moniae) polysaccharides may be preferred. In certain embodiments, Serotype-specific copolysaccharides of S. pneumoniae prepared in aprotic solvents. The percentage of conjugates (the number of polysaccharide serotypes prepared in aprotic solvents) was calculated by dividing the number of polysaccharide serotypes by the number of polysaccharide serotypes. The total number of solvents is calculated by dividing the total number of solvents in aprotic or protic solvents by the total number of solvents in protic or aprotic solvents. (including those prepared by the same method) is more than 50%, more than 60%, more than 70%, or more than 80% It may be greater than, or greater than 90%, or is 100%.
[0169] In certain embodiments of the invention, the serotype 3 polysaccharide-protein conjugate in the composition is prepared in an aprotic solvent, and the Mw of the conjugate is about 1,000 to about 5 ,000 kDa, or about 1,000 to about 4,000 kDa, or about 1,000 to about 3 ,000 kDa, or about 1,000 to about 2,500 kDa, or about 1,000 to about 2 ,000kDa.
[0170] One or more or all of the polysaccharide-protein conjugates in the multivalent immunogenic composition may be non-proteolytic. In certain embodiments of the present invention prepared in a rotonic solvent, the pneumococcus (Sp neumoniae polysaccharide-protein conjugate number average molecular weight (Mn) (composition The average of all conjugates in the sample is about 900 to about 3000 kDa, about 1000 to about 3 000kDa, about 1000 to about 2500kDa, about 1500 to about 2500kDa, about 18 00 to about 2500 kDa, about 1900 to about 2500 kDa, or about 2000 to about 2500 kDa.
[0171] One or more or all of the polysaccharide-protein conjugates in the multivalent immunogenic composition may be non-proteolytic. In certain embodiments of the present invention prepared in a rotonic solvent, the pneumococcus (Sp neumoniae polysaccharide-protein conjugates (for single serotypes) (approximately 700 to 7000 kDa, approximately 1000 to 6000 kDa, approximately 1000 to approx. 5000kDa, approx. 1000-approx. 4000kDa, approx. 1000-approx. 3000kDa, approx. 9 00 to about 5500 kDa, about 900 to about 5000 kDa, about 900 to about 4500 kDa, About 900 to about 4000 kDa, about 900 to about 3500 kDa, or about 900 to about 3000 kDa.
[0172] In an embodiment of the present invention, the S. pneumoniae polysaccharide protein in the composition The Mw and / or Mn of the protein conjugates were determined by measuring the Mw and / or Mn of the protein conjugates at 37°C for more than 4 weeks and at 25°C for more than 4 weeks. Stable for at least 12 weeks at 4°C and / or at 4°C.
[0173] In an embodiment of the invention, the polysaccharide concentration, Mw and / or Mn are determined by HPSEC UV / Determined using MALS / RI.
[0174] One or more or all of the polysaccharide-protein conjugates in the multivalent immunogenic composition may be non-proteolytic. In some embodiments of the present invention prepared in rotic solvents, 280 nanometers (n m) the emission maximum of the composition as measured using intrinsic protein fluorescence spectroscopy at an excitation wavelength of In some embodiments, the emission maximum is about 335 nm to about 342 nm. The fluorescence intensity remains stable at 37°C for at least one week. In some embodiments, the emission maximum is maintained at about 335 nm to about 342 nm, and the fluorescence intensity is maintained at 37° C. It is stable for one week.
[0175] In some embodiments, all of the pneumococcal polysaccharide conjugates in the multivalent composition are D In certain subembodiments, all are prepared using reductive amination in MSO. Multivalent compositions containing polysaccharide conjugates prepared using MSO contain adjuvants. Does not include.
[0176] Without being bound by any theory, it is believed that the glycoconjugates prepared in DMSO One possible mechanism for the enhanced immunogenicity observed in mice is the interaction between the protein and polysaccharide. Provides additional attachment points to confer stability and prevents chemical depolymerization or depolymerization of carbohydrate bonds of peptides The binding of carbohydrates (capsular polysaccharides) to lysine residues on the surface of the carrier protein resists degradation. For example, Hsieh, Characterization n of Saccharide-CRM197 Conjugate Vaccine s in Brown F,Corbel M,Griffiths E(eds):P hysico-Chemical Procedures for the Chara cterization of Vaccines.Dev.Biol.Basel,K See Arger, 2000, vol 103, pp. 93-104. The additional benefit of the increased polysaccharide-protein bonds created during conjugation in solvent This may be an additional opportunity for successful peptide-carbohydrate presentation to T cells. Loading with specific peptide sequences conjugated to carbohydrate antigens or these Genetic diversity in human populations resulting in different capacities and susceptibilities to association with carrier proteins Additional attachment points on the protein increase the chances of successful antigen presentation on the surface of antigen-presenting cells (APCs). This allows increased cell proliferation and allows T-cell-dependent responses to other T-cell-independent antigens. It can be seen that the immunogenicity observed by conjugation in DMSO solvent Another possible mechanism of enhancement is the exposure of additional lysines for polysaccharide binding to different peptides. Mechanism of glycopeptide presentation on the surface of APCs for T cell-dependent responses to glycopeptide epitopes. This may be due to the denaturation of CRM 197 in organic solvents, which leads to an increase in the affinity of Avc i et al.,2011,Nature Medicine 17:1602-16 Please refer to 10.
[0177] Conjugation in organic solvents yielding denatured CRM197 in the conjugate Yet another advantage is the immunological interference of reduced antibodies against the native CRM 197 epitope. Polysaccharide-protein complexes produced during conjugation in DMSO solvent may be An additional benefit of increased protein binding is the larger size of the polysaccharides, resulting in improved immunogenicity. The compositions of the invention may be capable of eliciting a human response. It is believed to provide important advantages in
[0178] In certain embodiments, the conjugation reaction is carried out by reductive amination; To increase the efficiency of the conjugation reaction and to aid in the removal of free cyanide Nickel is used. Transition metals are known to form stable complexes with cyanides. The reduction of protein amino groups and formaldehyde by sodium cyanoborohydride was It is known that it improves basal methylation (S Gidley et al., Biol. chem J.1982,203:331-334;Jentoft et al.An al Biochem. 1980,106:186-190). By complexing, the addition of nickel reduces the consumption of protein during conjugation. This increases the binding affinity of the antibody, leading to the formation of larger and potentially more immunogenic conjugates.
[0179] Differences in starting cyanide levels between sodium cyanoborohydride reagent lots also contributed to the consistency and provides conjugation performance without The addition of nickel changes product attributes such as the Ps to CRM197 ratio. Complexation of the substance reduces conjugation mismatch, and sodium cyanoborohydride Lot differences were eliminated.
[0180] Suitable alternative chemistries include 1-cyano-4-dimethylaminopyridinium tetrafluoroborate. The process involves activating sugars with a cyanate ester (CDAP). Thus, the activated sugar can be attached to a carrier protein, either directly or via a spacer (linker) group. For example, the spacer can be coupled to an amino group on a protein. The thiolated polysaccharide may be cystamine or cysteamine to give a thiolated polysaccharide, and the thiolated polysaccharide may be maleimide. Deactivated carrier proteins (e.g., using GMBS) or haloacetylated carrier proteins Substrates (e.g., iodoacetimide [e.g., ethyl iodoacetimide HCl] or N -Succinimidyl bromoacetate or SIAB, or SIA, or SBAP It can be coupled to the support via a thioether bond obtained after reaction with Preferably, a cyanate ester (which may be produced by CDAP chemistry) is coupled with hexanediamine or adipic dihydrazide (ADH) to give the amine The derivatized sugar is coupled to a carbodiimide (e.g., The conjugated protein is conjugated to a carrier protein using EDAC or EDC chemistry. Suitable conjugates are described in International Patent Application Publication No. WO 93 / 15760, International ... No. 95 / 08348 and WO 96 / 29094; and Chu et al. I., 1983, Infect. Immunity 40:245-256 There are.
[0181] Other suitable techniques include carbodiimides, hydrazides, active esters, norborane, p-nitrophenyl Uses benzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation is the process by which carboxylates (CDI) react with the free hydroxyl groups of sugars to form carboxylates. Bonyl linker (Bethell et al., 1979, J. Biol. Chem. 254:2572-4;Hearn et al., 1981, J. Chromatog 218:509-18), which subsequently reacts with proteins to produce carbamates. This is achieved by reduction of the anomeric terminal to the primary hydroxyl group, optional protection / deprotection of the hydroxyl group, and CDI cation synthesis by reaction of the primary hydroxyl group with CDI Formation of carbamate intermediates and the catalysis of CDI carbamate intermediates with amino groups on proteins Coupling may be included.
[0182] After conjugation of the capsular polysaccharide to a carrier protein, the polysaccharide-protein conjugate The gates are purified by one or more of a variety of techniques (e.g., purification of polysaccharide-protein conjugates). Examples of these techniques are well known to those skilled in the art and are described in the following: concentration / diafiltration filtration, ultrafiltration, precipitation / elution, column chromatography and depth filtration. See, for example, U.S. Patent No. 6,146,902.
[0183] After the individual glycoconjugates are purified, they are combined to form the immunogenic composition of the invention. These pneumococcal conjugates are prepared by separate methods and formulated into single doses. The formulation is bulk formulated.
[0184] An alternative method for characterizing the glycoconjugates of the present invention is to characterize the conjugated lysine Conjugated to sugars can be characterized as the extent of conjugation This is due to the number of lysine residues in the carrier protein (eg, CRM197) that was chosen. Evidence for lysine modification of carrier proteins by covalent attachment to polysaccharides is known to those skilled in the art. This can be obtained by amino acid analysis using routine methods. compared to the carrier protein starting material used to generate the conjugate. In a preferred embodiment, the glycoconjugates of the present invention are The degree of conjugation of jugates was 2–15, 2–13, 2–10, 2–8, and 2 ~6, 2~5, 2~4, 3~15, 3~13, 3~10, 3~8, 3~6, 3~5, 3~ 4, 5-15, 5-10, 8-15, 8-12, 10-15 or 10-12. In embodiments, the degree of conjugation of the glycoconjugates of the present invention is about 2, about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or about 15. In a preferred embodiment, the conjugate of the glycoconjugate of the present invention In some such embodiments, the degree of ionization is 4 to 7. It's CRM197.
[0185] The glycoconjugates of the compositions of the invention may also be modified by adjusting the ratio of saccharide to carrier protein (weight / weight In some embodiments, the glycosylation rate of the composition may be characterized by Ps:Pr. The polysaccharide to carrier protein ratio (w / w) of the coconjugate is 0.5–3.0 (e.g. , approx. 0.5, approx. 0.6, approx. 0.7, approx. 0.8, approx. 0.9, approx. 1.0, approx. 1.1, approx. 1.2 , approx. 1.3, approx. 1.4, approx. 1.5, approx. 1.6, approx. 1.7, approx. 1.8, approx. 1.9, approx. 2.0 , approx. 2.1, approx. 2.2, approx. 2.3, approx. 2.4, approx. 2.5, approx. 2.6, approx. 2.7, approx. 2.8 , about 2.9 or about 3.0). In other embodiments, the ratio of saccharide to carrier protein (w / w) is about 2.9 or about 3.0. w) is 0.5~2.5, 0.5~1.5, 0.8~2.5, 0.5~1.0, 1.0~ 1.5, 1.0~2.0, 0.8~2.4, 0.8~2.3, 0.8~2.2, 0.8~ 2.1, 0.8~2.0, 0.8~1.9, 0.8~1.8, 0.8~1.7, 0.8~ 1.6, 0.8~1.5, 0.8~1.4, 0.8~1.3, 0.9~2.4, 0.9~ 2.3, 0.9~2.2, 0.9~2.1, 0.9~2.0, 0.9~1.9, 0.9~ 1.8, 0.9~1.7, 0.9~1.6, 0.9~1.5, 0.9~1.4, 0.9~ 1.3, 0.9~1.2, 1.0~2.4, 1.0~2.3, 1.0~2.2, 1.0~ 2.1, 1.0~2.0, 1.0~1.9, 1.0~1.8, 1.0~1.7, 1.0~ 1.6, 1.0-1.5, 1.0-1.4, 1.0-1.3 or 1.0-1.2 In a further embodiment, the sugar to carrier protein ratio (w / w) is between 0.8 and 1.2. In some such embodiments, the carrier protein is CRM197. The glycoconjugates and immunogenic compositions are covalently conjugated to a carrier protein. Although not included in the glycoconjugate composition, it is nonetheless present in the glycoconjugate composition. The free sugar may include a free sugar that is non-covalently associated with the glycoconjugate. The ligand may be (i.e., non-covalently bound, adsorbed or entrapped).
[0186] In a specific embodiment, the saccharide and carrier protein for serotype 15A conjugates are The ratio (w / w) is about 1.0 to about 2.0, about 1.25 to about 1.75, or about 1.3 to about 1. In another embodiment, the saccharide to carrier protein ratio (w / w ) is approximately 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7 or 1.8 .
[0187] In a specific embodiment, the saccharide and carrier protein for the serotype 15C conjugate are The ratio (w / w) is about 1.0 to about 2.0, about 1.25 to about 1.75, or about 1.3 to about 1. In another embodiment, the saccharide to carrier protein ratio (w / w ) is approximately 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7 or 1.8 .
[0188] In a specific embodiment, the saccharide and carrier protein for the serotype 33F conjugate are The ratio (w / w) is about 1.0 to about 2.0, about 1.25 to about 1.75, or about 1.3 to about 1. In another embodiment, the saccharide to carrier protein ratio (w / w ) is approximately 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7 or 1.8 .
[0189] In a specific embodiment, the saccharide and carrier protein for serotype 35B conjugates are The ratio (w / w) is about 1.25 to about 2.25, about 1.25 to about 2.0, or about 1.3 to about 1. In another embodiment, the saccharide to carrier protein ratio (w / w) for serotype 33B is w) is about 1.2, 1.3, 1.3, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 .0.
[0190] In a specific embodiment, the saccharide and carrier protein for the serotype 24F conjugate are The ratio (w / w) is about 0.5 to about 1.5, about 0.75 to about 1.25, or about 0.8 to about 1. In another embodiment, the saccharide to carrier protein ratio (w / w ) is about 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0.
[0191] In a preferred embodiment, the glycoconjugate comprises about 50% relative to the total amount of polysaccharide; Contains less than 45%, 40%, 35%, 30%, 25%, 20% or 15% free polysaccharides In a preferred embodiment, the glycoconjugate comprises less than about 25% of the total polysaccharide. In a preferred embodiment, the glycoconjugate contains less than about 100% free polysaccharide. In a preferred embodiment, the glycoconjugates contain less than about 20% free polysaccharides compared to The saccharide contains less than about 15% free polysaccharides compared to the total amount of polysaccharides.
[0192] IV.How to use Embodiments of the invention also include: (a) therapeutic (e.g., of the human body); (b) pharmaceutical; (c) pulmonary Inhibition of infection by Streptococcus pneumoniae; (d ) Induction of an immune response or a protective immune response against S. pneumoniae; (e) Prevention of infection with Streptococcus pneumoniae (S. pneumoniae); (f) Prevention of infection with Streptococcus pneumoniae (S. (g) preventing recurrent B. pneumoniae infections; and (g) preventing associated disorders such as brain damage, hearing loss, and seizures. Prevention of pathological symptoms associated with S. pneumoniae infection, including prevention of complications (h) reduction in the progression, onset, or severity of pneumococcal (S. pneumoniae) infection or (i) reducing the likelihood of, but not limited to, pneumococcal pneumonia, pneumococcal Pneumococcal disease (one or more), including bacteremia, pneumococcal meningitis, otitis media, and sinusitis (i) for use in treating, preventing or delaying the onset, severity or progression of or (iii) for use in the preparation of a medicament, These uses also include one or more of the multivalent immunogenic compositions described herein. The pneumococcal polysaccharide-conjugate compositions may be combined with one or more adjuvants or It may be used with or without adjuvant.
[0193] Thus, the present invention relates to a multivalent immunogenic pneumococcal polysaccharide-protein conjugate of the invention. The method includes administering to a patient in need of treatment one or more of the following compositions: Preventive treatment (i.e., protection) against pneumococcal infection or disease The present invention provides a method for
[0194] The compositions and formulations of the present invention can be used via systemic or mucosal routes to administer the compositions of the present invention. By administering can be treated.
[0195] In one embodiment, the present invention relates to an immune response to S. pneumoniae. A method for inducing a cellular immune response comprising administering to a patient an immunologically effective amount of a multivalent immunogenic composition of the invention. In another embodiment, the present invention provides a method for treating pneumococcal infections comprising administering to said patient a A method of vaccinating a human comprising administering to a subject an immunologically effective amount of a multivalent immunogenic composition of the present invention. to a human.
[0196] Thus, in one aspect, the present invention provides a method for the treatment of cancer, comprising: (1) inducing an immune response in a human patient; (3) induce a protective immune response in patients with S. pneumoniae infection or (4) vaccinating a human patient against S. pneumoniae in a human patient. moniae infection, comprising administering to the patient a multivalent immunogenic composition of the present invention. That is, any of the multivalent immunogenic compositions described herein, e.g., the "multivalent Administering to the patient a multivalent immunogenic composition (a multivalent immunogenic composition as described in Section II entitled "Immunogenic Compositions"). The present invention provides a method comprising the steps of:
[0197] In one embodiment, the present invention provides a method for treating pneumococcal pneumonia and invasive disease in adults aged 18 years or older. In another embodiment, the present invention provides a method for preventing infection with 24 strains of Streptococcus pneumoniae (Streptococcus pneumoniae). eptococcus pneumoniae) strains (3, 6A, 6C, 7F, 8, 9N , 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A , 20B, 22F, 23A, 23B, 24F, 31, 33F and 35B) The present invention provides a method for preventing pneumococcal pneumonia and invasive disease caused by the infection.
[0198] In one embodiment of the above method, the composition comprises a plurality of S. pneumoniae polysaccharide-protein conjugates, each of which is linked to a carrier protein. It contains polysaccharides of S. pneumoniae serotypes conjugated to a saccharide. Here, the serotypes of Streptococcus pneumoniae are serotypes: 3, 7F, 19 A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9 N, 10A, 11A, 12F, 15C, 17F and 20A sets. In one embodiment, the composition comprises a plurality of S. pneumoniae polysaccharide proteins. and a protein conjugate, wherein each of the conjugates is conjugated to a carrier protein. The polysaccharides of the gated S. pneumoniae serotypes, The serotypes of S. pneumoniae are serotypes: 3, 7F, 19A, 22F, 3 3F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 1 In one embodiment of the above method, the set includes: 1A, 12F, 15C, 17F and 20. The composition comprises a plurality of S. pneumoniae polysaccharide-protein conjugates. wherein each of the conjugates comprises a pneumonia conjugated to a carrier protein. The polysaccharides of the serotype S. pneumoniae are eumoniae) serotypes are serotypes: 3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, In another embodiment of the above method, the composition comprises the set of: 15C, 17F and 20B. Serotype 6A or 6C S. pneumoniae polysaccharide protein conjugates The present invention further includes a ugate.
[0199] Pneumococcal conjugate vaccines containing serotype 6A have some cross-reactivity to serotype 6C. It has been shown that vaccines can provide differential protection (Cooper et al., Vaccine 29(2011)7207-7211). Thus, some embodiments of the above method Therefore, the present invention also does not include serotype 6C, but instead serotype 6A or serotype 6A and In another embodiment, the immunogenic composition is , and serotype 6A, 6B and 6C pneumococcal conjugates. In terms of morphology, the serotypes of S. pneumoniae are: Ia)3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24 F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20A; Ib)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0A; Ic)3, 7F, 19A, 22F, 33F, 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and and 20A; and Id)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23B , 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 2 0A The set of serotypes selected from the group consisting of:
[0200] In a particular embodiment of the set of serotypes (Ia-Id) above, serotype 20 or 20 B may substitute for serotype 20A.
[0201] In a further embodiment of the above method, the serotype of S. pneumoniae is , II-a) 15A, 16F, 23A, 23B, 24F, 31 and 35B; II-b) 6A, 15A, 16F, 23A, 23B, 24F, 31 and 35B; II-c) 6A, 6B, 15A, 16F, 23A, 23B, 24F, 31 and 35B ; II-d) 6C, 15A, 16F, 23A, 23B, 24F, 31 and 35B; II-e) 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10 A, 11A, 12F, 15C, 17F and 20A; II-f)6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N , 10A, 11A, 12F, 15C, 17F, and 20A; II-g)6A, 6B, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8 , 9N, 10A, 11A, 12F, 15C, 17F and 20A; and II-h)6C, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N , 10A, 11A, 12F, 15C, 17F and 20A The set of serotypes selected from the group consisting of:
[0202] In a particular embodiment of the set of serotypes (II-e to II-h) above, serotype 20 or 2 0B may be substituted for serotype 20A.
[0203] In a further embodiment of the above method, the serotype of S. pneumoniae is , a set of serotypes as shown in any of embodiments Ia), II-a) or II-e). and further including serotypes 6A, 6B and 6C.
[0204] Pneumococcal conjugate vaccines containing serotype 10A have some protection against serotype 39. It has also been shown to provide cross-protection (see WO 2017 / 085586). Thus, in some embodiments of the above methods, the invention also includes serotype 10A. In another embodiment, the present invention provides for the use of a multivalent immunogenic composition that includes serotype 39 instead. The immunogenic composition comprises pneumococcal conjugates of serotypes 10A and 39. In certain embodiments of the method, the serotype of S. pneumoniae is III-a)3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 39, 11A, 12F, 15C, 17F and 20A ; III-b)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 2 3B, 24F, 31, 35B, 8, 9N, 39, 11A, 12F, 15C, 17F and 20A; III-c)3, 7F, 19A, 22F, 33F, 6A, 6B, 15A, 16F, 23 A, 23B, 24F, 31, 35B, 8, 9N, 39, 11A, 12F, 15C, 17F and 20A; III-d)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 2 3B, 24F, 31, 35B, 8, 9N, 39, 11A, 12F, 15C, 17F and 20A; III-e) 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 3 9, 11A, 12F, 15C, 17F and 20A; III-f)6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9 N, 39, 11A, 12F, 15C, 17F and 20A; III-g)6A, 6B, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 39, 11A, 12F, 15C, 17F and 20A; and III-h)6C, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9 N, 39, 11A, 12F, 15C, 17F and 20A The set of serotypes selected from the group consisting of:
[0205] In a particular embodiment of the set of serotypes (II-a to III-h) above, serotype 20 or 20B can be substituted for serotype 20A.
[0206] In a further embodiment of the above method, the serotype of S. pneumoniae is , comprising a set of serotypes as set forth in any of embodiments III-a) to III-h), and further including serotype 10A.
[0207] S. pneumoniae serotypes covalently bound to carrier proteins Immunogenic conjugates containing 15B capsular polysaccharide are capable of inhibiting serotype 15C and / or serotype 15D. It has also been shown that 15A may provide some cross-protection (WO 201 (See, for example, US Pat. No. 5,200,513, issued May 5, 2005, entitled "Methods for Producing and Administering a Medicinal Plant."). Thus, in some embodiments of the above methods, the present invention provides It also does not contain serotype 15C (or de-O-acetylated 15B), but instead serotype 15B (i.e., serotype 15B polysaccharide is not de-O-acetylated) In another embodiment, the immunogenic composition is an immunogenic composition comprising serotypes 15B and 1 The pneumococcal conjugates of 5C (or de-O-acetylated 15B) are included. In certain embodiments, the serotype of S. pneumoniae is IV-a)3, 7F, 19A, 22F, 33F, 15A, 16F, 23A, 23B, 2 4F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A ; IV-b)3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23 B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A; IV-c)3, 7F, 19A, 22F, 33F, 6A, 6B, 15A, 16F, 23A , 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A; IV-d)3, 7F, 19A, 22F, 33F, 6C, 15A, 16F, 23A, 23 B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A; IV-e) 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10 A, 11A, 12F, 15B, 17F and 20A; IV-f)6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N , 10A, 11A, 12F, 15B, 17F and 20A; IV-g)6A, 6B, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8 , 9N, 10A, 11A, 12F, 15B, 17F and 20A; and IV-h)6C, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N , 10A, 11A, 12F, 15B, 17F and 20A The set of serotypes selected from the group consisting of:
[0208] In a particular embodiment of the set of serotypes (IVa-IVh) above, serotype 20 or 20 B may be substituted for serotype 20A.
[0209] In a further embodiment of the above method, the serotype of S. pneumoniae is and a set of serotypes as shown in any of embodiments IV-a) to IV-h); and , further including serotype 15C (and / or de-O-acetylated 15B).
[0210] The compositions of the invention prevent and treat Streptococcus pneumoniae (S. The use of the antibody may be useful in methods of providing complementary protection against S. pneumoniae. The compositions of the invention are intended to protect against a specific pneumococcus (S. pneumoniae) against which a patient has not previously been vaccinated. eumoniae serotypes, and if the patient had previously been vaccinated Provides additional protection against selected S. pneumoniae serotypes or the patient is vaccinated against S. pneumoniae (S. pneumoniae) for which he or she was not previously vaccinated. iae serotype and the S. pneumoniae against which the patient had previously been vaccinated ) serotypes.
[0211] Thus, the present invention provides a method for enhancing an immune response against S. pneumoniae in a patient. A method of inducing, vaccinating or inducing a protective immune response comprising administering to a subject a multivalent immunogen The method includes administering to a patient a composition comprising: eumoniae polysaccharide-protein conjugates, wherein the polysaccharide-protein The conjugate is a pneumococcus (S. pneumoniae) conjugated to a carrier protein. iae serotype capsular polysaccharides, where the patient has previously The present invention provides a method for vaccinating against Vaccinia oniae. In the present invention, the multivalent immunogenic composition is any of the multivalent immunogenic compositions described herein. In certain embodiments of the methods of the invention, the multivalent immunogenic composition may be a multivalent pneumococcal antigen. The multivalent immunogenic vaccine is administered to patients who have been treated with a pneumococcal (Sp Prevent pneumococcal disease caused by two or more serotypes of Streptococcus pneumoniae The vaccine may be any vaccine required to
[0212] In a specific embodiment of the above method, the patient has previously a) 4, 6B, 9V, 14, 18C, 19F and 23F; b) 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A; c) 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F; d)4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19 A, 22F and 33F; e)4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 7F, 19A, 2 2F, 33F, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20; Call f)4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19 A, 22F, 33F, 8, 10A, 11A, 12F and 15B A pneumococcus (S. pneumoniae) serotype selected from the group consisting of Treated with a multivalent pneumococcal vaccine required to prevent pneumococcal disease caused by Ta.
[0213] In a specific embodiment of the above method, the multivalent pneumococcal vaccine is a multivalent pneumococcal vaccine comprising S. pneumoniae moniae) serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 7 F, 19A, 22F, 33F, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A capsular polysaccharide. In a specific embodiment of the above method, the multivalent pneumococcal vaccine Chin is a serotype 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 7F, 19A, 22F, 33F, 2, 8, 9N, 10A, The capsular polysaccharides of the above strains include 11A, 12F, 15B, 17F and 20. In an embodiment, the multivalent pneumococcal vaccine is a multivalent pneumococcal vaccine comprising ... , 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 7F, 19A, 22F, 3 Capsular polysaccharides of 3F, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20B Includes types.
[0214] In a specific embodiment of the above method, the multivalent pneumococcal vaccine comprises a plurality of polysaccharide protein covalents. and a polysaccharide-protein conjugate, wherein the polysaccharide-protein conjugate is conjugated to a carrier protein. Containing polysaccharides of conjugated serotypes of Streptococcus pneumoniae. In embodiments, the multivalent pneumococcal vaccine is not conjugated to a carrier protein. Contains multiple S. pneumoniae capsular polysaccharides.
[0215] In an additional embodiment of the above method, the patient has previously received PREVNAR® 13 (pulmonary Streptococcus pneumoniae 13-valent conjugate vaccine [diphtheria CRM197 protein], Pfiz The procedures were performed at Eppendorf ambulance, Inc., Philadelphia, PA, USA.
[0216] In a further embodiment of the above method, the patient has previously received PNEUMOVAX®2 3 (Pneumococcal Vaccine Multivalent, Merck & Co., Inc., Kenilworth, NJ, USA) ) was treated.
[0217] In yet a further embodiment of the above method, the patient has previously received SYNFLORIX™ ( Pneumococcal polysaccharide conjugate vaccine (adsorbed), GlaxoSmithKline B The patients were treated at the Iologics SA, Rixensart, Belgium.
[0218] In an embodiment of the above method, the multivalent immunogenic composition of the invention is administered to a medical professional, e.g., a physician. According to the treatment regimen provided by the present invention, a patient may receive a multivalent pneumococcal vaccine at any time after the patient has received the multivalent pneumococcal vaccine. In certain embodiments, the multivalent immunogenic composition of the invention is administered to a patient at a time point. 1 month to 5 years after receiving the multivalent pneumococcal vaccine, or 1 month to 1 year after receiving the treatment, 1 month to 2 years after receiving the treatment, 1 month to 3 years after receiving the treatment, 1 month to 4 years after receiving the treatment, 6 months later, 2 months to 6 months later, 2 months to 1 year later, 1 year to 5 years later, 6 months to 5 years later, 6 months ~4 years later, 6 months to 3 years later, 6 months to 2 years later, 6 months to 1 year later, 1 year to 4 years later, 1 year to 3 years later In a further embodiment, the multivalent immunogenic composition is administered to the patient after one or two years. The subjects were randomly assigned to receive the multivalent pneumococcal vaccine at approximately 1 month, 2 months, 3 months, and 4 months after the patient had received the vaccine. months later, about 5 months later, about 6 months later, about 7 months later, about 8 months later, about 9 months later, about 10 months later , about 11 months later, about 1 year later, about 1.25 years later, about 1.5 years later, about 1.75 years later, about 2 years later , about 2.25 years later, about 2.5 years later, about 2.75 years later, about 3 years later, about 3.25 years later, about 3. 5 years later, about 3.75 years later, about 4 years later, about 4.25 years later, about 4.5 years later, about 4.75 years later The drug is administered to patients about five years later.
[0219] In further embodiments, the present invention provides a method for (1) inducing an immune response in a human patient; (2) administering to a human (3) induce protective immune responses in patients with pneumonia caused by Streptococcus pneumoniae (4) to vaccinate a human patient against S. pneumoniae infection; or umoniae infection, comprising administering to said patient a multivalent immunization target of the present invention in any order. administering an immunogenic composition to a patient and administering a multivalent pneumococcal vaccine to a patient. The multivalent pneumococcal vaccine is a multivalent pneumococcal vaccine comprising a 200-mg dose of Streptococcus pneumoniae (S. pneumoniae e) required to prevent pneumococcal disease caused by two or more serotypes The vaccine may be any vaccine that is suitable for use in a vaccine.
[0220] In certain embodiments of the above methods, the patient is a) 4, 6B, 9V, 14, 18C, 19F and 23F; b) 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A; c) 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F; d)4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19 A, 22F and 33F; e)4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 7F, 19A, 2 2F, 33F, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20; Call f)4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19 A, 22F, 33F, 8, 10A, 11A, 12F and 15B A pneumococcus (S. pneumoniae) serotype selected from the group consisting of The multivalent immunogenic composition of the present invention is required to prevent pneumococcal disease caused by and a multivalent pneumococcal vaccine.
[0221] In a specific embodiment of the above method, the multivalent pneumococcal vaccine is a multivalent pneumococcal vaccine comprising S. pneumoniae moniae) serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 7 F, 19A, 22F, 33F, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A capsular polysaccharide.
[0222] In a specific embodiment of the above method, the multivalent pneumococcal vaccine comprises a plurality of polysaccharide protein covalents. and a polysaccharide-protein conjugate, wherein the polysaccharide-protein conjugate is conjugated to a carrier protein. Containing polysaccharides of conjugated serotypes of Streptococcus pneumoniae. In embodiments, the multivalent pneumococcal vaccine is not conjugated to a carrier protein. Contains multiple S. pneumoniae capsular polysaccharides.
[0223] In an additional embodiment of the above method, the patient is administered, in any order, a multivalent immunogenic composition of the invention. and PREVNAR® 13 (pneumococcal 13-valent conjugate vaccine) [Diphtheria CRM197 protein], Pfizer, Inc., Philadelphia, In one embodiment, the patient is first treated with PREVNAR®. 13 and the patient is secondly administered a multivalent immunogenic composition of the invention. In this study, patients were first administered the multivalent immunogenic composition of the invention and second administered PREVNAR. The patient was administered 13 mg of folate (registered trademark).
[0224] In a further embodiment of the above method, the patient receives, in any order, a multivalent immunogenic composition of the invention. and PNEUMOVAX® 23 (Pneumococcal Vaccine Multivalent, Merc In one embodiment, the patient is treated with 5-HT2A1 (Trifluoroethylene glycol) or 5-HT2A1 (Trifluoroethylene glycol). Patients were first administered PNEUMOVAX® 23 and patients were second administered the polyvalent In an alternative embodiment, the patient is first administered the multivalent immunogenic composition of the present invention. The first patient was administered the composition and the second was administered PNEUMOVAX® 23.
[0225] In yet a further embodiment of the above method, the patient receives, in any order, a multivalent immunogenic The composition is administered to the patient, and the patient is then treated with SYNFLORIX™ (pneumococcal polysaccharide conjugate vaccine). Adsorption, GlaxoSmithKline Biologicals sa, Li In one embodiment, patients are first treated with SYNFLOR. IX™ and the patient is secondarily administered a multivalent immunogenic composition of the invention. In an embodiment, a patient is first administered a multivalent immunogenic composition of the invention and secondly administered SYNFL The patient will be administered ORIX™.
[0226] In some embodiments of the above methods, the multivalent immunogenic compositions and multivalent pneumococcal vaccines As used herein, "co-administration" refers to administering two compositions at the same time. The present invention is not limited to administering the two or more compounds in the same order, but includes administering them one after the other in any order. In the form, the multivalent immunogenic composition and the multivalent pneumococcal vaccine are administered intramuscularly or subcutaneously. The vaccine is administered via a single injection into separate anatomical sites, for example into two different arms.
[0227] In some embodiments of the above methods, the multivalent immunogenic composition of the invention and the multivalent pneumococcal vaccine are In an alternative embodiment, the amount of time between administrations of the quinolone is about 4 weeks to about 1 year. It ranges from 1 month to about 5 years.
[0228] In one embodiment, the patient is first administered a multivalent pneumococcal vaccine and second administered a multivalent In an alternative embodiment, the patient is first administered the multivalent immunogenic composition of the present invention. First, they receive a immunization composition and second, they receive a multivalent pneumococcal vaccine.
[0229] Inducing an immune response against Streptococcus pneumoniae in patients 1. A method for inoculating a mammalian animal against a pathogenic bacterium or inducing a protective immune response comprising: (1) A multivalent immunogenic composition is administered to a patient, the composition comprising multiple S. pneumoniae antibodies. moniae) polysaccharide-protein conjugates, wherein the polysaccharide-protein conjugates Each of the conjugates contains a pneumococcus (S. pneumoniae) antibody conjugated to a carrier protein. and comprising a capsular polysaccharide of a serovar I. oniae. (2) waiting a predetermined amount of time to elapse; (3) administering a multivalent pneumococcal vaccine to the patient; A method is also provided that includes:
[0230] In this method, the multivalent immunogenic composition comprises an antibody against S. pneumoniae as described herein. oniae) polysaccharide-protein conjugates, Multivalent pneumococcal vaccines are vaccines that combine two or more strains of pneumococcus (S. pneumoniae). The vaccine may be any vaccine required to prevent disease caused by a serotype. do.
[0231] Inducing an immune response against Streptococcus pneumoniae in patients 1. A method for inoculating a mammalian animal against a pathogenic bacterium or inducing a protective immune response comprising: (1) administering a multivalent pneumococcal vaccine to a patient; (2) waiting a predetermined amount of time to elapse; (3) administering to a patient a multivalent immunogenic composition, the composition comprising multiple S. pneumoniae antibodies; oniae) polysaccharide-protein conjugates, Each of the above is a pneumococcus (S. pneumoniae) conjugated to a carrier protein. containing a capsular polysaccharide of a serotype; Also provided by the present invention is a method comprising:
[0232] In this method, the multivalent immunogenic composition comprises an antibody against S. pneumoniae as described herein. oniae) polysaccharide-protein conjugates, Multivalent pneumococcal vaccines are vaccines that combine two or more strains of pneumococcus (S. pneumoniae). The vaccine may be any vaccine required to prevent disease caused by a serotype. do.
[0233] In some embodiments of the above methods, the multivalent pneumococcal vaccine comprises multiple pneumococcal (Sp neumoniae polysaccharide-protein conjugates, wherein the polysaccharide-protein The protein conjugate is a pneumococcal antibody conjugated to a carrier protein. In an alternative embodiment, the multivalent pneumococcal vaccine comprises a capsular polysaccharide of the P. oniae serotype. S. pneumoniae capsules not conjugated to carrier proteins Contains membrane polysaccharides.
[0234] In any embodiment of the method of the present invention (i.e., any of the methods described herein), The method further comprises administering to the patient one or more additional doses of the multivalent immunogenic composition of the invention. In such a method, the patient may receive a multivalent immunogenic composition of the invention as described above. Patients may have already received a multivalent pneumococcal vaccine before receiving the first dose of this vaccine, or Prior to receiving the polyvalent immunogenic composition, Thus, in one embodiment, the bacteria may be inoculated with S. pneumoniae. Multivalent pneumococcal vaccines required to prevent pneumococcal disease caused by Streptococcus pneumoniae Patients who have received a pneumococcal vaccine may be administered two or more doses of a multivalent immunogenic composition of the invention. In an alternative embodiment, any vaccine previously required to prevent pneumococcal disease is administered. Patients not treated with IFN-α are administered two or more doses of the multivalent immunogenic composition of the invention. can be.
[0235] In an embodiment of the above method, two or more doses are the same multivalent immunogenic composition of the invention. In an alternative embodiment, the two or more doses are different multivalent immunogenic compositions of the invention.
[0236] In specific embodiments of any of these methods, the patient receives 2, 3 or 4 doses of In certain embodiments, the patient is administered a multivalent immunogenic composition of the invention. (Immunosuppressive regimen after cell transplantation) immunodeficiency, and the number of doses is three.
[0237] In some embodiments, the amount of time between administration of each dose of a multivalent immunogenic composition of the invention is: In an alternative embodiment, the administration of each dose of the multivalent immunogenic composition of the present invention is from about 4 weeks to about 1 year. The duration of the training period ranges from about one month to about five years.
[0238] In any embodiment of the method of the present invention, the patient treated with the composition(s) of the present invention The patient is a human. In certain embodiments, the human patient is an infant (approximately 12 to 24 months of age). The compositions of the present invention may also be used in older children, adolescents, or children (approximately 2-5 years of age). and adults (e.g., 18–45 years, 18–50 years, 18–55 years, 18–60 years, or In another embodiment of any of the methods of the present invention, The patient is about 2 to about 18 years old. In a further embodiment of any of the methods of the invention, the patient is 18 years of age or older.
[0239] In a further embodiment of the method of the invention, the human patient is elderly. In some embodiments of the present invention, the patient is 50 years of age or older. In some embodiments, the patient is 55 years of age or older. In an embodiment, the patient is 60 years of age or older. In some embodiments, the patient is 65 years of age or older. is over 70 years old.
[0240] In some embodiments of any of the methods of the invention, the subject is treated with an immunogenic composition of the invention. Patients who are susceptible to the disease are immunocompromised.
[0241] In some embodiments of any of the methods of the invention, the multivalent immunogenic composition is In certain embodiments, the vaccine is administered simultaneously with a vaccine against influenza. Chin is a "senior influenza vaccine," which is needed for the elderly, for example those aged 65 and over. It is a high-dose influenza vaccine.
[0242] The present invention provides a method for inducing a protective immune response in a patient against pneumococcal infection, comprising administering to the patient an a therapeutically effective amount of the multivalent immunogenic pneumococcal polysaccharide-protein conjugate described herein The present invention provides a method for the treatment of a patient comprising administering to the patient any one of the following vaccine compositions: The optimal amount of the components (i.e., the multivalent immunogenic composition) is determined in view of an appropriate immune response in the subject. This can be confirmed by standard tests, including observation. For example, in another embodiment, Dosages for vaccination are determined by extrapolation from animal studies to human data. In another embodiment, dosages are empirically determined.
[0243] The method of the present invention can be used to treat invasive infections (meningitis, pneumonia and bacteremia) and non-invasive infections (acute Microorganisms, including both otitis media and sinusitis, such as S. pneumoniae ) may be used to prevent and / or reduce the primary clinical syndrome caused by Cut.
[0244] Administration of the compositions of the invention may be by injection via intramuscular, intraperitoneal, intradermal or subcutaneous routes; may include one or more of oral / dietary, mucosal administration to the respiratory or genitourinary tract. In one embodiment, intranasal administration is used to treat pneumonia or otitis media (e.g., pneumococcal nasal It may be possible to more effectively prevent pharyngeal carriage, thereby attenuating the infection at its early stage. In a specific embodiment, the compositions of the invention are administered to a patient via intramuscular or subcutaneous administration. It is given.
[0245] All publications mentioned herein are incorporated by reference in their entirety for purposes of illustration only and are not intended to be limiting unless otherwise specified. No. 6,399,413, filed on Oct. 23, 2007, and is incorporated by reference for purposes of describing and disclosing the fees.
[0246] Different embodiments of the present invention have been described herein with reference to the accompanying drawings, in which: It is to be understood that the scope of the invention is not limited to these precise embodiments, but is instead defined in the appended claims. Various changes and modifications may be made therein by those skilled in the art without departing from the spirit or scope of the present invention. It should be understood that this may be the case.
[0247] The following examples illustrate, but do not limit, the present invention.
[0248] [Example 1] Preparation of Pneumococcus (S. Pneumoniae) Capsular Polysaccharide Methods for culturing pneumococci are well known in the art. See, e.g., Chase, 1967 ,Methods of Immunology and Immunochemist See, for example, U.S. Pat. No. 1,233,363, and U.S. Pat. No. 1,522,621. Methods for preparing pneumococcal capsular polysaccharides are also well known in the art. See, for example, European Patent No. 0 497 524. The method generally follows that described in EP 0 497 524, Generally applicable to all pneumococcal serotypes.
[0249] Isolates of pneumococcal strains of serotypes 6C, 23B, and 31 were identified by the United States Department of Disease Control and Prevention. Serotypes 3, 8, 10A, 11A, and 12 were obtained from the National Institute of Infectious Diseases (Atlanta, GA). Strains for F, 15B, 22F, and 33F were obtained from Robert Strains for serotypes 17F and 19A were obtained from The serotype 7F was obtained from the FDA Office of Biologics (Dr. John Robbins). Gerald Schmidt, Downstate Medical Center, New York State University Isolates of pneumococcal serotypes not listed above were obtained from the American Cell lineages were obtained from the Italian Type Culture Collection (Manassas, VA). Subtypes were determined as necessary. The antibodies were differentiated based on the Querlung reaction using specific antisera. The resulting isolates were grown on soybean peptides without hemin. Agar plates made from an animal component-free medium containing tonsils, yeast extract and glucose Further clonal isolation was performed by successively plating on serotype 7F in two steps. The agar plates used also contained hemin. Clonal isolates for each serotype were Soy peptone, yeast extract, HEPES, sodium chloride, sodium bicarbonate, potassium phosphate Liquid culture using an animal component-free medium containing sodium, glucose and glycerol. The cells were then further expanded in culture to prepare a pre-master cell bank.
[0250] The production of each serotype of pneumococcal polysaccharide was carried out by cell expansion and batch fermentation followed by downstream The purification consisted of chemical inactivation prior to purification. Soy peptone or soy peptone ultrafiltrate, Yeast extract or yeast extract ultrafiltrate, HEPES, sodium chloride, sodium bicarbonate Contains a sterile, animal component-free growth medium containing cellulose, potassium phosphate and glucose. Expand the thawed cell bank vials of each serotype using shake flasks or culture bottles. Cell expansion cultures were grown in sealed shake flasks or bottles and were regulated by temperature and agitation. Gas exchange was minimized by control. Serotypes 3, 7F, 8, 9N, 10A, 11A, 12F For 15B, 17F, 19A, 20, 22F and 33F, fermenters containing the same medium were used. During cell expansion of these serotypes, temperature Temperature, pH, pressure and agitation were controlled. No sparging was used, so there was no aeration overflow. The incubation period was also controlled. A certain culture density was reached, as measured by optical density at 600 nm. After that, a portion of the cell expansion culture was cultured in soy peptone or soy peptone ultrafiltrate, yeast extract, or or yeast extract ultrafiltrate, containing sodium chloride, potassium phosphate and glucose The culture was transferred to a production fermenter containing sterile, animal component-free growth medium. Temperature, pH, pressure and The aeration overlay was also controlled since no sparging was used. .
[0251] When glucose was almost depleted, the chemical inactivator phenol was added to the batch. Fermentation was terminated. Pure phenol was added to a final concentration of 0.8–1.2% to inactivate the cells. The primary inactivation was performed in a fermenter for a specified time period to release the capsular polysaccharides from the cell walls. After primary inactivation, the batch is transferred to a separate vessel where temperature and agitation remain controlled. This is then held at a controlled temperature for a further specified period and agitated for complete inactivation. This was verified by microbial plating techniques or by verification of phenol concentrations and time periods. The inactivated broth was then purified.
[0252] [Example 2] Purification of pneumococcal polysaccharides Several purification methods for pneumococcal polysaccharides include centrifugation, depth filtration, concentration / diafiltration, and All procedures consisted of a purification procedure, a treatment procedure and a precipitation step. was carried out at room temperature.
[0253] Cationic fermentation of inactivated broth from fermenter cultures of S. pneumoniae Resistant polymer (BPA-1000, TRETOLITE® (Baker Hug) hes Inc., Houston, TX), Spectrum 8160, Poly(ethylene The cationic cations were aggregated with dimethylaminoimine and Millipore pDADMAC. The polymer bound impurity proteins, nucleic acids and cell debris. Aggregation step and maturation After that period, the flocculated solids were removed via centrifugation and multiple depth filtration steps. Concentrate the clarified broth to a concentration of 100 kDa to 500 kDa MWCO (molecular weight cut-off). The filter was used for diafiltration. Tris, MgCl 2 Buffers and Diafiltration was accomplished using sodium phosphate buffer. Residual nucleic acids and proteins were removed by lysis.
[0254] Sodium acetate and phenanthrene with denatured alcohol and / or isopropanol Further removal of impurities was achieved by reprecipitation of the polysaccharides in ethanol. In the flask, sodium acetate and phenol (liquefied phenol) in sodium phosphate saline buffer were The diafiltration retentate was then charged with phenol or solid phenol. The alcohol fractionation of polysaccharides was carried out in two stages. In the first stage, low-concentration alcohol was prepared. was added to precipitate cell debris and other unwanted impurities, while the crude polysaccharides remained in solution. Impurities were removed via centrifugation followed by a depth filtration step. Add additional isopropanol or denatured alcohol to the batch to keep it out of solution. The precipitated polysaccharide pellet was collected by centrifugation, triturated, and powdered. The mixture was dried and stored frozen at -70°C.
[0255] [Example 3] Structural identity analysis of certain pneumococcal serotypes by NMR studies. 0.01% dimethyl sulfoxide (DMSO) and 0.01% 2,2-dimethyl-2 -Silapentane-5-sulfonate-d 6 Sodium salt (DSS-d 6 ) containing heavy water (D 2 Prepare the polysaccharide powder for NMR analysis by dissolving it in 0) at 5 mg powder / mL solution. Samples were prepared. DMSO was the internal standard used for quantitative analysis, and DSS-d 6 Chemical Society The NMR spectrum was used to set the spectral scale to 0 ppm. was acquired at 50°C, and the portion of the spectrum containing the anomeric resonances was then analyzed using a Microsof t I want to store x,y coordinates in an ASCII file for analysis using an Excel workbook. The Y coordinate (i.e., the spectral profile) was then written selectively as a target. The spectral profiles of capsular bacterial polysaccharides were compared with those in a reference database. The file is then created for the selected preparation of each serotype that is designated as a reference lot. The y values from the sample spectrum and the reference spectrum were compared pairwise to determine the The correlation coefficient (ρ xy ) was created. A ρ value of .95 or greater was considered a positive identification of a polysaccharide structure.
[0256] 1 to 4 show the results of S. pneumoniae serotypes 6C, 15A, and 600MHz one-dimensional analysis of de-O-acetylated 15B and 35B capsular polysaccharides 1 H NMR Spectrum is provided. Streptococcus pneumoniae (S. pneumonia) serotype 6C, 15A, deoxyribonucleic acid Used for serotyping of acetylated 15B and 35B 1 The H NMR identification region is These are provided in FIGS. 5 to 8, respectively.
[0257] Capsules of S. pneumoniae serotypes 15B and 15C de-O-acetylated Structure of membrane polysaccharides An immunogenicity study was conducted using PCV21 in New Zealand White rabbits (see below). (See Example 43 below.) In these studies, de-O-acetylated polysaccharides were used instead of serotype 15C. Saccharide serotype 15B was used in the polyvalent composition. NMR studies were performed to confirm the de-O-acetylated 15 It was confirmed that the B polysaccharide is identical to the serotype 15C polysaccharide.
[0258] Structural differences between capsular polysaccharide serotypes are manifested as differences in chemical shifts in NMR spectra. The anomeric region (approximately 4.4 ppm to 6.0 ppm) contains all the structures of the repeating units of polysaccharides. It is sensitive to the specific features of the glycosylation site. It is sensitive to the differences in stereochemistry, monosaccharide composition, O-acetylation and glycosidic linkages. However, leaving this region of the spectrum unique to each serotype, the chemical shifts of the anomeric signals In the case of de-O-acetylated serotype 15B polysaccharide, the complete 1 H NMR spectrum Toru is a serotype 15C polysaccharide. 1 The H NMR spectra are identical, and the repeating units of both polysaccharides are These results show that the saccharides are composed of the same monosaccharide substituents and glycosidic binding sites (Figures 9B to 9C). 10B-10C). The de-O-acetylation step reduces the amount of acetylated 15B polysaccharide present. The O-acetate groups present in the acetylated cellulose were removed, and the O-acetate groups observed were essentially It is also clearly shown that no sphingosine monophosphate (SNP) remains in the blood (see FIGS. 10A to 10F).
[0259] [Example 4] Preparation of serotype 3 conjugates for multivalent testing using DMSO conjugation Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The buffer was exchanged. The activated polysaccharide and purified CRM 197 were lyophilized separately. The polysaccharide solution was then dissolved in dimethyl sulfoxide (DMSO) and redissolved. The and CRM197 solutions were combined and conjugated as described below. The gates were purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step, such as temperature and time, are controlled to obtain the desired A conjugate having the desired properties was obtained.
[0260] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 380 bar / 5 passes.
[0261] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0262] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.25 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 12 hours at 22°C.
[0263] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. followed by filtration using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water at 2-8°C.
[0264] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0265] The activated polysaccharide was lyophilized at 2 mg Ps / mL in a sucrose concentration of 10% w / v. CRM197 was formulated for drying at 6 mg Pr / mL with a sucrose concentration of 1% w / v. It was formulated for lyophilization at 20°C for 10 min.
[0266] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain polysaccharide concentrations of 1.0 g Ps / L and polysaccharide and CRM197. The mass ratio of polysaccharide to CRM197 in the resulting conjugate was 1.3. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 1 hour at 22°C.
[0267] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation The reaction was then added and incubated at 22°C for 1.6 hours. The batch was then incubated at approximately 4°C and The solution was diluted in 150 mM sodium chloride containing 0.025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated and diluted with 30 Using a Da NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 2 Diafiltered against 5 mM potassium phosphate pH 7 at approximately 4°C.
[0268] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0269] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 2]
[0270] [Example 5] Preparation of serotype 6C for conjugate multivalent testing using DMSO conjugation The polysaccharides were dissolved, chemically activated, and buffer exchanged by ultrafiltration. The polysaccharide and purified CRM197 were separately lyophilized and redissolved in DMSO. The reconstituted polysaccharide solution and CRM197 solution were combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step such as pH, temperature, concentration and time were set. The parameters were controlled to obtain conjugates with desired attributes.
[0271] Polysaccharide oxidation The purified pneumococcal Ps capsule powder was dissolved in water and filtered through a 0.45 micron filter. The digested polysaccharides were concentrated and purified using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The mixture was diafiltered against
[0272] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.10 moles of metaperiodic acid were added per mole of polysaccharide repeat unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0273] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0274] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0275] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0276] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solution was blended to obtain a polysaccharide concentration of 2.2 g Ps / L and a polysaccharide and CRM197 The mass ratio of the resulting conjugate polysaccharide to CRM197 was 1.4. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 15 hours at 22°C.
[0277] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 3 hours. The batch was cooled to approximately 4° C. and cooled to approximately 0° C. Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0278] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0279] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 3]
[0280] [Example 6] Preparation of serotype 6C conjugates for multivalent testing using DMSO conjugation The polysaccharides were dissolved, chemically activated, and buffer exchanged by ultrafiltration. The polysaccharide and purified CRM197 were separately lyophilized and redissolved in DMSO. The reconstituted polysaccharide solution and CRM197 solution were combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step such as pH, temperature, concentration and time were set. The parameters were controlled to obtain conjugates with desired attributes.
[0281] Polysaccharide oxidation The purified pneumococcal Ps capsule powder was dissolved in water and filtered through a 0.45 micron filter. The digested polysaccharides were concentrated and purified using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The mixture was diafiltered against
[0282] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.10 moles of metaperiodic acid were added per mole of polysaccharide repeat unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0283] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0284] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0285] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0286] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain polysaccharide concentrations of 1.9 g Ps / L and polysaccharide and CRM197. The mass ratio of the resulting conjugate polysaccharide to CRM197 was 1.4. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 15 hours at 22°C.
[0287] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 3 hours. The batch was cooled to approximately 4° C. and cooled to approximately 0° C. Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0288] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0289] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 4]
[0290] Preparation of serotype 6A conjugates for monovalent testing using DMSO conjugation The polysaccharides were dissolved, chemically activated, and buffer exchanged by ultrafiltration. The polysaccharide and purified CRM197 were separately lyophilized and redissolved in DMSO. The reconstituted polysaccharide solution and CRM197 solution were combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step such as pH, temperature, concentration and time were set. The parameters were controlled to obtain conjugates with desired attributes.
[0291] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 200 bar / 5 passes. The size-reduced polysaccharides were concentrated and Diafiltered against water using a 10 kDa NMWCO tangential flow ultrafiltration membrane ration.
[0292] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.10 moles of metaperiodic acid were added per mole of polysaccharide repeat unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0293] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0294] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0295] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0296] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain polysaccharide concentrations of 1.5 g Ps / L and polysaccharide and CRM197. The mass ratio of the resulting conjugate polysaccharide to CRM197 was 1.4. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 15 hours at 22°C.
[0297] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 3 hours. The batch was cooled to approximately 4° C. and cooled to approximately 0° C. Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0298] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0299] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 5]
[0300] [Example 7] Preparation of serotype 7F conjugates for multivalent testing using DMSO conjugation Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0301] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 150 bar / 7 passes.
[0302] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0303] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.24 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 4 hours at 4°C.
[0304] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0305] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0306] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0307] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solution was blended to obtain a polysaccharide concentration of 2.6 g Ps / L and a polysaccharide and CRM197 The mass ratio of the resulting conjugate polysaccharide to CRM197 was 1.5. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 4 hours at 22°C.
[0308] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 3 hours. The batch was cooled to approximately 4° C. and cooled to approximately 0° C. Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0309] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0310] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 6]
[0311] [Example 8] Preparation of serotype 8 conjugates for multivalent testing using DMSO conjugation Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0312] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 600 bar / 5 passes.
[0313] Size-reduced polysaccharides were concentrated and filtered through a 5 kDa NMWCO tangential flow ultrafiltration membrane. Diafiltered against water using 100% ethanol.
[0314] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.18 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 4 hours at 22°C.
[0315] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. and subsequently filtered into water using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0316] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0317] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0318] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain polysaccharide concentrations of 4.0 g Ps / L and polysaccharide and CRM197. The mass ratio of the resulting conjugate polysaccharide to CRM197 was 1.5. After blending, the conjugation reaction was carried out at 22°C for 2 h. The addition of sodium cyanoborohydride accelerated the conjugation of serotype 8. It was observed that irreversible precipitation may occur during the reaction, so cyanoborohydride No sodium was added to the conjugation reaction. Omission of thorium avoids precipitation without significantly affecting the properties of the conjugate. It was done.
[0319] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0320] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0321] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 7]
[0322] [Example 9] Preparation of serotype 9N conjugates for multivalent testing using DMSO conjugation Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0323] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 250 bar / 5 passes.
[0324] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0325] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.16 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 4 hours at 22°C.
[0326] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0327] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0328] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0329] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain a polysaccharide concentration of 3.25 g Ps / L and a polysaccharide and CRM19 A mass ratio of 1.5 was achieved for the resulting conjugate polysaccharide to CRM19. The ratio of sodium cyanoborohydride (polysaccharide repeating unit 1) was selected to control the amount of 7. 1 mole per unit) was added and conjugation was allowed to proceed for 1 hour at 22°C.
[0330] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0331] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0332] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 8]
[0333] [Example 10] Preparation of serotype 10A conjugates for monovalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0334] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes is controlled to 200 bar / 5 passes, followed by 600 bar / 5 passes. The target molecular mass was achieved.
[0335] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0336] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.15 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0337] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0338] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0339] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0340] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain polysaccharide concentrations of 5.0 g Ps / L and polysaccharide and CRM197. The mass ratio of the resulting conjugate polysaccharide to CRM197 was 2.0. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 4 hours at 22°C.
[0341] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0342] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0343] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 9]
[0344] [Example 11] Preparation of serotype 10A conjugates for multivalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0345] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 600 bar / 5 passes.
[0346] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0347] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.16 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0348] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0349] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0350] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0351] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solutions were blended to obtain polysaccharide concentrations of 4.0 g Ps / L and polysaccharide and CRM197. The mass ratio of the resulting conjugate polysaccharide to CRM19 was 1.75. The ratio of sodium cyanoborohydride (polysaccharide repeating unit 1) was selected to control the amount of 7. 1 mole per unit) was added and conjugation was allowed to proceed for 4 hours at 22°C.
[0352] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0353] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0354] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 10]
[0355] [Example 12] Preparation of serotype 11A conjugates for multivalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0356] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were size-reduced by acid hydrolysis by adding acetic acid to 200 mM and then incubated at 92°C. Incubate for 75 minutes, then add cold potassium phosphate pH 7 buffer to 400 mM And neutralized it.
[0357] Size-reduced polysaccharides were concentrated and filtered through a 5 kDa NMWCO tangential flow ultrafiltration membrane. Diafiltered against water using 100% ethanol.
[0358] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.13 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0359] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. and subsequently filtered into water using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0360] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0361] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0362] The formulated Ps and CRM197 solutions were lyophilized separately. and CRM197 materials were individually redissolved in an equal volume of DMSO containing 25 mM sodium chloride. The polysaccharide solution and CRM197 solution were blended to obtain a polysaccharide concentration of 3.5 g Ps / The mass ratio of polysaccharide to CRM197 was 1.5. The ratio of polysaccharides and CRM197 in the gate was selected to control. sodium (1 mole per mole of polysaccharide repeating unit) was added and the conjugation was allowed to proceed at 22°C. It advanced by 4 hours.
[0363] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0364] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0365] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 11]
[0366] [Example 13] Preparation of serotype 12F conjugates for multivalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0367] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were size-reduced by acid hydrolysis by adding acetic acid to 200 mM and incubated at 90°C. Incubate for 45 minutes, then add cold potassium phosphate pH 7 buffer to 400 mM And neutralized it.
[0368] Size-reduced polysaccharides were concentrated and filtered through a 5 kDa NMWCO tangential flow ultrafiltration membrane. Diafiltered against water using 100% ethanol.
[0369] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.26 moles of metaperiodic acid were added per mole of polysaccharide repeat unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0370] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. and subsequently filtered into water using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0371] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0372] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0373] The formulated Ps and CRM197 solutions were lyophilized separately. and CRM197 materials were individually redissolved in an equal volume of DMSO containing 25 mM sodium chloride. The polysaccharide solution and CRM197 solution were blended to obtain a polysaccharide concentration of 3.0 g Ps / The mass ratio of polysaccharide to CRM197 was 1.5. The ratio of polysaccharides and CRM197 in the gate was selected to control. sodium (1 mole per mole of polysaccharide repeating unit) was added and the conjugation was allowed to proceed at 22°C. It advanced by 4 hours.
[0374] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 3 hours. The batch was cooled to approximately 4° C. and cooled to approximately 0° C. Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0375] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0376] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 12]
[0377] [Example 14] Preparation of serotype 15A conjugates for monovalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0378] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 200 bar / 5 passes.
[0379] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0380] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 1.75 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 20 hours at 22°C.
[0381] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0382] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0383] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0384] The formulated Ps and CRM197 solutions were lyophilized separately. and CRM197 materials were individually redissolved in an equal volume of DMSO containing 25 mM sodium chloride. The polysaccharide solution and CRM197 solution were blended to obtain a polysaccharide concentration of 6.0 g Ps / The mass ratio of polysaccharide to CRM197 was 2.0. The ratio of polysaccharides and CRM197 in the gate was selected to control. sodium (1 mole per mole of polysaccharide repeating unit) was added and the conjugation was allowed to proceed at 22°C. Advance 2.5 hours.
[0385] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0386] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0387] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 13]
[0388] [Example 15] Serotype 15A conjugate for 15A / B / C cross-protection testing using aqueous conjugation Preparation of jugates Polysaccharides are dissolved, size reduced, chemically activated, and buffer exchanged by ultrafiltration The purified CRM197 was then activated using nickel chloride in an aqueous reaction mixture. The resulting conjugate was subjected to a final 0.2 micron filtration. Prior to purification, the mixture was purified by ultrafiltration. Various adjustments were made within each step, such as pH, temperature, concentration and time. Several process parameters were controlled to obtain conjugates with desired attributes.
[0389] Size reduction and oxidation of polysaccharides Purified pneumococcal capsular polysaccharide powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass. The number of passes was controlled at 200 bar / 5 passes to achieve the target molecular mass. Polysaccharides with reduced molecular weight were concentrated and filtered using a 10 kDa NMWCO tangential flow ultrafiltration membrane. and diafiltered against water.
[0390] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the addition of the polysaccharide repeating units. The amount of sodium metaperiodate was 0.45 moles per mole of unit. The oxidation reaction was carried out at 22°C. The reaction was allowed to proceed for 20 hours. The activated product was purified by 10 kDa NMWCO tangential current limiting. Diafiltrate using a membrane filter against 10 mM potassium phosphate, pH 6.4. Ultrafiltration was carried out at 2-8°C. The ultrafiltration product was adjusted to 22°C and pH 5. Further activation was achieved by increasing the concentration of glycerol in the 100% glycerol complex. 2.0 moles of sodium metaperiodate per mole of polysaccharide repeating unit ( (moles of aldehyde per mole of aldehyde) and 100 mM sodium metaperiodate The activation was carried out by adding the solution. The oxidation reaction proceeded for 20 hours at 22°C. The product was filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane at 10 mM The filtrate was diafiltered against potassium phosphate, pH 6.4. Ultrafiltration was performed at 2-8 °C. The test was performed at °C.
[0391] Polysaccharide conjugation to CRM197 The oxidized polysaccharide solution was mixed with water and 1.5 M potassium phosphate pH 6.0. The buffer pH is intended to improve the stability of the activated polysaccharide during the conjugation reaction. As previously described (WO 2012 / 173876), Pseudomonas fluorescens (P Purified CRM obtained through expression in Pseudomonas fluorescens 197, filtered at 0.2 microns, and buffered with a polysaccharide to CRM197 mass ratio of 0.6. The mass ratio controls the ratio of polysaccharide to CRM197 in the resulting conjugate. The polysaccharide and phosphate concentrations were 9.75 g / L and 10.0 g / L, respectively. The polysaccharide concentration was adjusted to control the size of the resulting conjugate. A 100 mM nickel chloride solution was used to add nickel chloride to approximately 2 mM. Sodium cyanoborohydride (2 moles per mole of polysaccharide repeating unit) was added. The conjugates were incubated at 10°C for 148 hours to maximize the consumption of polysaccharide and protein. We proceeded with the project.
[0392] Reduction with sodium borohydride After the conjugation reaction, the batch was diluted to a polysaccharide concentration of approximately 3.0 g / L and The batch was cooled to 8° C. and 1.2 micron filtered. Using a fast-flow ultrafiltration membrane, the solution was filtered at 2-8°C in 100 mM potassium phosphate, pH 7.0. The batch collected in the retentate was then diafiltered at approximately 2.0 Dilute to g polysaccharide / L and adjust pH to 9.4 by adding 1.2 M sodium bicarbonate. Sodium borohydride (1 mole per mole of polysaccharide repeat unit) was added. M potassium phosphate, pH 6.0 was added later.
[0393] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. and 10 mM L-histidine in 150 mM sodium chloride, pH 7.0 at 4°C. Polysorbate 20 was added to the retentate batch at 0.05% ( w / v) and the batch was then 0.2 micron filtered (0.5 micron (Use prefilter).
[0394] The batches were diluted with 150 mM sodium chloride containing 0.03% (w / v) polysorbate 20. , with additional 10 mM L-histidine in pH 7.0 buffer to a polysaccharide concentration of 1.0 g / L. The batch was divided into aliquots and frozen at -60°C or below. [Table 14]
[0395] [Example 16] Preparation of serotype 15A conjugates for multivalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0396] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 200 bar / 5 passes.
[0397] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0398] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 1.75 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 20 hours at 22°C.
[0399] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0400] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0401] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0402] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharides and CRM197 materials were separately redissolved in an equal volume of DMSO preheated to 34°C. Sodium chloride was added to the solution to a concentration of 50 mM. The liquids were blended to obtain a polysaccharide concentration of 5.0 g Ps / L and a mass ratio of polysaccharide to CRM197 of The mass ratio was controlled by the ratio of polysaccharide to CRM197 in the resulting conjugate. Sodium cyanoborohydride (1 mole per polysaccharide repeat unit) was selected to control the mol) was added and conjugation was allowed to proceed for 2 hours at 34°C.
[0403] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0404] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0405] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 15]
[0406] [Example 17] Serotype 15B for 15A / B / C cross-protection testing using DMSO conjugation Preparation of conjugates Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0407] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 300 bar / 5 passes.
[0408] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0409] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.20 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 4 hours at 22°C.
[0410] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0411] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0412] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0413] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solution was blended to obtain a polysaccharide concentration of 3.0 g Ps / L and a polysaccharide and CRM197 The mass ratio of the resulting conjugate polysaccharide to CRM197 was 2.0. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 5 hours at 22°C.
[0414] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0415] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0416] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 16]
[0417] [Example 18] For monovalent and 15A / B / C cross-protection testing using DMSO conjugation Preparation of serotype 15C conjugates Derived from Streptococcus pneumoniae serotype 15B The polysaccharides to be synthesized are dissolved, sized to the target molecular mass, and subjected to mild base hydrolysis to obtain O-aryl groups. The cetyl groups were released, chemically activated, and buffer exchanged by ultrafiltration. The polysaccharide and purified CRM197 were separately lyophilized and redissolved in DMSO. The reconstituted polysaccharide solution and CRM197 solution were combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step such as pH, temperature, concentration and time were set. The parameters were controlled to obtain conjugates with desired attributes.
[0418] Size reduction, base hydrolysis and oxidation of polysaccharides Purified serotype 15B pneumococcal capsular Ps powder was dissolved in water and 0.45 micron filtered. The dissolved polysaccharides were homogenized to reduce the molecular mass of Ps. The number of passes through the genizer was controlled at 300 bar / 5 passes.
[0419] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0420] Heat the polysaccharide solution to 60 °C and add sodium bicarbonate pH 9 buffer to a final concentration of 50 mM. The batch was incubated at 60° C. for 13 hours with mixing to remove the O-acetyl groups. The pH was neutralized by adding potassium phosphate pH 6 buffer to a final concentration of 136 mM. The solution was then concentrated and eluted with 10 kDa NMWCO tandem. The solution was diafiltered against water using a vent flow ultrafiltration membrane.
[0421] The polysaccharide solution was kept at 22°C and pH was adjusted to 5 with sodium acetate buffer to determine the amount of polysaccharide produced by activation. Size reduction of saccharides was minimized. Polysaccharide activation was performed with 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined based on the target amount of polysaccharide activation. To achieve this level, 0.20 moles of sodium metaperiodate per mole of polysaccharide repeating unit were added. The oxidation reaction was carried out at 22°C. The session continued for two hours.
[0422] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0423] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0424] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0425] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solution was blended to obtain a polysaccharide concentration of 3.0 g Ps / L and a polysaccharide and CRM197 The mass ratio of the resulting conjugate polysaccharide to CRM197 was 2.0. The ratio of sodium cyanoborohydride (1 mole of polysaccharide repeating unit) was selected to control the amount of (1 mole per unit time) was added and conjugation was allowed to proceed for 4 hours at 22°C.
[0426] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0427] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0428] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 17]
[0429] [Example 19] Preparation of serotype 15C conjugates for multivalent testing using DMSO conjugation Manufacturing Derived from Streptococcus pneumoniae serotype 15B The polysaccharides to be synthesized are dissolved, sized to the target molecular mass, and subjected to mild base hydrolysis to obtain O-aryl groups. The cetyl groups were released, chemically activated, and buffer exchanged by ultrafiltration. The polysaccharide and purified CRM197 were separately lyophilized and redissolved in DMSO. The reconstituted polysaccharide solution and CRM197 solution were combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step such as pH, temperature, concentration and time were set. The parameters were controlled to obtain conjugates with desired attributes.
[0430] Size reduction, base hydrolysis and oxidation of polysaccharides Purified serotype 15B pneumococcal capsular Ps powder was dissolved in water and 0.45 micron filtered. The dissolved polysaccharides were homogenized to reduce the molecular mass of Ps. The number of passes through the genizer was controlled at 300 bar / 5 passes.
[0431] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0432] Heat the polysaccharide solution to 60 °C and add sodium bicarbonate pH 9 buffer to a final concentration of 50 mM. The batch was incubated at 60° C. for 13 hours with mixing to remove the O-acetyl groups. The pH was neutralized by adding potassium phosphate pH 6 buffer to a final concentration of 136 mM. and the solution was cooled to ambient temperature.
[0433] The solution was then concentrated and filtered using a 10 kDa NMWCO tangential flow ultrafiltration membrane. Diafiltered against water.
[0434] The polysaccharide solution was kept at 22°C and pH was adjusted to 5 with sodium acetate buffer to determine the amount of polysaccharide produced by activation. Size reduction of saccharides was minimized. Polysaccharide activation was performed with 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined based on the target amount of polysaccharide activation. To achieve this level, 0.20 moles of sodium metaperiodate per mole of polysaccharide repeating unit were added. The oxidation reaction was carried out at 22°C. The session continued for two hours.
[0435] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0436] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0437] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0438] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solution was blended to obtain a polysaccharide concentration of 3.0 g Ps / L and a polysaccharide and CRM197 The mass ratio of the resulting conjugate polysaccharide to CRM19 was 1.75. The ratio of sodium cyanoborohydride (polysaccharide repeating unit 1) was selected to control the amount of 7. 1 mole per unit) was added and conjugation was allowed to proceed for 8 hours at 22°C.
[0439] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0440] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0441] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 18]
[0442] [Example 20] Preparation of serotype 16F conjugates for monovalent testing using aqueous conjugation Polysaccharides are dissolved, size reduced, chemically activated, and buffer exchanged by ultrafiltration The purified CRM197 was then activated using nickel chloride in an aqueous reaction mixture. The resulting conjugate was subjected to a final 0.2 micron filtration. Prior to purification, the mixture was purified by ultrafiltration. Various adjustments were made within each step, such as pH, temperature, concentration and time. Several process parameters were controlled to obtain conjugates with desired attributes.
[0443] Size reduction and oxidation of polysaccharides Purified pneumococcal capsular polysaccharide powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass. The number of passes is controlled to 200 bar / 5 passes, followed by 500 bar / 5 passes. The size-reduced polysaccharides were then concentrated to obtain the 10 kDa NMWC. The solution was diafiltered against water using a tangential flow ultrafiltration membrane.
[0444] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.15 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0445] The activated product was purified using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The mixture was diafiltered against 10 mM potassium phosphate, pH 6.4. Filtration was carried out at 2 to 8°C.
[0446] Polysaccharide conjugation to CRM197 The oxidized polysaccharide solution was mixed with water and 1.5 M potassium phosphate pH 7.0. The buffer pH is intended to improve the stability of the activated polysaccharide during the conjugation reaction. As previously described (WO 2012 / 173876), Pseudomonas fluorescens (P Purified CRM obtained through expression in Pseudomonas fluorescens 197, filtered at 0.2 microns, and buffered with a polysaccharide to CRM197 mass ratio of 0.7. The mass ratio controls the ratio of polysaccharide to CRM197 in the resulting conjugate. The polysaccharide and phosphate concentrations were selected to be 7.5 g / L and 1 The polysaccharide concentration was chosen to control the size of the resulting conjugates. The solution was then filtered through 0.2 microns. A 100 mM nickel chloride solution was used. Nickel chloride was added to approximately 2 mM. Sodium cyanoborohydride (polysaccharide 2 moles per mole of repeating unit) was added to maximize polysaccharide and protein consumption. Conjugation was allowed to proceed for 122 hours at 22°C.
[0447] Reduction with sodium borohydride After the conjugation reaction, the batch was diluted to a polysaccharide concentration of approximately 3.0 g / L and The batch was cooled to 8° C. and 1.2 micron filtered. Using a fast-flow ultrafiltration membrane, the solution was filtered at 2-8°C in 100 mM potassium phosphate, pH 7.0. The batch collected in the retentate was then diafiltered at approximately 2.0 Dilute to g polysaccharide / L and adjust pH to 9.4 by adding 1.2 M sodium bicarbonate. Sodium borohydride (1 mole per mole of polysaccharide repeat unit) was added. M potassium phosphate, pH 6.0 was added later.
[0448] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. and 10 mM L-histidine in 150 mM sodium chloride, pH 7.0 at 4°C. Polysorbate 20 was added to the retentate batch at 0.05% ( w / v) and the batch was then 0.2 micron filtered (0.5 micron (Use prefilter).
[0449] The batches were diluted with 150 mM sodium chloride containing 0.03% (w / v) polysorbate 20. , with additional 10 mM L-histidine in pH 7.0 buffer to a polysaccharide concentration of 1.0 g / L. The batch was divided into aliquots and frozen at -60°C or below. [Table 19]
[0450] [Example 21] Preparation of serotype 16F conjugates for multivalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0451] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 1000 bar / 5 passes.
[0452] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0453] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.15 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0454] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0455] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0456] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0457] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide and CRM197 materials were separately redissolved in an equal volume of DMSO. The polysaccharide solution and CRM197 solution were blended to a concentration of 50 mM. , a polysaccharide concentration of 2.0 g Ps / L and a polysaccharide to CRM197 mass ratio of 1.5 were achieved. The mass ratio was chosen to control the ratio of polysaccharide to CRM197 in the resulting conjugate. Sodium cyanoborohydride (1 mole per mole of polysaccharide repeat unit) was added, Conjugation was allowed to proceed for 2 hours at 22°C.
[0458] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kD Using NMWCO tangential flow ultrafiltration membranes, 150 mM sodium chloride, 25 mM Diafiltered against potassium phosphate pH 7 at approximately 4°C.
[0459] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0460] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 20]
[0461] [Example 22] Preparation of serotype 17F conjugates for monovalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0462] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 200 bar / 5 passes.
[0463] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0464] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.11 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0465] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0466] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0467] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0468] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide and CRM197 materials were separately redissolved in an equal volume of DMSO. The polysaccharide solution and CRM197 solution were blended to a concentration of 50 mM. , a polysaccharide concentration of 2.0 g Ps / L and a polysaccharide to CRM197 mass ratio of 1.5 were achieved. The mass ratio was chosen to control the ratio of polysaccharide to CRM197 in the resulting conjugate. Sodium cyanoborohydride (1 mole per mole of polysaccharide repeat unit) was added, Conjugation was allowed to proceed for 2 hours at 22°C.
[0469] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0470] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0471] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 21]
[0472] [Example 23] Preparation of serotype 17F conjugates for multivalent testing using DMSO conjugation Manufacturing Polysaccharides are dissolved, sized to target molecular mass, chemically activated, and purified by ultrafiltration. The activated polysaccharide and purified CRM197 were lyophilized separately. The polysaccharide solution and CRM197 solution were then mixed together. The resulting conjugate was added to the final 0.2 μl of The mixture was purified by ultrafiltration before filtration. Each step, such as pH, temperature, concentration and time, was Several process parameters within the process can be controlled to produce conjugates with desired attributes. obtained.
[0473] Size reduction and oxidation of polysaccharides The purified pneumococcal Ps capsule powder was dissolved in water and 0.45 micron filtered. The polysaccharides were homogenized to reduce the molecular mass of Ps. The homogenization pressure and homogenizer The number of passes was controlled at 200 bar / 5 passes.
[0474] Size-reduced polysaccharides were concentrated and filtered through a 10 kDa NMWCO tangential flow ultrafiltration membrane. The diafiltration was performed against water using
[0475] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.11 moles of metaperiodic acid were added per mole of polysaccharide repeating unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 2 hours at 22°C.
[0476] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0477] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0478] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0479] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide and CRM197 materials were separately redissolved in an equal volume of DMSO. The polysaccharide solution and CRM197 solution were blended to obtain a solution of 20 mM. A polysaccharide concentration of 2.1 g Ps / L and a polysaccharide to CRM197 mass ratio of 1.5 were achieved. The mass ratio was chosen to control the ratio of polysaccharide to CRM197 in the resulting conjugate. Sodium cyanoborohydride (1 mole per mole of polysaccharide repeat unit) was added, Conjugation was allowed to proceed for 2 hours at 22°C.
[0480] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 1 hour. The batch was cooled to approximately 4° C. and incubated at approximately 0 Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0481] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0482] The retentate batch was filtered at 0.2 microns (using a 0.5 micron prefilter) and then , 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20, pH 7 Dilute with additional 10 mM histidine in 0.0 mL of 100 mM NaCl, dispense into aliquots, and freeze at -60°C or colder. did. [Table 22]
[0483] [Example 24] Preparation of serotype 19A conjugates for multivalent testing using DMSO conjugation Manufacturing The polysaccharides were dissolved, chemically activated, and buffer exchanged by ultrafiltration. The polysaccharide and purified CRM197 were separately lyophilized and redissolved in DMSO. The reconstituted polysaccharide solution and CRM197 solution were combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Several process parameters within each step such as pH, temperature, concentration and time were set. The parameters were controlled to obtain conjugates with desired attributes.
[0484] Polysaccharide oxidation The purified pneumococcal Ps capsule powder was dissolved in water and filtered through a 0.45 micron filter. Concentrate and diafilter against water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. It was filtered.
[0485] The polysaccharide solution was then incubated at 22° C. and adjusted to pH 5 with sodium acetate buffer to activate Polysaccharide activation was performed using 100 mM sodium metaperiodate. The amount of sodium metaperiodate added was determined by the amount of polysaccharide activity. To achieve the target level of polymerization, 0.26 moles of metaperiodic acid were added per mole of polysaccharide repeat unit. Sodium urate (moles of aldehyde per mole of polysaccharide repeating unit). Oxidation reaction The reaction proceeded for 20 hours at 22°C.
[0486] The activated product was diafiltered against 10 mM potassium phosphate, pH 6.4. The solution was then irradiated with water using a 10 kDa NMWCO tangential flow ultrafiltration membrane. The ultrafiltration was carried out at 2-8°C.
[0487] Polysaccharide conjugation to CRM197 As previously described (WO 2012 / 173876), Pseudomonas fluorescens ( Purified CRM197 obtained through expression in Domonas fluorescens 100 ml of 2 mM phosphate, pH 7.0, using a 5 kDa NMWCO tangential flow ultrafiltration membrane. The solution was diafiltered against 0.2 buffer and 0.2 micron filtered.
[0488] The activated polysaccharide was lyophilized at 6 mg Ps / mL in 5% w / v sucrose concentration. CRM197 was formulated at 6 mg Pr / mL with a sucrose concentration of 1% w / v. Formulated for lyophilization.
[0489] The formulated Ps and CRM197 solutions were lyophilized separately. The polysaccharide solution and CRM197 materials were separately redissolved in an equal volume of DMSO. The 197 solution was blended to obtain a polysaccharide concentration of 3.8 g Ps / L and a polysaccharide and CRM197 The mass ratio of the resulting conjugate polysaccharide to CRM19 was 1.33. The ratio of sodium cyanoborohydride (polysaccharide repeating unit 1) was selected to control the amount of 7. C. (1 mole per unit) was added and conjugation was allowed to proceed for 1.5 hours at 22.degree.
[0490] Reduction with sodium borohydride Sodium borohydride (2 moles per mole of polysaccharide repeating unit) for conjugation After the reaction, the mixture was incubated at 22° C. for 3 hours. The batch was cooled to approximately 4° C. and cooled to approximately 0° C. Diluted in 150 mM sodium chloride containing .025% (w / v) polysorbate 20. The pH was then neutralized by adding potassium phosphate buffer. The batch was concentrated to 30 kDa. Using NMWCO tangential flow ultrafiltration membrane, 150 mM sodium chloride, 25 mM The solution was diafiltered against 1 M potassium phosphate pH 7 at approximately 4°C.
[0491] Final Filtration and Product Storage The batch was then concentrated and filtered using a 300 kDa NMWCO tangential flow ultrafiltration membrane. The solution was incubated at 4°C in 150 mM sodium chloride containing 0.015% (w / v) polysorbate 20. The solution was diafiltered against 10 mM histidine in 10 ml of 100 mM sodium dodecyl sulfate, pH 7.0.
[0492] The retentate batch was 0.2 micron filtered and then diluted with 0.015% (w / v) polysorbate. Dilute with additional 10 mM histidine in 150 mM sodium chloride, pH 7.0 containing 20 mM phosphate. The mixture was diluted, dispensed into aliquots, and frozen at -60°C or below. [Table 23]
[0493] [Example 25] Preparation of serotype 20A conjugates for monovalent testing using DMSO conjugation Manufacturing A polysaccharide previously determined to be serotype 20A (Calix et al., Biochem hemical, Genetic, and Serological Characte rization of Two Capsule Sub...
Claims
1. 1. A pharmaceutical composition for preventing invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) in a patient, comprising a multivalent immunogenic composition, comprising: The multivalent immunogenic composition comprises a S. pneumoniae polysaccharide carrier protein conjugate, wherein Each of said conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, de-O-acetylated 15B, 17F and 20A, and said carrier protein is CRM197. Pharmaceutical compositions.
2. 2. The pharmaceutical composition of claim 1, wherein the de-O-acetylated 15B polysaccharide has an O-acetyl content per repeating unit of less than 5%.
3. 1. A pharmaceutical composition for preventing invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) in a patient, comprising a multivalent immunogenic composition, comprising: The multivalent immunogenic composition comprises a S. pneumoniae polysaccharide carrier protein conjugate, wherein Each of said conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F and 20A, and said carrier protein is CRM197. Pharmaceutical compositions.
4. 1. A pharmaceutical composition for preventing invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) in a patient, comprising a multivalent immunogenic composition, comprising: The multivalent immunogenic composition comprises a S. pneumoniae polysaccharide carrier protein conjugate, wherein Each of said conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15B, 17F and 20A, and said carrier protein is CRM197. Pharmaceutical compositions.
5. 1. A multivalent immunogenic composition comprising S. pneumoniae polysaccharide carrier protein conjugates, each of said conjugates comprising a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein: 1) S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, de-O-acetylated 15B, 17F, and 20A; 2) the carrier protein is CRM197; and 3) The concentration of each polysaccharide is 8 μg / mL (w / v); composition.
6. The multivalent immunogenic composition of claim 5 further comprising an adjuvant.
7. The multivalent immunogenic composition of claim 6, wherein the adjuvant is an aluminum phosphate adjuvant.
8. 1. A multivalent immunogenic composition comprising S. pneumoniae polysaccharide carrier protein conjugates, each of said conjugates comprising a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein: 1) S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15C, 17F, and 20A; 2) the carrier protein is CRM197; and 3) The concentration of each polysaccharide is 8 μg / mL (w / v); composition.
9. The multivalent immunogenic composition of claim 8, further comprising an adjuvant.
10. 10. The multivalent immunogenic composition of claim 9, wherein the adjuvant is an aluminum phosphate adjuvant.
11. 1. A multivalent immunogenic composition comprising S. pneumoniae polysaccharide carrier protein conjugates, each of said conjugates comprising a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein: 1) S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, 15B, 17F, and 20A; 2) the carrier protein is CRM197; and 3) The concentration of each polysaccharide is 8 μg / mL (w / v); composition.
12. The multivalent immunogenic composition of claim 11, further comprising an adjuvant.
13. 13. The multivalent immunogenic composition of claim 12, wherein the adjuvant is an aluminum phosphate adjuvant.
Citation Information
Patent Citations
High-efficiency 14-valent pneumococcal conjugate vaccine
CN101590224A
15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
JP2013518891A
Streptococcus pneumoniae capsular polysaccharides and their conjugates
JP2017504661A
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2017509656A
Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228380A1
